date generated: 2023-10-06
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
bu | |
---|---|
FLNC | 0.4697347 |
TMEM91 | 0.4610404 |
CSNK1A1 | 0.5673118 |
LINC01273 | -0.1819099 |
MIR124-2 | -0.8328384 |
CPN2 | 0.7720343 |
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genesets | 2584 |
num_genes_in_profile | 25739 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 10218 |
num_profile_genes_not_in_sets | 15521 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Here are some metrics about the gene sets used:
GMT file of genesets: ReactomePathways.gmtGene sets metrics | |
---|---|
num_genesets | 2584 |
num_genesets_excluded | 1038 |
num_genesets_included | 1546 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Top N= 50 gene sets
## Warning in kable_styling(., "hover", full_width = FALSE): Please specify format
## in kable. kableExtra can customize either HTML or LaTeX outputs. See
## https://haozhu233.github.io/kableExtra/ for details.
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Chylomicron remodeling | 10 | 3.05e-03 | 0.541 | 8.13e-02 |
TRAF6 mediated IRF7 activation | 26 | 2.37e-05 | -0.479 | 1.27e-03 |
SARS-CoV-1 modulates host translation machinery | 34 | 8.57e-06 | 0.441 | 5.09e-04 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 9.89e-03 | -0.430 | 2.07e-01 |
Interaction With Cumulus Cells And The Zona Pellucida | 11 | 1.70e-02 | -0.416 | 2.91e-01 |
Expression and translocation of olfactory receptors | 358 | 2.87e-37 | -0.391 | 4.43e-34 |
Class C/3 (Metabotropic glutamate/pheromone receptors) | 39 | 2.37e-05 | -0.391 | 1.27e-03 |
Caspase activation via Death Receptors in the presence of ligand | 16 | 8.13e-03 | -0.382 | 1.75e-01 |
Olfactory Signaling Pathway | 365 | 4.02e-36 | -0.381 | 3.11e-33 |
Glucuronidation | 25 | 1.16e-03 | -0.375 | 4.17e-02 |
Diseases associated with glycosylation precursor biosynthesis | 15 | 1.19e-02 | 0.375 | 2.30e-01 |
Chylomicron assembly | 10 | 4.23e-02 | 0.371 | 4.91e-01 |
Phase 4 - resting membrane potential | 19 | 6.33e-03 | 0.362 | 1.46e-01 |
mRNA Editing | 10 | 5.27e-02 | -0.354 | 5.69e-01 |
NF-kB is activated and signals survival | 12 | 3.44e-02 | 0.353 | 4.38e-01 |
Signaling by cytosolic FGFR1 fusion mutants | 17 | 1.24e-02 | -0.350 | 2.36e-01 |
Synthesis of PIPs at the late endosome membrane | 10 | 6.56e-02 | -0.336 | 6.11e-01 |
Viral mRNA Translation | 84 | 1.40e-07 | 0.332 | 2.70e-05 |
Cytosolic iron-sulfur cluster assembly | 10 | 7.01e-02 | 0.331 | 6.23e-01 |
Regulation of NF-kappa B signaling | 17 | 1.83e-02 | 0.330 | 3.05e-01 |
Eukaryotic Translation Termination | 87 | 1.07e-07 | 0.329 | 2.70e-05 |
Peptide chain elongation | 84 | 2.21e-07 | 0.327 | 3.45e-05 |
Regulation of IFNA/IFNB signaling | 22 | 8.14e-03 | -0.326 | 1.75e-01 |
Pexophagy | 11 | 6.45e-02 | 0.322 | 6.08e-01 |
Telomere C-strand synthesis initiation | 11 | 6.69e-02 | -0.319 | 6.17e-01 |
p75NTR recruits signalling complexes | 12 | 5.57e-02 | 0.319 | 5.83e-01 |
p75NTR signals via NF-kB | 15 | 3.27e-02 | 0.318 | 4.29e-01 |
Intrinsic Pathway of Fibrin Clot Formation | 21 | 1.15e-02 | -0.318 | 2.29e-01 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 89 | 2.67e-07 | 0.315 | 3.45e-05 |
Selenocysteine synthesis | 87 | 4.02e-07 | 0.314 | 4.61e-05 |
Eukaryotic Translation Elongation | 88 | 4.17e-07 | 0.312 | 4.61e-05 |
TRAF3-dependent IRF activation pathway | 15 | 3.68e-02 | -0.311 | 4.41e-01 |
Platelet Adhesion to exposed collagen | 13 | 5.24e-02 | -0.311 | 5.69e-01 |
SUMOylation of immune response proteins | 10 | 9.25e-02 | 0.307 | 6.73e-01 |
Metabolism of folate and pterines | 16 | 3.41e-02 | -0.306 | 4.38e-01 |
Alpha-protein kinase 1 signaling pathway | 10 | 9.69e-02 | 0.303 | 6.75e-01 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 54 | 1.48e-04 | 0.298 | 6.55e-03 |
Translation initiation complex formation | 53 | 1.78e-04 | 0.298 | 7.64e-03 |
Biosynthesis of DHA-derived SPMs | 17 | 3.48e-02 | 0.296 | 4.38e-01 |
Pausing and recovery of Tat-mediated HIV elongation | 27 | 8.16e-03 | 0.294 | 1.75e-01 |
Tat-mediated HIV elongation arrest and recovery | 27 | 8.16e-03 | 0.294 | 1.75e-01 |
Selenoamino acid metabolism | 103 | 2.62e-07 | 0.293 | 3.45e-05 |
Formation of the ternary complex, and subsequently, the 43S complex | 46 | 5.76e-04 | 0.293 | 2.33e-02 |
SARS-CoV-2 modulates host translation machinery | 46 | 5.87e-04 | 0.293 | 2.33e-02 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 9.64e-02 | 0.289 | 6.75e-01 |
STAT5 activation downstream of FLT3 ITD mutants | 10 | 1.13e-01 | -0.289 | 7.01e-01 |
Receptor Mediated Mitophagy | 10 | 1.13e-01 | 0.289 | 7.01e-01 |
DAP12 interactions | 40 | 1.56e-03 | -0.289 | 5.36e-02 |
Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 10 | 1.16e-01 | 0.287 | 7.06e-01 |
Ribosomal scanning and start codon recognition | 53 | 3.12e-04 | 0.286 | 1.30e-02 |
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Chylomicron remodeling | 10 | 3.05e-03 | 5.41e-01 | 8.13e-02 |
TRAF6 mediated IRF7 activation | 26 | 2.37e-05 | -4.79e-01 | 1.27e-03 |
SARS-CoV-1 modulates host translation machinery | 34 | 8.57e-06 | 4.41e-01 | 5.09e-04 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 9.89e-03 | -4.30e-01 | 2.07e-01 |
Interaction With Cumulus Cells And The Zona Pellucida | 11 | 1.70e-02 | -4.16e-01 | 2.91e-01 |
Expression and translocation of olfactory receptors | 358 | 2.87e-37 | -3.91e-01 | 4.43e-34 |
Class C/3 (Metabotropic glutamate/pheromone receptors) | 39 | 2.37e-05 | -3.91e-01 | 1.27e-03 |
Caspase activation via Death Receptors in the presence of ligand | 16 | 8.13e-03 | -3.82e-01 | 1.75e-01 |
Olfactory Signaling Pathway | 365 | 4.02e-36 | -3.81e-01 | 3.11e-33 |
Glucuronidation | 25 | 1.16e-03 | -3.75e-01 | 4.17e-02 |
Diseases associated with glycosylation precursor biosynthesis | 15 | 1.19e-02 | 3.75e-01 | 2.30e-01 |
Chylomicron assembly | 10 | 4.23e-02 | 3.71e-01 | 4.91e-01 |
Phase 4 - resting membrane potential | 19 | 6.33e-03 | 3.62e-01 | 1.46e-01 |
mRNA Editing | 10 | 5.27e-02 | -3.54e-01 | 5.69e-01 |
NF-kB is activated and signals survival | 12 | 3.44e-02 | 3.53e-01 | 4.38e-01 |
Signaling by cytosolic FGFR1 fusion mutants | 17 | 1.24e-02 | -3.50e-01 | 2.36e-01 |
Synthesis of PIPs at the late endosome membrane | 10 | 6.56e-02 | -3.36e-01 | 6.11e-01 |
Viral mRNA Translation | 84 | 1.40e-07 | 3.32e-01 | 2.70e-05 |
Cytosolic iron-sulfur cluster assembly | 10 | 7.01e-02 | 3.31e-01 | 6.23e-01 |
Regulation of NF-kappa B signaling | 17 | 1.83e-02 | 3.30e-01 | 3.05e-01 |
Eukaryotic Translation Termination | 87 | 1.07e-07 | 3.29e-01 | 2.70e-05 |
Peptide chain elongation | 84 | 2.21e-07 | 3.27e-01 | 3.45e-05 |
Regulation of IFNA/IFNB signaling | 22 | 8.14e-03 | -3.26e-01 | 1.75e-01 |
Pexophagy | 11 | 6.45e-02 | 3.22e-01 | 6.08e-01 |
Telomere C-strand synthesis initiation | 11 | 6.69e-02 | -3.19e-01 | 6.17e-01 |
p75NTR recruits signalling complexes | 12 | 5.57e-02 | 3.19e-01 | 5.83e-01 |
p75NTR signals via NF-kB | 15 | 3.27e-02 | 3.18e-01 | 4.29e-01 |
Intrinsic Pathway of Fibrin Clot Formation | 21 | 1.15e-02 | -3.18e-01 | 2.29e-01 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 89 | 2.67e-07 | 3.15e-01 | 3.45e-05 |
Selenocysteine synthesis | 87 | 4.02e-07 | 3.14e-01 | 4.61e-05 |
Eukaryotic Translation Elongation | 88 | 4.17e-07 | 3.12e-01 | 4.61e-05 |
TRAF3-dependent IRF activation pathway | 15 | 3.68e-02 | -3.11e-01 | 4.41e-01 |
Platelet Adhesion to exposed collagen | 13 | 5.24e-02 | -3.11e-01 | 5.69e-01 |
SUMOylation of immune response proteins | 10 | 9.25e-02 | 3.07e-01 | 6.73e-01 |
Metabolism of folate and pterines | 16 | 3.41e-02 | -3.06e-01 | 4.38e-01 |
Alpha-protein kinase 1 signaling pathway | 10 | 9.69e-02 | 3.03e-01 | 6.75e-01 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 54 | 1.48e-04 | 2.98e-01 | 6.55e-03 |
Translation initiation complex formation | 53 | 1.78e-04 | 2.98e-01 | 7.64e-03 |
Biosynthesis of DHA-derived SPMs | 17 | 3.48e-02 | 2.96e-01 | 4.38e-01 |
Pausing and recovery of Tat-mediated HIV elongation | 27 | 8.16e-03 | 2.94e-01 | 1.75e-01 |
Tat-mediated HIV elongation arrest and recovery | 27 | 8.16e-03 | 2.94e-01 | 1.75e-01 |
Selenoamino acid metabolism | 103 | 2.62e-07 | 2.93e-01 | 3.45e-05 |
Formation of the ternary complex, and subsequently, the 43S complex | 46 | 5.76e-04 | 2.93e-01 | 2.33e-02 |
SARS-CoV-2 modulates host translation machinery | 46 | 5.87e-04 | 2.93e-01 | 2.33e-02 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 9.64e-02 | 2.89e-01 | 6.75e-01 |
STAT5 activation downstream of FLT3 ITD mutants | 10 | 1.13e-01 | -2.89e-01 | 7.01e-01 |
Receptor Mediated Mitophagy | 10 | 1.13e-01 | 2.89e-01 | 7.01e-01 |
DAP12 interactions | 40 | 1.56e-03 | -2.89e-01 | 5.36e-02 |
Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 10 | 1.16e-01 | 2.87e-01 | 7.06e-01 |
Ribosomal scanning and start codon recognition | 53 | 3.12e-04 | 2.86e-01 | 1.30e-02 |
Interleukin-15 signaling | 13 | 7.56e-02 | -2.85e-01 | 6.32e-01 |
Recycling of bile acids and salts | 18 | 3.69e-02 | -2.84e-01 | 4.41e-01 |
Synthesis of PIPs at the early endosome membrane | 15 | 5.82e-02 | -2.82e-01 | 5.84e-01 |
Formation of a pool of free 40S subunits | 94 | 2.23e-06 | 2.82e-01 | 1.50e-04 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 95 | 1.98e-06 | 2.82e-01 | 1.39e-04 |
Interleukin-2 family signaling | 40 | 2.06e-03 | -2.82e-01 | 6.36e-02 |
Downregulation of ERBB2:ERBB3 signaling | 13 | 8.02e-02 | 2.80e-01 | 6.39e-01 |
TICAM1,TRAF6-dependent induction of TAK1 complex | 10 | 1.28e-01 | 2.78e-01 | 7.28e-01 |
Josephin domain DUBs | 11 | 1.15e-01 | 2.74e-01 | 7.06e-01 |
Sensory perception of sweet, bitter, and umami (glutamate) taste | 41 | 2.38e-03 | -2.74e-01 | 6.95e-02 |
Neurotoxicity of clostridium toxins | 10 | 1.35e-01 | 2.73e-01 | 7.33e-01 |
L13a-mediated translational silencing of Ceruloplasmin expression | 103 | 1.66e-06 | 2.73e-01 | 1.22e-04 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 108 | 1.32e-06 | 2.69e-01 | 1.13e-04 |
Nonsense-Mediated Decay (NMD) | 108 | 1.32e-06 | 2.69e-01 | 1.13e-04 |
HSF1-dependent transactivation | 35 | 5.87e-03 | 2.69e-01 | 1.38e-01 |
Assembly of active LPL and LIPC lipase complexes | 17 | 5.61e-02 | 2.68e-01 | 5.83e-01 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 104 | 2.40e-06 | 2.67e-01 | 1.55e-04 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 8.40e-02 | 2.67e-01 | 6.52e-01 |
HIV elongation arrest and recovery | 29 | 1.29e-02 | 2.67e-01 | 2.38e-01 |
Pausing and recovery of HIV elongation | 29 | 1.29e-02 | 2.67e-01 | 2.38e-01 |
Cap-dependent Translation Initiation | 111 | 1.57e-06 | 2.64e-01 | 1.21e-04 |
Eukaryotic Translation Initiation | 111 | 1.57e-06 | 2.64e-01 | 1.21e-04 |
Early Phase of HIV Life Cycle | 14 | 9.98e-02 | 2.54e-01 | 6.75e-01 |
Regulation of signaling by NODAL | 10 | 1.64e-01 | 2.54e-01 | 7.41e-01 |
Triglyceride catabolism | 23 | 3.71e-02 | -2.51e-01 | 4.41e-01 |
Major pathway of rRNA processing in the nucleolus and cytosol | 171 | 1.52e-08 | 2.51e-01 | 5.89e-06 |
CASP8 activity is inhibited | 11 | 1.50e-01 | -2.50e-01 | 7.37e-01 |
Dimerization of procaspase-8 | 11 | 1.50e-01 | -2.50e-01 | 7.37e-01 |
Regulation by c-FLIP | 11 | 1.50e-01 | -2.50e-01 | 7.37e-01 |
SRP-dependent cotranslational protein targeting to membrane | 105 | 1.06e-05 | 2.49e-01 | 6.09e-04 |
Sema4D induced cell migration and growth-cone collapse | 20 | 5.77e-02 | 2.45e-01 | 5.83e-01 |
NRIF signals cell death from the nucleus | 16 | 9.07e-02 | 2.44e-01 | 6.71e-01 |
Assembly Of The HIV Virion | 16 | 9.08e-02 | 2.44e-01 | 6.71e-01 |
Role of LAT2/NTAL/LAB on calcium mobilization | 13 | 1.29e-01 | -2.43e-01 | 7.28e-01 |
MyD88 deficiency (TLR2/4) | 16 | 9.25e-02 | -2.43e-01 | 6.73e-01 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 23 | 4.45e-02 | 2.42e-01 | 5.02e-01 |
Sensory Perception | 569 | 6.53e-23 | -2.41e-01 | 3.36e-20 |
VLDLR internalisation and degradation | 16 | 9.60e-02 | 2.40e-01 | 6.75e-01 |
DAP12 signaling | 28 | 2.79e-02 | -2.40e-01 | 3.85e-01 |
Tandem pore domain potassium channels | 12 | 1.50e-01 | 2.40e-01 | 7.37e-01 |
Tie2 Signaling | 18 | 7.85e-02 | -2.40e-01 | 6.39e-01 |
IRAK4 deficiency (TLR2/4) | 17 | 8.75e-02 | -2.39e-01 | 6.63e-01 |
Signaling by FLT3 fusion proteins | 19 | 7.33e-02 | -2.37e-01 | 6.28e-01 |
Cellular response to starvation | 147 | 7.98e-07 | 2.36e-01 | 8.22e-05 |
Attenuation phase | 25 | 4.29e-02 | 2.34e-01 | 4.95e-01 |
rRNA processing in the nucleus and cytosol | 180 | 6.92e-08 | 2.33e-01 | 2.14e-05 |
Signal regulatory protein family interactions | 13 | 1.48e-01 | -2.32e-01 | 7.37e-01 |
Interleukin-2 signaling | 11 | 1.84e-01 | -2.31e-01 | 7.67e-01 |
Phospholipase C-mediated cascade: FGFR1 | 16 | 1.11e-01 | 2.30e-01 | 6.96e-01 |
Chemokine receptors bind chemokines | 56 | 2.91e-03 | -2.30e-01 | 7.98e-02 |
Glyoxylate metabolism and glycine degradation | 30 | 2.95e-02 | 2.30e-01 | 3.94e-01 |
Degradation of cysteine and homocysteine | 14 | 1.39e-01 | 2.28e-01 | 7.37e-01 |
Spry regulation of FGF signaling | 16 | 1.16e-01 | 2.27e-01 | 7.06e-01 |
Regulation of localization of FOXO transcription factors | 11 | 1.93e-01 | 2.26e-01 | 7.73e-01 |
Organic cation transport | 10 | 2.15e-01 | -2.26e-01 | 7.82e-01 |
Plasma lipoprotein assembly | 19 | 8.95e-02 | 2.25e-01 | 6.71e-01 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 6.20e-02 | 2.25e-01 | 6.02e-01 |
Constitutive Signaling by NOTCH1 HD Domain Mutants | 15 | 1.33e-01 | 2.24e-01 | 7.28e-01 |
Signaling by NOTCH1 HD Domain Mutants in Cancer | 15 | 1.33e-01 | 2.24e-01 | 7.28e-01 |
rRNA processing | 186 | 1.39e-07 | 2.24e-01 | 2.70e-05 |
Caspase activation via extrinsic apoptotic signalling pathway | 25 | 5.35e-02 | -2.23e-01 | 5.74e-01 |
Signaling by EGFR in Cancer | 25 | 5.45e-02 | 2.22e-01 | 5.81e-01 |
Gap junction degradation | 10 | 2.24e-01 | -2.22e-01 | 7.82e-01 |
APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 6.10e-02 | 2.21e-01 | 6.01e-01 |
Regulation of PTEN mRNA translation | 25 | 5.72e-02 | 2.20e-01 | 5.83e-01 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 36 | 2.42e-02 | 2.17e-01 | 3.64e-01 |
NPAS4 regulates expression of target genes | 21 | 8.53e-02 | 2.17e-01 | 6.53e-01 |
rRNA modification in the nucleus and cytosol | 55 | 5.42e-03 | 2.17e-01 | 1.29e-01 |
MET receptor recycling | 10 | 2.37e-01 | 2.16e-01 | 7.98e-01 |
Transcriptional regulation of testis differentiation | 12 | 1.96e-01 | -2.16e-01 | 7.73e-01 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 22 | 7.99e-02 | 2.16e-01 | 6.39e-01 |
Scavenging of heme from plasma | 12 | 1.96e-01 | -2.16e-01 | 7.73e-01 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 1.63e-01 | 2.15e-01 | 7.37e-01 |
Negative regulation of FGFR1 signaling | 32 | 3.54e-02 | 2.15e-01 | 4.41e-01 |
FGFR1 ligand binding and activation | 15 | 1.50e-01 | 2.15e-01 | 7.37e-01 |
Regulation of expression of SLITs and ROBOs | 159 | 3.18e-06 | 2.14e-01 | 1.97e-04 |
mTORC1-mediated signalling | 23 | 7.63e-02 | 2.14e-01 | 6.34e-01 |
Acyl chain remodelling of PE | 24 | 7.18e-02 | 2.12e-01 | 6.27e-01 |
Regulation of innate immune responses to cytosolic DNA | 14 | 1.69e-01 | 2.12e-01 | 7.53e-01 |
Initial triggering of complement | 21 | 9.28e-02 | 2.12e-01 | 6.73e-01 |
Regulation of TLR by endogenous ligand | 17 | 1.30e-01 | -2.12e-01 | 7.28e-01 |
Methylation | 14 | 1.71e-01 | 2.12e-01 | 7.53e-01 |
Formation of Fibrin Clot (Clotting Cascade) | 37 | 2.64e-02 | -2.11e-01 | 3.76e-01 |
Sema4D in semaphorin signaling | 24 | 7.44e-02 | 2.10e-01 | 6.28e-01 |
HSF1 activation | 27 | 5.86e-02 | 2.10e-01 | 5.85e-01 |
Cleavage of the damaged purine | 11 | 2.27e-01 | -2.10e-01 | 7.82e-01 |
Depurination | 11 | 2.27e-01 | -2.10e-01 | 7.82e-01 |
Recognition and association of DNA glycosylase with site containing an affected purine | 11 | 2.27e-01 | -2.10e-01 | 7.82e-01 |
GRB2:SOS provides linkage to MAPK signaling for Integrins | 15 | 1.61e-01 | -2.09e-01 | 7.37e-01 |
cGMP effects | 15 | 1.61e-01 | -2.09e-01 | 7.37e-01 |
N-Glycan antennae elongation | 15 | 1.62e-01 | -2.09e-01 | 7.37e-01 |
Reactions specific to the complex N-glycan synthesis pathway | 10 | 2.54e-01 | -2.08e-01 | 8.14e-01 |
Membrane binding and targetting of GAG proteins | 14 | 1.79e-01 | 2.08e-01 | 7.64e-01 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 1.79e-01 | 2.08e-01 | 7.64e-01 |
XBP1(S) activates chaperone genes | 47 | 1.39e-02 | 2.07e-01 | 2.47e-01 |
Biosynthesis of specialized proresolving mediators (SPMs) | 19 | 1.18e-01 | 2.07e-01 | 7.09e-01 |
Influenza Viral RNA Transcription and Replication | 129 | 5.17e-05 | 2.06e-01 | 2.42e-03 |
Receptor-type tyrosine-protein phosphatases | 16 | 1.54e-01 | 2.06e-01 | 7.37e-01 |
GPVI-mediated activation cascade | 32 | 4.41e-02 | -2.06e-01 | 5.01e-01 |
Aspirin ADME | 44 | 1.91e-02 | -2.04e-01 | 3.10e-01 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 38 | 2.96e-02 | 2.04e-01 | 3.94e-01 |
HIV Transcription Elongation | 38 | 2.96e-02 | 2.04e-01 | 3.94e-01 |
Tat-mediated elongation of the HIV-1 transcript | 38 | 2.96e-02 | 2.04e-01 | 3.94e-01 |
Keratan sulfate degradation | 12 | 2.25e-01 | -2.02e-01 | 7.82e-01 |
Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 15 | 1.79e-01 | -2.00e-01 | 7.64e-01 |
Aggrephagy | 23 | 9.74e-02 | 2.00e-01 | 6.75e-01 |
Interconversion of nucleotide di- and triphosphates | 29 | 6.32e-02 | 1.99e-01 | 6.03e-01 |
N-glycan antennae elongation in the medial/trans-Golgi | 26 | 7.89e-02 | -1.99e-01 | 6.39e-01 |
Bile acid and bile salt metabolism | 45 | 2.10e-02 | -1.99e-01 | 3.21e-01 |
Regulation of NPAS4 gene expression | 13 | 2.15e-01 | 1.99e-01 | 7.82e-01 |
Condensation of Prometaphase Chromosomes | 11 | 2.55e-01 | 1.98e-01 | 8.14e-01 |
Thyroxine biosynthesis | 10 | 2.81e-01 | -1.97e-01 | 8.20e-01 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 20 | 1.30e-01 | -1.96e-01 | 7.28e-01 |
IRE1alpha activates chaperones | 49 | 1.82e-02 | 1.95e-01 | 3.05e-01 |
Mitochondrial translation termination | 87 | 1.69e-03 | 1.95e-01 | 5.45e-02 |
Acyl chain remodelling of PC | 26 | 8.64e-02 | 1.94e-01 | 6.58e-01 |
Mitochondrial translation initiation | 87 | 1.77e-03 | 1.94e-01 | 5.60e-02 |
Acyl chain remodelling of PI | 16 | 1.80e-01 | 1.94e-01 | 7.64e-01 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 20 | 1.35e-01 | 1.93e-01 | 7.33e-01 |
Na+/Cl- dependent neurotransmitter transporters | 18 | 1.56e-01 | 1.93e-01 | 7.37e-01 |
SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 12 | 2.48e-01 | 1.93e-01 | 8.07e-01 |
Budding and maturation of HIV virion | 28 | 7.90e-02 | 1.92e-01 | 6.39e-01 |
SARS-CoV-1-host interactions | 90 | 1.66e-03 | 1.92e-01 | 5.45e-02 |
Signaling by FGFR1 | 49 | 2.02e-02 | 1.92e-01 | 3.19e-01 |
MAP2K and MAPK activation | 36 | 4.66e-02 | -1.92e-01 | 5.22e-01 |
MTOR signalling | 40 | 3.61e-02 | 1.91e-01 | 4.41e-01 |
TAK1-dependent IKK and NF-kappa-B activation | 41 | 3.40e-02 | 1.91e-01 | 4.38e-01 |
Negative regulation of FGFR4 signaling | 30 | 7.01e-02 | 1.91e-01 | 6.23e-01 |
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 17 | 1.75e-01 | -1.90e-01 | 7.59e-01 |
Synthesis of PE | 12 | 2.55e-01 | 1.90e-01 | 8.14e-01 |
Signaling by NODAL | 21 | 1.33e-01 | 1.89e-01 | 7.28e-01 |
Regulation of gene expression by Hypoxia-inducible Factor | 11 | 2.78e-01 | 1.89e-01 | 8.20e-01 |
Formation of HIV elongation complex in the absence of HIV Tat | 40 | 3.90e-02 | 1.89e-01 | 4.61e-01 |
Sensory perception of taste | 47 | 2.54e-02 | -1.88e-01 | 3.73e-01 |
Transcriptional Regulation by NPAS4 | 33 | 6.14e-02 | 1.88e-01 | 6.01e-01 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 25 | 1.04e-01 | 1.88e-01 | 6.75e-01 |
GAB1 signalosome | 17 | 1.82e-01 | 1.87e-01 | 7.64e-01 |
Retinoid metabolism and transport | 42 | 3.67e-02 | 1.86e-01 | 4.41e-01 |
Mitochondrial translation elongation | 87 | 2.70e-03 | 1.86e-01 | 7.59e-02 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 1.72e-01 | 1.86e-01 | 7.57e-01 |
Heme degradation | 16 | 1.98e-01 | -1.86e-01 | 7.73e-01 |
Signaling by FLT3 ITD and TKD mutants | 16 | 1.99e-01 | -1.85e-01 | 7.73e-01 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 31 | 7.41e-02 | 1.85e-01 | 6.28e-01 |
Translation | 262 | 2.42e-07 | 1.85e-01 | 3.45e-05 |
RNA Polymerase III Transcription Termination | 23 | 1.25e-01 | 1.85e-01 | 7.22e-01 |
Defective pyroptosis | 11 | 2.89e-01 | -1.85e-01 | 8.21e-01 |
Mitochondrial translation | 93 | 2.20e-03 | 1.84e-01 | 6.68e-02 |
RMTs methylate histone arginines | 30 | 8.25e-02 | 1.83e-01 | 6.48e-01 |
Phospholipase C-mediated cascade; FGFR4 | 14 | 2.40e-01 | 1.81e-01 | 8.04e-01 |
Signaling by KIT in disease | 20 | 1.61e-01 | -1.81e-01 | 7.37e-01 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 1.61e-01 | -1.81e-01 | 7.37e-01 |
ERKs are inactivated | 13 | 2.62e-01 | 1.80e-01 | 8.19e-01 |
Organic anion transporters | 10 | 3.29e-01 | 1.78e-01 | 8.37e-01 |
Common Pathway of Fibrin Clot Formation | 21 | 1.58e-01 | -1.78e-01 | 7.37e-01 |
ER Quality Control Compartment (ERQC) | 20 | 1.70e-01 | 1.77e-01 | 7.53e-01 |
Formation of RNA Pol II elongation complex | 53 | 2.61e-02 | 1.77e-01 | 3.76e-01 |
RNA Polymerase II Transcription Elongation | 53 | 2.61e-02 | 1.77e-01 | 3.76e-01 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 3.11e-01 | 1.77e-01 | 8.23e-01 |
Prednisone ADME | 10 | 3.34e-01 | -1.77e-01 | 8.37e-01 |
Selective autophagy | 59 | 1.93e-02 | 1.76e-01 | 3.10e-01 |
RHO GTPases Activate ROCKs | 19 | 1.86e-01 | 1.75e-01 | 7.67e-01 |
RHO GTPases activate CIT | 19 | 1.86e-01 | 1.75e-01 | 7.67e-01 |
Phase 2 - plateau phase | 14 | 2.57e-01 | 1.75e-01 | 8.17e-01 |
Signaling by BMP | 27 | 1.17e-01 | -1.74e-01 | 7.06e-01 |
Other interleukin signaling | 24 | 1.40e-01 | 1.74e-01 | 7.37e-01 |
Regulated proteolysis of p75NTR | 11 | 3.19e-01 | 1.73e-01 | 8.29e-01 |
A tetrasaccharide linker sequence is required for GAG synthesis | 23 | 1.52e-01 | 1.73e-01 | 7.37e-01 |
Triglyceride metabolism | 36 | 7.31e-02 | -1.73e-01 | 6.28e-01 |
SUMOylation of ubiquitinylation proteins | 37 | 6.99e-02 | -1.72e-01 | 6.23e-01 |
Citric acid cycle (TCA cycle) | 21 | 1.74e-01 | 1.72e-01 | 7.58e-01 |
Zinc influx into cells by the SLC39 gene family | 10 | 3.50e-01 | 1.71e-01 | 8.37e-01 |
Synthesis of glycosylphosphatidylinositol (GPI) | 17 | 2.23e-01 | 1.71e-01 | 7.82e-01 |
Negative regulation of FGFR2 signaling | 33 | 9.03e-02 | 1.70e-01 | 6.71e-01 |
Androgen biosynthesis | 11 | 3.30e-01 | -1.70e-01 | 8.37e-01 |
Activation of AMPK downstream of NMDARs | 10 | 3.57e-01 | 1.68e-01 | 8.43e-01 |
Signaling by ROBO receptors | 203 | 3.85e-05 | 1.67e-01 | 1.98e-03 |
Formation of the Early Elongation Complex | 32 | 1.01e-01 | 1.67e-01 | 6.75e-01 |
Formation of the HIV-1 Early Elongation Complex | 32 | 1.01e-01 | 1.67e-01 | 6.75e-01 |
Plasma lipoprotein remodeling | 32 | 1.02e-01 | 1.67e-01 | 6.75e-01 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 120 | 1.63e-03 | -1.66e-01 | 5.45e-02 |
NCAM1 interactions | 36 | 8.45e-02 | 1.66e-01 | 6.52e-01 |
Insulin receptor recycling | 26 | 1.43e-01 | 1.66e-01 | 7.37e-01 |
Sulfur amino acid metabolism | 27 | 1.36e-01 | 1.66e-01 | 7.37e-01 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 18 | 2.25e-01 | 1.65e-01 | 7.82e-01 |
Hormone ligand-binding receptors | 13 | 3.03e-01 | -1.65e-01 | 8.21e-01 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 3.03e-01 | 1.65e-01 | 8.21e-01 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 25 | 1.54e-01 | 1.65e-01 | 7.37e-01 |
SARS-CoV-2 activates/modulates innate and adaptive immune responses | 110 | 2.94e-03 | -1.64e-01 | 7.98e-02 |
RHO GTPases activate PKNs | 34 | 9.84e-02 | 1.64e-01 | 6.75e-01 |
Activation of HOX genes during differentiation | 61 | 2.71e-02 | 1.64e-01 | 3.78e-01 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 61 | 2.71e-02 | 1.64e-01 | 3.78e-01 |
Signaling by FGFR4 | 40 | 7.38e-02 | 1.63e-01 | 6.28e-01 |
NOTCH2 intracellular domain regulates transcription | 11 | 3.48e-01 | -1.63e-01 | 8.37e-01 |
mRNA Splicing - Minor Pathway | 51 | 4.39e-02 | 1.63e-01 | 5.01e-01 |
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | 11 | 3.50e-01 | 1.63e-01 | 8.37e-01 |
MECP2 regulates neuronal receptors and channels | 17 | 2.46e-01 | -1.63e-01 | 8.07e-01 |
GRB2 events in EGFR signaling | 13 | 3.11e-01 | 1.62e-01 | 8.23e-01 |
Antimicrobial peptides | 78 | 1.43e-02 | -1.60e-01 | 2.51e-01 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 19 | 2.27e-01 | 1.60e-01 | 7.82e-01 |
Signaling by Ligand-Responsive EGFR Variants in Cancer | 19 | 2.27e-01 | 1.60e-01 | 7.82e-01 |
TBC/RABGAPs | 42 | 7.30e-02 | 1.60e-01 | 6.28e-01 |
FGFR4 ligand binding and activation | 13 | 3.19e-01 | 1.60e-01 | 8.29e-01 |
Cell-extracellular matrix interactions | 14 | 3.01e-01 | 1.60e-01 | 8.21e-01 |
Defective B4GALT7 causes EDS, progeroid type | 17 | 2.55e-01 | 1.59e-01 | 8.14e-01 |
Interactions of Vpr with host cellular proteins | 33 | 1.13e-01 | -1.59e-01 | 7.01e-01 |
Germ layer formation at gastrulation | 16 | 2.70e-01 | -1.59e-01 | 8.19e-01 |
SUMOylation of DNA damage response and repair proteins | 71 | 2.08e-02 | -1.59e-01 | 3.21e-01 |
Myogenesis | 29 | 1.40e-01 | -1.58e-01 | 7.37e-01 |
Regulation of FZD by ubiquitination | 21 | 2.10e-01 | 1.58e-01 | 7.82e-01 |
FLT3 signaling in disease | 28 | 1.52e-01 | -1.56e-01 | 7.37e-01 |
Synthesis of substrates in N-glycan biosythesis | 60 | 3.63e-02 | 1.56e-01 | 4.41e-01 |
Activation of RAC1 | 11 | 3.73e-01 | -1.55e-01 | 8.58e-01 |
RHOU GTPase cycle | 37 | 1.03e-01 | -1.55e-01 | 6.75e-01 |
Glutamate Neurotransmitter Release Cycle | 23 | 1.98e-01 | 1.55e-01 | 7.73e-01 |
Transport of organic anions | 10 | 3.96e-01 | -1.55e-01 | 8.64e-01 |
Influenza Infection | 148 | 1.19e-03 | 1.54e-01 | 4.19e-02 |
Signaling by Leptin | 11 | 3.77e-01 | -1.54e-01 | 8.58e-01 |
SUMOylation of intracellular receptors | 29 | 1.51e-01 | -1.54e-01 | 7.37e-01 |
SARS-CoV-2 modulates autophagy | 11 | 3.77e-01 | -1.54e-01 | 8.58e-01 |
Negative regulation of FGFR3 signaling | 28 | 1.59e-01 | 1.54e-01 | 7.37e-01 |
Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 1.59e-01 | 1.54e-01 | 7.37e-01 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 74 | 2.25e-02 | 1.53e-01 | 3.42e-01 |
Mitotic Telophase/Cytokinesis | 10 | 4.02e-01 | -1.53e-01 | 8.65e-01 |
Downstream signaling of activated FGFR1 | 31 | 1.41e-01 | 1.53e-01 | 7.37e-01 |
Erythrocytes take up carbon dioxide and release oxygen | 12 | 3.61e-01 | 1.52e-01 | 8.43e-01 |
O2/CO2 exchange in erythrocytes | 12 | 3.61e-01 | 1.52e-01 | 8.43e-01 |
Incretin synthesis, secretion, and inactivation | 23 | 2.06e-01 | -1.52e-01 | 7.79e-01 |
Calnexin/calreticulin cycle | 25 | 1.88e-01 | 1.52e-01 | 7.71e-01 |
p38MAPK events | 13 | 3.42e-01 | 1.52e-01 | 8.37e-01 |
Association of TriC/CCT with target proteins during biosynthesis | 38 | 1.05e-01 | -1.52e-01 | 6.75e-01 |
Pregnenolone biosynthesis | 10 | 4.06e-01 | 1.52e-01 | 8.66e-01 |
Metabolism of Angiotensinogen to Angiotensins | 15 | 3.11e-01 | -1.51e-01 | 8.23e-01 |
RHO GTPases activate PAKs | 19 | 2.54e-01 | 1.51e-01 | 8.14e-01 |
FCERI mediated Ca+2 mobilization | 27 | 1.75e-01 | -1.51e-01 | 7.59e-01 |
Transport of Ribonucleoproteins into the Host Nucleus | 30 | 1.53e-01 | -1.51e-01 | 7.37e-01 |
Norepinephrine Neurotransmitter Release Cycle | 16 | 2.97e-01 | 1.51e-01 | 8.21e-01 |
EGFR downregulation | 30 | 1.54e-01 | 1.50e-01 | 7.37e-01 |
Folding of actin by CCT/TriC | 10 | 4.11e-01 | -1.50e-01 | 8.66e-01 |
NS1 Mediated Effects on Host Pathways | 39 | 1.05e-01 | -1.50e-01 | 6.75e-01 |
Formation of TC-NER Pre-Incision Complex | 51 | 6.50e-02 | 1.49e-01 | 6.09e-01 |
FOXO-mediated transcription of cell cycle genes | 16 | 3.01e-01 | 1.49e-01 | 8.21e-01 |
Amino acids regulate mTORC1 | 52 | 6.28e-02 | 1.49e-01 | 6.03e-01 |
G beta:gamma signalling through BTK | 17 | 2.88e-01 | -1.49e-01 | 8.21e-01 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 3.35e-01 | 1.49e-01 | 8.37e-01 |
ADP signalling through P2Y purinoceptor 12 | 22 | 2.27e-01 | -1.49e-01 | 7.82e-01 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 75 | 2.65e-02 | -1.48e-01 | 3.76e-01 |
NEP/NS2 Interacts with the Cellular Export Machinery | 30 | 1.61e-01 | -1.48e-01 | 7.37e-01 |
RNA Polymerase III Chain Elongation | 18 | 2.78e-01 | 1.48e-01 | 8.20e-01 |
Acyl chain remodelling of PG | 18 | 2.78e-01 | 1.48e-01 | 8.20e-01 |
Eicosanoids | 12 | 3.76e-01 | 1.47e-01 | 8.58e-01 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 37 | 1.21e-01 | 1.47e-01 | 7.12e-01 |
Uptake and function of anthrax toxins | 11 | 3.99e-01 | -1.47e-01 | 8.64e-01 |
SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 16 | 3.10e-01 | 1.47e-01 | 8.23e-01 |
Signaling by FGFR | 85 | 1.97e-02 | 1.46e-01 | 3.14e-01 |
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 13 | 3.61e-01 | 1.46e-01 | 8.44e-01 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 28 | 1.82e-01 | -1.46e-01 | 7.64e-01 |
Lysine catabolism | 12 | 3.83e-01 | -1.46e-01 | 8.60e-01 |
FGFRL1 modulation of FGFR1 signaling | 13 | 3.64e-01 | 1.45e-01 | 8.47e-01 |
RNA Polymerase I Transcription Termination | 27 | 1.92e-01 | 1.45e-01 | 7.71e-01 |
Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 15 | 3.33e-01 | 1.44e-01 | 8.37e-01 |
Apoptotic factor-mediated response | 17 | 3.03e-01 | -1.44e-01 | 8.21e-01 |
Signaling by SCF-KIT | 43 | 1.03e-01 | -1.44e-01 | 6.75e-01 |
p130Cas linkage to MAPK signaling for integrins | 15 | 3.35e-01 | -1.44e-01 | 8.37e-01 |
Formation of tubulin folding intermediates by CCT/TriC | 26 | 2.05e-01 | -1.43e-01 | 7.79e-01 |
CYP2E1 reactions | 11 | 4.10e-01 | -1.43e-01 | 8.66e-01 |
Intra-Golgi traffic | 43 | 1.04e-01 | -1.43e-01 | 6.75e-01 |
FGFR2 mutant receptor activation | 32 | 1.62e-01 | 1.43e-01 | 7.37e-01 |
Regulation of TP53 Activity through Association with Co-factors | 14 | 3.55e-01 | 1.43e-01 | 8.43e-01 |
Phospholipase C-mediated cascade; FGFR2 | 17 | 3.08e-01 | 1.43e-01 | 8.23e-01 |
Defective B3GAT3 causes JDSSDHD | 17 | 3.08e-01 | 1.43e-01 | 8.23e-01 |
Cytochrome c-mediated apoptotic response | 12 | 3.92e-01 | -1.43e-01 | 8.64e-01 |
Cyclin D associated events in G1 | 46 | 9.37e-02 | 1.43e-01 | 6.74e-01 |
G1 Phase | 46 | 9.37e-02 | 1.43e-01 | 6.74e-01 |
Induction of Cell-Cell Fusion | 12 | 3.92e-01 | 1.43e-01 | 8.64e-01 |
Glutamate and glutamine metabolism | 12 | 3.92e-01 | 1.43e-01 | 8.64e-01 |
Transcriptional Regulation by MECP2 | 60 | 5.70e-02 | -1.42e-01 | 5.83e-01 |
Positive epigenetic regulation of rRNA expression | 43 | 1.07e-01 | 1.42e-01 | 6.81e-01 |
Hh mutants are degraded by ERAD | 54 | 7.14e-02 | 1.42e-01 | 6.27e-01 |
Metabolism of fat-soluble vitamins | 46 | 9.61e-02 | 1.42e-01 | 6.75e-01 |
Zinc transporters | 17 | 3.12e-01 | 1.42e-01 | 8.23e-01 |
Glucocorticoid biosynthesis | 10 | 4.38e-01 | 1.42e-01 | 8.76e-01 |
DNA Damage Recognition in GG-NER | 36 | 1.41e-01 | 1.42e-01 | 7.37e-01 |
Defective GALNT12 causes CRCS1 | 18 | 2.98e-01 | 1.42e-01 | 8.21e-01 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 2.03e-01 | 1.41e-01 | 7.79e-01 |
Regulation of pyruvate dehydrogenase (PDH) complex | 14 | 3.60e-01 | 1.41e-01 | 8.43e-01 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 29 | 1.88e-01 | -1.41e-01 | 7.71e-01 |
Fertilization | 26 | 2.14e-01 | -1.41e-01 | 7.82e-01 |
CD209 (DC-SIGN) signaling | 20 | 2.77e-01 | -1.40e-01 | 8.20e-01 |
MicroRNA (miRNA) biogenesis | 26 | 2.16e-01 | 1.40e-01 | 7.82e-01 |
RNA Pol II CTD phosphorylation and interaction with CE | 26 | 2.17e-01 | 1.40e-01 | 7.82e-01 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 26 | 2.17e-01 | 1.40e-01 | 7.82e-01 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 29 | 1.92e-01 | 1.40e-01 | 7.71e-01 |
Meiotic recombination | 26 | 2.17e-01 | -1.40e-01 | 7.82e-01 |
Interleukin-20 family signaling | 24 | 2.36e-01 | -1.40e-01 | 7.98e-01 |
Downregulation of ERBB2 signaling | 28 | 2.03e-01 | 1.39e-01 | 7.79e-01 |
Butyrophilin (BTN) family interactions | 12 | 4.04e-01 | -1.39e-01 | 8.66e-01 |
Transferrin endocytosis and recycling | 30 | 1.87e-01 | 1.39e-01 | 7.71e-01 |
Laminin interactions | 23 | 2.50e-01 | 1.39e-01 | 8.09e-01 |
Vpr-mediated nuclear import of PICs | 32 | 1.75e-01 | -1.38e-01 | 7.59e-01 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 30 | 1.90e-01 | -1.38e-01 | 7.71e-01 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 30 | 1.90e-01 | -1.38e-01 | 7.71e-01 |
PI-3K cascade:FGFR1 | 21 | 2.74e-01 | 1.38e-01 | 8.20e-01 |
Serotonin Neurotransmitter Release Cycle | 16 | 3.40e-01 | 1.38e-01 | 8.37e-01 |
Depolymerisation of the Nuclear Lamina | 14 | 3.73e-01 | 1.37e-01 | 8.58e-01 |
Peroxisomal lipid metabolism | 28 | 2.09e-01 | 1.37e-01 | 7.82e-01 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 4.53e-01 | 1.37e-01 | 8.76e-01 |
Smooth Muscle Contraction | 43 | 1.20e-01 | 1.37e-01 | 7.12e-01 |
Voltage gated Potassium channels | 42 | 1.25e-01 | 1.37e-01 | 7.22e-01 |
SUMOylation of chromatin organization proteins | 54 | 8.23e-02 | -1.37e-01 | 6.48e-01 |
FOXO-mediated transcription | 65 | 5.69e-02 | 1.37e-01 | 5.83e-01 |
Transport of vitamins, nucleosides, and related molecules | 38 | 1.47e-01 | 1.36e-01 | 7.37e-01 |
LGI-ADAM interactions | 14 | 3.78e-01 | 1.36e-01 | 8.59e-01 |
Uptake and actions of bacterial toxins | 29 | 2.07e-01 | 1.35e-01 | 7.79e-01 |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | 17 | 3.34e-01 | 1.35e-01 | 8.37e-01 |
APC-Cdc20 mediated degradation of Nek2A | 26 | 2.34e-01 | 1.35e-01 | 7.96e-01 |
Pyrimidine salvage | 10 | 4.60e-01 | -1.35e-01 | 8.77e-01 |
Glycogen storage diseases | 14 | 3.83e-01 | 1.35e-01 | 8.60e-01 |
SHC-mediated cascade:FGFR1 | 21 | 2.85e-01 | 1.35e-01 | 8.21e-01 |
RHOV GTPase cycle | 36 | 1.63e-01 | -1.34e-01 | 7.37e-01 |
TP53 Regulates Transcription of DNA Repair Genes | 57 | 7.95e-02 | 1.34e-01 | 6.39e-01 |
Creation of C4 and C2 activators | 14 | 3.84e-01 | 1.34e-01 | 8.60e-01 |
SUMOylation of RNA binding proteins | 45 | 1.19e-01 | -1.34e-01 | 7.11e-01 |
Regulation of commissural axon pathfinding by SLIT and ROBO | 10 | 4.62e-01 | -1.34e-01 | 8.77e-01 |
Diseases of mitotic cell cycle | 37 | 1.59e-01 | 1.34e-01 | 7.37e-01 |
Dermatan sulfate biosynthesis | 10 | 4.64e-01 | 1.34e-01 | 8.77e-01 |
RNA Polymerase II Pre-transcription Events | 73 | 4.85e-02 | 1.33e-01 | 5.32e-01 |
Signaling by FGFR2 IIIa TM | 19 | 3.14e-01 | 1.33e-01 | 8.23e-01 |
Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function | 23 | 2.72e-01 | 1.32e-01 | 8.19e-01 |
Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function | 23 | 2.72e-01 | 1.32e-01 | 8.19e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 23 | 2.72e-01 | 1.32e-01 | 8.19e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 23 | 2.72e-01 | 1.32e-01 | 8.19e-01 |
Impaired BRCA2 binding to PALB2 | 23 | 2.72e-01 | 1.32e-01 | 8.19e-01 |
FGFR1 mutant receptor activation | 30 | 2.10e-01 | -1.32e-01 | 7.82e-01 |
FGFR1c ligand binding and activation | 11 | 4.48e-01 | 1.32e-01 | 8.76e-01 |
Signaling by activated point mutants of FGFR1 | 11 | 4.48e-01 | 1.32e-01 | 8.76e-01 |
SHC1 events in EGFR signaling | 14 | 3.93e-01 | 1.32e-01 | 8.64e-01 |
Acetylcholine binding and downstream events | 14 | 3.95e-01 | 1.31e-01 | 8.64e-01 |
Postsynaptic nicotinic acetylcholine receptors | 14 | 3.95e-01 | 1.31e-01 | 8.64e-01 |
Signaling by FGFR4 in disease | 11 | 4.52e-01 | 1.31e-01 | 8.76e-01 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 76 | 4.83e-02 | 1.31e-01 | 5.32e-01 |
RNA Polymerase I Transcription | 47 | 1.21e-01 | 1.31e-01 | 7.12e-01 |
Phenylalanine and tyrosine metabolism | 10 | 4.75e-01 | 1.31e-01 | 8.82e-01 |
G beta:gamma signalling through PLC beta | 20 | 3.13e-01 | -1.30e-01 | 8.23e-01 |
Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 2.60e-01 | 1.30e-01 | 8.19e-01 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression | 15 | 3.84e-01 | 1.30e-01 | 8.60e-01 |
Fatty acids | 15 | 3.85e-01 | 1.30e-01 | 8.60e-01 |
MASTL Facilitates Mitotic Progression | 10 | 4.78e-01 | 1.30e-01 | 8.84e-01 |
Diseases associated with the TLR signaling cascade | 29 | 2.28e-01 | -1.29e-01 | 7.82e-01 |
Diseases of Immune System | 29 | 2.28e-01 | -1.29e-01 | 7.82e-01 |
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 12 | 4.38e-01 | -1.29e-01 | 8.76e-01 |
Mitophagy | 27 | 2.46e-01 | 1.29e-01 | 8.07e-01 |
SUMOylation of DNA methylation proteins | 16 | 3.73e-01 | -1.29e-01 | 8.58e-01 |
mRNA Splicing | 184 | 2.59e-03 | 1.29e-01 | 7.41e-02 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 3.58e-01 | 1.29e-01 | 8.43e-01 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 3.58e-01 | 1.29e-01 | 8.43e-01 |
Diseases associated with O-glycosylation of proteins | 66 | 7.14e-02 | 1.28e-01 | 6.27e-01 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 1.07e-01 | 1.28e-01 | 6.81e-01 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 62 | 8.15e-02 | 1.28e-01 | 6.46e-01 |
Dopamine Neurotransmitter Release Cycle | 20 | 3.23e-01 | 1.28e-01 | 8.37e-01 |
Listeria monocytogenes entry into host cells | 19 | 3.36e-01 | 1.28e-01 | 8.37e-01 |
RHO GTPases Activate NADPH Oxidases | 22 | 3.01e-01 | -1.27e-01 | 8.21e-01 |
Eicosanoid ligand-binding receptors | 14 | 4.10e-01 | -1.27e-01 | 8.66e-01 |
B-WICH complex positively regulates rRNA expression | 29 | 2.36e-01 | 1.27e-01 | 7.98e-01 |
TP53 Regulates Transcription of Cell Cycle Genes | 49 | 1.25e-01 | 1.27e-01 | 7.22e-01 |
Maturation of spike protein 9694548 | 35 | 1.95e-01 | -1.27e-01 | 7.73e-01 |
Export of Viral Ribonucleoproteins from Nucleus | 31 | 2.23e-01 | -1.26e-01 | 7.82e-01 |
Signaling by Non-Receptor Tyrosine Kinases | 55 | 1.05e-01 | 1.26e-01 | 6.75e-01 |
Signaling by PTK6 | 55 | 1.05e-01 | 1.26e-01 | 6.75e-01 |
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 14 | 4.14e-01 | -1.26e-01 | 8.69e-01 |
Diseases of hemostasis | 14 | 4.14e-01 | -1.26e-01 | 8.69e-01 |
Regulation of KIT signaling | 16 | 3.83e-01 | -1.26e-01 | 8.60e-01 |
RNA Polymerase I Promoter Clearance | 46 | 1.40e-01 | 1.26e-01 | 7.37e-01 |
Acetylcholine regulates insulin secretion | 10 | 4.91e-01 | -1.26e-01 | 8.92e-01 |
Resolution of D-Loop Structures | 31 | 2.27e-01 | 1.25e-01 | 7.82e-01 |
FRS-mediated FGFR1 signaling | 23 | 2.98e-01 | 1.25e-01 | 8.21e-01 |
Hh mutants abrogate ligand secretion | 57 | 1.02e-01 | 1.25e-01 | 6.75e-01 |
Prolactin receptor signaling | 15 | 4.01e-01 | -1.25e-01 | 8.64e-01 |
Signaling by FGFR2 in disease | 42 | 1.62e-01 | 1.25e-01 | 7.37e-01 |
SCF(Skp2)-mediated degradation of p27/p21 | 58 | 1.00e-01 | 1.25e-01 | 6.75e-01 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 3.34e-01 | 1.25e-01 | 8.37e-01 |
Nuclear Pore Complex (NPC) Disassembly | 34 | 2.08e-01 | -1.25e-01 | 7.82e-01 |
Activated NOTCH1 Transmits Signal to the Nucleus | 31 | 2.30e-01 | 1.25e-01 | 7.85e-01 |
Constitutive Signaling by Overexpressed ERBB2 | 10 | 4.96e-01 | 1.24e-01 | 8.92e-01 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 58 | 1.02e-01 | 1.24e-01 | 6.75e-01 |
Miscellaneous transport and binding events | 21 | 3.25e-01 | -1.24e-01 | 8.37e-01 |
RHOH GTPase cycle | 36 | 1.97e-01 | -1.24e-01 | 7.73e-01 |
Plasma lipoprotein assembly, remodeling, and clearance | 73 | 6.72e-02 | 1.24e-01 | 6.17e-01 |
Signaling by FGFR2 | 72 | 6.94e-02 | 1.24e-01 | 6.23e-01 |
Carnitine metabolism | 11 | 4.79e-01 | 1.23e-01 | 8.84e-01 |
Non-integrin membrane-ECM interactions | 40 | 1.77e-01 | 1.23e-01 | 7.64e-01 |
FOXO-mediated transcription of cell death genes | 15 | 4.10e-01 | 1.23e-01 | 8.66e-01 |
Activated point mutants of FGFR2 | 16 | 3.95e-01 | 1.23e-01 | 8.64e-01 |
SARS-CoV-1 Infection | 134 | 1.45e-02 | 1.22e-01 | 2.52e-01 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 43 | 1.66e-01 | 1.22e-01 | 7.44e-01 |
Signaling by PDGFR in disease | 20 | 3.44e-01 | -1.22e-01 | 8.37e-01 |
Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 2.05e-01 | 1.22e-01 | 7.79e-01 |
Defensins | 36 | 2.06e-01 | -1.22e-01 | 7.79e-01 |
Transcriptional Regulation by E2F6 | 32 | 2.35e-01 | -1.21e-01 | 7.96e-01 |
Interleukin-37 signaling | 20 | 3.48e-01 | -1.21e-01 | 8.37e-01 |
Metabolism of amino acids and derivatives | 344 | 1.14e-04 | 1.21e-01 | 5.21e-03 |
Transcription of the HIV genome | 62 | 1.00e-01 | 1.21e-01 | 6.75e-01 |
Defective CFTR causes cystic fibrosis | 59 | 1.09e-01 | 1.21e-01 | 6.88e-01 |
Interleukin receptor SHC signaling | 24 | 3.07e-01 | -1.20e-01 | 8.23e-01 |
BBSome-mediated cargo-targeting to cilium | 23 | 3.19e-01 | -1.20e-01 | 8.29e-01 |
Defective C1GALT1C1 causes TNPS | 18 | 3.78e-01 | 1.20e-01 | 8.59e-01 |
Cleavage of the damaged pyrimidine | 16 | 4.07e-01 | -1.20e-01 | 8.66e-01 |
Depyrimidination | 16 | 4.07e-01 | -1.20e-01 | 8.66e-01 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 16 | 4.07e-01 | -1.20e-01 | 8.66e-01 |
Signaling by EGFR | 49 | 1.47e-01 | 1.20e-01 | 7.37e-01 |
Defective GALNT3 causes HFTC | 18 | 3.80e-01 | 1.20e-01 | 8.60e-01 |
RAC1 GTPase cycle | 170 | 7.14e-03 | -1.20e-01 | 1.62e-01 |
Signaling by FGFR3 | 39 | 1.98e-01 | 1.19e-01 | 7.73e-01 |
Acyl chain remodelling of PS | 21 | 3.45e-01 | 1.19e-01 | 8.37e-01 |
Epigenetic regulation of gene expression | 83 | 6.08e-02 | 1.19e-01 | 6.01e-01 |
FGFR2 alternative splicing | 26 | 2.94e-01 | 1.19e-01 | 8.21e-01 |
HS-GAG degradation | 18 | 3.83e-01 | 1.19e-01 | 8.60e-01 |
Heparan sulfate/heparin (HS-GAG) metabolism | 49 | 1.53e-01 | 1.18e-01 | 7.37e-01 |
HDL remodeling | 10 | 5.19e-01 | 1.18e-01 | 8.95e-01 |
Ketone body metabolism | 10 | 5.20e-01 | -1.18e-01 | 8.95e-01 |
ABC transporter disorders | 75 | 7.84e-02 | 1.18e-01 | 6.39e-01 |
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 10 | 5.20e-01 | 1.17e-01 | 8.95e-01 |
RHOBTB2 GTPase cycle | 22 | 3.41e-01 | -1.17e-01 | 8.37e-01 |
Vitamin B5 (pantothenate) metabolism | 16 | 4.17e-01 | -1.17e-01 | 8.71e-01 |
Hedgehog ligand biogenesis | 63 | 1.08e-01 | 1.17e-01 | 6.81e-01 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 2.84e-01 | 1.17e-01 | 8.21e-01 |
Striated Muscle Contraction | 33 | 2.46e-01 | 1.17e-01 | 8.07e-01 |
IKK complex recruitment mediated by RIP1 | 22 | 3.44e-01 | -1.17e-01 | 8.37e-01 |
mRNA Capping | 28 | 2.86e-01 | 1.16e-01 | 8.21e-01 |
Glycogen breakdown (glycogenolysis) | 11 | 5.07e-01 | 1.16e-01 | 8.93e-01 |
FLT3 Signaling | 38 | 2.20e-01 | -1.15e-01 | 7.82e-01 |
RNA Polymerase I Transcription Initiation | 42 | 1.98e-01 | 1.15e-01 | 7.73e-01 |
Apoptotic cleavage of cell adhesion proteins | 11 | 5.11e-01 | 1.14e-01 | 8.93e-01 |
Calcitonin-like ligand receptors | 10 | 5.31e-01 | -1.14e-01 | 9.03e-01 |
Peroxisomal protein import | 62 | 1.21e-01 | 1.14e-01 | 7.12e-01 |
Erythropoietin activates RAS | 14 | 4.62e-01 | 1.14e-01 | 8.77e-01 |
Complex I biogenesis | 49 | 1.72e-01 | 1.13e-01 | 7.57e-01 |
Signaling by high-kinase activity BRAF mutants | 32 | 2.70e-01 | -1.13e-01 | 8.19e-01 |
Synaptic adhesion-like molecules | 19 | 3.96e-01 | 1.13e-01 | 8.64e-01 |
Metabolism of RNA | 639 | 1.13e-06 | 1.13e-01 | 1.09e-04 |
Transport of bile salts and organic acids, metal ions and amine compounds | 84 | 7.48e-02 | 1.12e-01 | 6.28e-01 |
Signaling by ERBB2 ECD mutants | 15 | 4.51e-01 | 1.12e-01 | 8.76e-01 |
Polymerase switching on the C-strand of the telomere | 24 | 3.42e-01 | -1.12e-01 | 8.37e-01 |
Cytosolic sulfonation of small molecules | 21 | 3.75e-01 | 1.12e-01 | 8.58e-01 |
G beta:gamma signalling through PI3Kgamma | 25 | 3.33e-01 | -1.12e-01 | 8.37e-01 |
CREB1 phosphorylation through the activation of Adenylate Cyclase | 11 | 5.21e-01 | -1.12e-01 | 8.96e-01 |
Lysosome Vesicle Biogenesis | 33 | 2.67e-01 | 1.12e-01 | 8.19e-01 |
G beta:gamma signalling through CDC42 | 19 | 4.01e-01 | -1.11e-01 | 8.64e-01 |
mRNA Splicing - Major Pathway | 174 | 1.13e-02 | 1.11e-01 | 2.29e-01 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 34 | 2.62e-01 | 1.11e-01 | 8.19e-01 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 30 | 2.92e-01 | 1.11e-01 | 8.21e-01 |
Diseases of glycosylation | 137 | 2.47e-02 | 1.11e-01 | 3.68e-01 |
Transport of Mature mRNA Derived from an Intronless Transcript | 40 | 2.25e-01 | -1.11e-01 | 7.82e-01 |
Late endosomal microautophagy | 32 | 2.80e-01 | 1.10e-01 | 8.20e-01 |
Surfactant metabolism | 28 | 3.13e-01 | 1.10e-01 | 8.23e-01 |
Dual incision in TC-NER | 63 | 1.30e-01 | 1.10e-01 | 7.28e-01 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 41 | 2.22e-01 | -1.10e-01 | 7.82e-01 |
Condensation of Prophase Chromosomes | 12 | 5.09e-01 | -1.10e-01 | 8.93e-01 |
FCERI mediated MAPK activation | 29 | 3.05e-01 | -1.10e-01 | 8.23e-01 |
InlB-mediated entry of Listeria monocytogenes into host cell | 14 | 4.76e-01 | 1.10e-01 | 8.83e-01 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 11 | 5.28e-01 | -1.10e-01 | 9.00e-01 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 16 | 4.47e-01 | 1.10e-01 | 8.76e-01 |
TP53 Regulates Metabolic Genes | 83 | 8.43e-02 | 1.10e-01 | 6.52e-01 |
Regulation of Complement cascade | 45 | 2.03e-01 | -1.10e-01 | 7.79e-01 |
Synthesis of bile acids and bile salts | 34 | 2.69e-01 | -1.10e-01 | 8.19e-01 |
Signaling by NTRK3 (TRKC) | 17 | 4.36e-01 | 1.09e-01 | 8.76e-01 |
ROS and RNS production in phagocytes | 35 | 2.64e-01 | 1.09e-01 | 8.19e-01 |
G alpha (i) signalling events | 305 | 1.04e-03 | -1.09e-01 | 3.92e-02 |
SUMOylation of SUMOylation proteins | 33 | 2.79e-01 | -1.09e-01 | 8.20e-01 |
Presynaptic depolarization and calcium channel opening | 12 | 5.13e-01 | 1.09e-01 | 8.94e-01 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 4.52e-01 | 1.09e-01 | 8.76e-01 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 95 | 6.75e-02 | 1.09e-01 | 6.17e-01 |
Phase 0 - rapid depolarisation | 31 | 2.96e-01 | 1.08e-01 | 8.21e-01 |
Cell surface interactions at the vascular wall | 127 | 3.48e-02 | -1.08e-01 | 4.38e-01 |
RHOBTB1 GTPase cycle | 22 | 3.80e-01 | -1.08e-01 | 8.60e-01 |
Mitochondrial iron-sulfur cluster biogenesis | 12 | 5.18e-01 | 1.08e-01 | 8.95e-01 |
O-glycosylation of TSR domain-containing proteins | 37 | 2.57e-01 | 1.08e-01 | 8.17e-01 |
Vitamin D (calciferol) metabolism | 12 | 5.19e-01 | -1.08e-01 | 8.95e-01 |
Processing of Capped Intron-Containing Pre-mRNA | 232 | 4.76e-03 | 1.07e-01 | 1.21e-01 |
Heme signaling | 45 | 2.12e-01 | -1.07e-01 | 7.82e-01 |
Metabolism of polyamines | 55 | 1.69e-01 | 1.07e-01 | 7.53e-01 |
Diseases of carbohydrate metabolism | 30 | 3.11e-01 | 1.07e-01 | 8.23e-01 |
Cobalamin (Cbl, vitamin B12) transport and metabolism | 20 | 4.09e-01 | 1.07e-01 | 8.66e-01 |
IL-6-type cytokine receptor ligand interactions | 17 | 4.47e-01 | 1.07e-01 | 8.76e-01 |
Transport of the SLBP independent Mature mRNA | 33 | 2.91e-01 | -1.06e-01 | 8.21e-01 |
RHOG GTPase cycle | 69 | 1.28e-01 | -1.06e-01 | 7.28e-01 |
Nitric oxide stimulates guanylate cyclase | 22 | 3.91e-01 | -1.06e-01 | 8.64e-01 |
Ovarian tumor domain proteases | 36 | 2.73e-01 | -1.06e-01 | 8.20e-01 |
Cytosolic sensors of pathogen-associated DNA | 60 | 1.57e-01 | 1.06e-01 | 7.37e-01 |
ABC transporters in lipid homeostasis | 17 | 4.58e-01 | 1.04e-01 | 8.76e-01 |
Defective B3GALTL causes PpS | 36 | 2.80e-01 | 1.04e-01 | 8.20e-01 |
The citric acid (TCA) cycle and respiratory electron transport | 143 | 3.19e-02 | 1.04e-01 | 4.21e-01 |
Ubiquitin-dependent degradation of Cyclin D | 50 | 2.05e-01 | 1.04e-01 | 7.79e-01 |
Attachment and Entry 9694614 | 16 | 4.74e-01 | 1.03e-01 | 8.81e-01 |
RNA Polymerase II Transcription Termination | 62 | 1.59e-01 | 1.03e-01 | 7.37e-01 |
Plasma lipoprotein clearance | 37 | 2.78e-01 | 1.03e-01 | 8.20e-01 |
Phosphorylation of the APC/C | 20 | 4.26e-01 | 1.03e-01 | 8.76e-01 |
Autodegradation of Cdh1 by Cdh1:APC/C | 62 | 1.62e-01 | 1.03e-01 | 7.37e-01 |
SCF-beta-TrCP mediated degradation of Emi1 | 53 | 1.96e-01 | 1.03e-01 | 7.73e-01 |
Adherens junctions interactions | 26 | 3.67e-01 | -1.02e-01 | 8.48e-01 |
VEGFR2 mediated cell proliferation | 19 | 4.42e-01 | 1.02e-01 | 8.76e-01 |
Macroautophagy | 111 | 6.38e-02 | 1.02e-01 | 6.05e-01 |
RUNX3 regulates p14-ARF | 10 | 5.78e-01 | -1.02e-01 | 9.23e-01 |
Regulation of ornithine decarboxylase (ODC) | 49 | 2.18e-01 | 1.02e-01 | 7.82e-01 |
CRMPs in Sema3A signaling | 15 | 4.96e-01 | 1.02e-01 | 8.92e-01 |
Oxidative Stress Induced Senescence | 66 | 1.54e-01 | -1.01e-01 | 7.37e-01 |
Binding and Uptake of Ligands by Scavenger Receptors | 41 | 2.62e-01 | -1.01e-01 | 8.19e-01 |
Deactivation of the beta-catenin transactivating complex | 39 | 2.77e-01 | 1.01e-01 | 8.20e-01 |
Reproduction | 82 | 1.16e-01 | -1.00e-01 | 7.06e-01 |
Glutathione synthesis and recycling | 12 | 5.49e-01 | 1.00e-01 | 9.14e-01 |
Respiratory electron transport | 90 | 1.01e-01 | 9.99e-02 | 6.75e-01 |
Dectin-1 mediated noncanonical NF-kB signaling | 60 | 1.81e-01 | 9.99e-02 | 7.64e-01 |
Signaling by NOTCH2 | 32 | 3.30e-01 | 9.95e-02 | 8.37e-01 |
Muscle contraction | 193 | 1.72e-02 | 9.94e-02 | 2.91e-01 |
Signaling by MET | 66 | 1.62e-01 | 9.94e-02 | 7.37e-01 |
Interferon alpha/beta signaling | 69 | 1.54e-01 | -9.93e-02 | 7.37e-01 |
Telomere C-strand (Lagging Strand) Synthesis | 32 | 3.31e-01 | -9.92e-02 | 8.37e-01 |
Keratinization | 213 | 1.27e-02 | -9.90e-02 | 2.38e-01 |
Other semaphorin interactions | 18 | 4.68e-01 | -9.88e-02 | 8.80e-01 |
The role of Nef in HIV-1 replication and disease pathogenesis | 27 | 3.76e-01 | 9.85e-02 | 8.58e-01 |
NCAM signaling for neurite out-growth | 57 | 1.98e-01 | 9.85e-02 | 7.73e-01 |
LDL clearance | 19 | 4.58e-01 | 9.84e-02 | 8.76e-01 |
Negative regulation of NOTCH4 signaling | 52 | 2.21e-01 | 9.81e-02 | 7.82e-01 |
Gluconeogenesis | 32 | 3.38e-01 | 9.79e-02 | 8.37e-01 |
MET promotes cell motility | 29 | 3.64e-01 | 9.75e-02 | 8.47e-01 |
PIWI-interacting RNA (piRNA) biogenesis | 29 | 3.66e-01 | 9.69e-02 | 8.48e-01 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 54 | 2.19e-01 | 9.66e-02 | 7.82e-01 |
Autophagy | 125 | 6.25e-02 | 9.64e-02 | 6.03e-01 |
Negative epigenetic regulation of rRNA expression | 45 | 2.65e-01 | 9.61e-02 | 8.19e-01 |
p53-Dependent G1 DNA Damage Response | 64 | 1.85e-01 | 9.58e-02 | 7.67e-01 |
p53-Dependent G1/S DNA damage checkpoint | 64 | 1.85e-01 | 9.58e-02 | 7.67e-01 |
FCGR activation | 12 | 5.66e-01 | -9.57e-02 | 9.18e-01 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 38 | 3.07e-01 | -9.57e-02 | 8.23e-01 |
Xenobiotics | 24 | 4.17e-01 | -9.57e-02 | 8.71e-01 |
Iron uptake and transport | 57 | 2.12e-01 | 9.55e-02 | 7.82e-01 |
Pyroptosis | 26 | 4.00e-01 | -9.54e-02 | 8.64e-01 |
Nucleotide Excision Repair | 107 | 8.86e-02 | 9.53e-02 | 6.68e-01 |
APC/C:Cdc20 mediated degradation of Securin | 66 | 1.81e-01 | 9.51e-02 | 7.64e-01 |
HS-GAG biosynthesis | 28 | 3.87e-01 | 9.45e-02 | 8.61e-01 |
Fanconi Anemia Pathway | 36 | 3.27e-01 | 9.45e-02 | 8.37e-01 |
Nuclear Envelope Breakdown | 50 | 2.48e-01 | -9.44e-02 | 8.07e-01 |
CDK-mediated phosphorylation and removal of Cdc6 | 71 | 1.69e-01 | 9.44e-02 | 7.53e-01 |
Regulation of TP53 Degradation | 36 | 3.27e-01 | 9.43e-02 | 8.37e-01 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 41 | 2.97e-01 | -9.41e-02 | 8.21e-01 |
VxPx cargo-targeting to cilium | 20 | 4.67e-01 | 9.40e-02 | 8.79e-01 |
Interleukin-6 signaling | 11 | 5.89e-01 | -9.40e-02 | 9.27e-01 |
HIV Life Cycle | 139 | 5.56e-02 | 9.40e-02 | 5.83e-01 |
Negative regulation of FLT3 | 15 | 5.29e-01 | -9.39e-02 | 9.00e-01 |
Signaling by NOTCH3 | 48 | 2.62e-01 | 9.35e-02 | 8.19e-01 |
AKT phosphorylates targets in the cytosol | 14 | 5.45e-01 | 9.33e-02 | 9.11e-01 |
Rev-mediated nuclear export of HIV RNA | 33 | 3.54e-01 | -9.33e-02 | 8.43e-01 |
Diseases of metabolism | 234 | 1.39e-02 | 9.33e-02 | 2.47e-01 |
Complement cascade | 56 | 2.29e-01 | -9.30e-02 | 7.82e-01 |
Phospholipase C-mediated cascade; FGFR3 | 12 | 5.77e-01 | 9.29e-02 | 9.23e-01 |
Presynaptic function of Kainate receptors | 21 | 4.62e-01 | -9.26e-02 | 8.77e-01 |
MET activates PTK2 signaling | 18 | 4.97e-01 | 9.25e-02 | 8.92e-01 |
Formation of apoptosome | 10 | 6.13e-01 | -9.25e-02 | 9.28e-01 |
Regulation of the apoptosome activity | 10 | 6.13e-01 | -9.25e-02 | 9.28e-01 |
NoRC negatively regulates rRNA expression | 43 | 2.94e-01 | 9.25e-02 | 8.21e-01 |
Senescence-Associated Secretory Phenotype (SASP) | 53 | 2.44e-01 | 9.25e-02 | 8.07e-01 |
HDR through Homologous Recombination (HRR) | 64 | 2.01e-01 | 9.24e-02 | 7.77e-01 |
Advanced glycosylation endproduct receptor signaling | 13 | 5.64e-01 | 9.23e-02 | 9.18e-01 |
p75 NTR receptor-mediated signalling | 89 | 1.32e-01 | 9.23e-02 | 7.28e-01 |
PI-3K cascade:FGFR4 | 19 | 4.86e-01 | 9.23e-02 | 8.92e-01 |
Signaling by FGFR1 in disease | 37 | 3.32e-01 | -9.22e-02 | 8.37e-01 |
Adrenaline,noradrenaline inhibits insulin secretion | 28 | 4.00e-01 | 9.20e-02 | 8.64e-01 |
Initiation of Nuclear Envelope (NE) Reformation | 18 | 5.00e-01 | 9.17e-02 | 8.92e-01 |
RAC2 GTPase cycle | 80 | 1.56e-01 | -9.17e-02 | 7.37e-01 |
Cyclin A:Cdk2-associated events at S phase entry | 83 | 1.49e-01 | 9.15e-02 | 7.37e-01 |
Negative regulation of activity of TFAP2 (AP-2) family transcription factors | 10 | 6.17e-01 | 9.13e-02 | 9.28e-01 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | 21 | 4.70e-01 | 9.11e-02 | 8.80e-01 |
Nucleotide biosynthesis | 14 | 5.55e-01 | 9.10e-02 | 9.18e-01 |
Signaling by NOTCH4 | 79 | 1.62e-01 | 9.09e-02 | 7.37e-01 |
Metabolism of non-coding RNA | 50 | 2.66e-01 | -9.08e-02 | 8.19e-01 |
snRNP Assembly | 50 | 2.66e-01 | -9.08e-02 | 8.19e-01 |
Inhibition of DNA recombination at telomere | 20 | 4.82e-01 | 9.08e-02 | 8.87e-01 |
Autodegradation of the E3 ubiquitin ligase COP1 | 50 | 2.68e-01 | 9.06e-02 | 8.19e-01 |
Cyclin E associated events during G1/S transition | 81 | 1.61e-01 | 9.00e-02 | 7.37e-01 |
Activation of gene expression by SREBF (SREBP) | 42 | 3.13e-01 | 9.00e-02 | 8.23e-01 |
EPH-ephrin mediated repulsion of cells | 48 | 2.82e-01 | 8.98e-02 | 8.20e-01 |
Translesion Synthesis by POLH | 19 | 5.00e-01 | 8.94e-02 | 8.92e-01 |
Sensory processing of sound by inner hair cells of the cochlea | 62 | 2.23e-01 | 8.94e-02 | 7.82e-01 |
Nuclear events stimulated by ALK signaling in cancer | 18 | 5.12e-01 | -8.93e-02 | 8.94e-01 |
Adenylate cyclase activating pathway | 10 | 6.25e-01 | 8.92e-02 | 9.29e-01 |
Interleukin-10 signaling | 45 | 3.01e-01 | -8.92e-02 | 8.21e-01 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 87 | 1.51e-01 | 8.91e-02 | 7.37e-01 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 71 | 1.94e-01 | 8.91e-02 | 7.73e-01 |
Passive transport by Aquaporins | 13 | 5.78e-01 | 8.91e-02 | 9.23e-01 |
Activation of BH3-only proteins | 30 | 3.99e-01 | 8.90e-02 | 8.64e-01 |
SHC-mediated cascade:FGFR4 | 19 | 5.04e-01 | 8.86e-02 | 8.93e-01 |
Potassium Channels | 102 | 1.23e-01 | 8.83e-02 | 7.20e-01 |
Post-chaperonin tubulin folding pathway | 23 | 4.64e-01 | -8.81e-02 | 8.77e-01 |
RHO GTPases activate KTN1 | 11 | 6.14e-01 | 8.79e-02 | 9.28e-01 |
Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 4.97e-01 | 8.77e-02 | 8.92e-01 |
ADP signalling through P2Y purinoceptor 1 | 25 | 4.48e-01 | -8.77e-02 | 8.76e-01 |
Unfolded Protein Response (UPR) | 90 | 1.51e-01 | 8.76e-02 | 7.37e-01 |
HDACs deacetylate histones | 29 | 4.15e-01 | 8.75e-02 | 8.70e-01 |
Post-translational protein phosphorylation | 100 | 1.31e-01 | -8.73e-02 | 7.28e-01 |
Metabolism of nucleotides | 95 | 1.43e-01 | 8.70e-02 | 7.37e-01 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 2.79e-01 | 8.68e-02 | 8.20e-01 |
Unblocking of NMDA receptors, glutamate binding and activation | 19 | 5.13e-01 | -8.66e-02 | 8.94e-01 |
Scavenging by Class A Receptors | 19 | 5.14e-01 | -8.65e-02 | 8.94e-01 |
Downstream signaling of activated FGFR4 | 26 | 4.45e-01 | 8.65e-02 | 8.76e-01 |
PD-1 signaling | 21 | 4.93e-01 | 8.64e-02 | 8.92e-01 |
Vpu mediated degradation of CD4 | 50 | 2.91e-01 | 8.64e-02 | 8.21e-01 |
Glycerophospholipid biosynthesis | 114 | 1.11e-01 | 8.63e-02 | 6.96e-01 |
Transport of the SLBP Dependant Mature mRNA | 34 | 3.84e-01 | -8.62e-02 | 8.60e-01 |
Nuclear import of Rev protein | 32 | 3.99e-01 | -8.62e-02 | 8.64e-01 |
Signaling by ERBB2 | 49 | 2.98e-01 | 8.60e-02 | 8.21e-01 |
Constitutive Signaling by AKT1 E17K in Cancer | 25 | 4.57e-01 | 8.59e-02 | 8.76e-01 |
Activation of BAD and translocation to mitochondria | 15 | 5.65e-01 | 8.59e-02 | 9.18e-01 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 72 | 2.08e-01 | 8.59e-02 | 7.81e-01 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 3.60e-01 | 8.58e-02 | 8.43e-01 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 20 | 5.06e-01 | -8.58e-02 | 8.93e-01 |
Homology Directed Repair | 99 | 1.40e-01 | 8.58e-02 | 7.37e-01 |
CS/DS degradation | 12 | 6.08e-01 | 8.54e-02 | 9.28e-01 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 49 | 3.01e-01 | 8.53e-02 | 8.21e-01 |
Axon guidance | 503 | 1.07e-03 | 8.51e-02 | 3.94e-02 |
RNA Polymerase I Promoter Escape | 28 | 4.36e-01 | 8.50e-02 | 8.76e-01 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 12 | 6.11e-01 | 8.47e-02 | 9.28e-01 |
Defective EXT2 causes exostoses 2 | 12 | 6.11e-01 | 8.47e-02 | 9.28e-01 |
Nervous system development | 527 | 8.64e-04 | 8.47e-02 | 3.34e-02 |
Aspartate and asparagine metabolism | 11 | 6.29e-01 | -8.41e-02 | 9.29e-01 |
Chaperone Mediated Autophagy | 19 | 5.26e-01 | 8.41e-02 | 8.99e-01 |
G1/S DNA Damage Checkpoints | 66 | 2.37e-01 | 8.41e-02 | 7.98e-01 |
Sodium/Calcium exchangers | 11 | 6.30e-01 | -8.38e-02 | 9.30e-01 |
PINK1-PRKN Mediated Mitophagy | 21 | 5.07e-01 | 8.36e-02 | 8.93e-01 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 74 | 2.14e-01 | 8.35e-02 | 7.82e-01 |
Phase I - Functionalization of compounds | 100 | 1.50e-01 | 8.32e-02 | 7.37e-01 |
Endosomal/Vacuolar pathway | 12 | 6.18e-01 | 8.31e-02 | 9.28e-01 |
Insulin processing | 26 | 4.63e-01 | -8.31e-02 | 8.77e-01 |
Frs2-mediated activation | 12 | 6.19e-01 | 8.30e-02 | 9.28e-01 |
Metabolism of porphyrins | 27 | 4.55e-01 | -8.30e-02 | 8.76e-01 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 13 | 6.04e-01 | 8.30e-02 | 9.28e-01 |
DNA Double-Strand Break Repair | 129 | 1.04e-01 | 8.30e-02 | 6.75e-01 |
FRS-mediated FGFR4 signaling | 21 | 5.11e-01 | 8.29e-02 | 8.93e-01 |
G0 and Early G1 | 27 | 4.56e-01 | 8.29e-02 | 8.76e-01 |
Translocation of ZAP-70 to Immunological synapse | 17 | 5.55e-01 | 8.26e-02 | 9.18e-01 |
HIV Transcription Initiation | 43 | 3.50e-01 | 8.24e-02 | 8.37e-01 |
RNA Polymerase II HIV Promoter Escape | 43 | 3.50e-01 | 8.24e-02 | 8.37e-01 |
RNA Polymerase II Promoter Escape | 43 | 3.50e-01 | 8.24e-02 | 8.37e-01 |
RNA Polymerase II Transcription Initiation | 43 | 3.50e-01 | 8.24e-02 | 8.37e-01 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 43 | 3.50e-01 | 8.24e-02 | 8.37e-01 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 43 | 3.50e-01 | 8.24e-02 | 8.37e-01 |
Endogenous sterols | 26 | 4.70e-01 | 8.19e-02 | 8.80e-01 |
G-protein beta:gamma signalling | 30 | 4.37e-01 | -8.19e-02 | 8.76e-01 |
Chondroitin sulfate/dermatan sulfate metabolism | 45 | 3.43e-01 | 8.17e-02 | 8.37e-01 |
Meiosis | 56 | 2.91e-01 | -8.16e-02 | 8.21e-01 |
Suppression of phagosomal maturation | 13 | 6.11e-01 | 8.15e-02 | 9.28e-01 |
Beta defensins | 28 | 4.56e-01 | -8.14e-02 | 8.76e-01 |
TICAM1-dependent activation of IRF3/IRF7 | 12 | 6.26e-01 | 8.13e-02 | 9.29e-01 |
G-protein activation | 24 | 4.91e-01 | -8.13e-02 | 8.92e-01 |
Potential therapeutics for SARS | 92 | 1.78e-01 | 8.13e-02 | 7.64e-01 |
NIK–>noncanonical NF-kB signaling | 57 | 2.89e-01 | 8.11e-02 | 8.21e-01 |
Regulation of TNFR1 signaling | 37 | 3.94e-01 | 8.10e-02 | 8.64e-01 |
PECAM1 interactions | 12 | 6.28e-01 | -8.09e-02 | 9.29e-01 |
TNF signaling | 45 | 3.48e-01 | 8.08e-02 | 8.37e-01 |
Regulation of APC/C activators between G1/S and early anaphase | 79 | 2.14e-01 | 8.08e-02 | 7.82e-01 |
Cardiac conduction | 123 | 1.22e-01 | 8.08e-02 | 7.12e-01 |
Late Phase of HIV Life Cycle | 126 | 1.17e-01 | 8.08e-02 | 7.06e-01 |
Nicotinamide salvaging | 17 | 5.66e-01 | 8.05e-02 | 9.18e-01 |
Neutrophil degranulation | 458 | 3.20e-03 | -8.02e-02 | 8.38e-02 |
Activation of the phototransduction cascade | 11 | 6.46e-01 | 8.01e-02 | 9.42e-01 |
Thromboxane signalling through TP receptor | 24 | 4.97e-01 | -8.00e-02 | 8.92e-01 |
RNA polymerase II transcribes snRNA genes | 77 | 2.25e-01 | 8.00e-02 | 7.82e-01 |
Integration of energy metabolism | 106 | 1.55e-01 | 7.99e-02 | 7.37e-01 |
Semaphorin interactions | 61 | 2.81e-01 | 7.98e-02 | 8.20e-01 |
Synthesis, secretion, and deacylation of Ghrelin | 19 | 5.47e-01 | 7.98e-02 | 9.12e-01 |
Cell death signalling via NRAGE, NRIF and NADE | 69 | 2.53e-01 | 7.96e-02 | 8.14e-01 |
Presynaptic nicotinic acetylcholine receptors | 12 | 6.33e-01 | 7.96e-02 | 9.31e-01 |
Regulation of TP53 Expression and Degradation | 37 | 4.03e-01 | 7.94e-02 | 8.66e-01 |
Acetylcholine Neurotransmitter Release Cycle | 16 | 5.83e-01 | 7.93e-02 | 9.25e-01 |
Glycogen metabolism | 22 | 5.20e-01 | 7.93e-02 | 8.95e-01 |
Processing of Capped Intronless Pre-mRNA | 28 | 4.69e-01 | 7.91e-02 | 8.80e-01 |
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 24 | 5.02e-01 | -7.91e-02 | 8.92e-01 |
Visual phototransduction | 93 | 1.88e-01 | 7.90e-02 | 7.71e-01 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 3.45e-01 | 7.88e-02 | 8.37e-01 |
Homologous DNA Pairing and Strand Exchange | 41 | 3.84e-01 | 7.86e-02 | 8.60e-01 |
Crosslinking of collagen fibrils | 10 | 6.67e-01 | 7.86e-02 | 9.50e-01 |
Protein methylation | 16 | 5.90e-01 | -7.79e-02 | 9.27e-01 |
Organic cation/anion/zwitterion transport | 15 | 6.04e-01 | 7.74e-02 | 9.28e-01 |
Signaling by Activin | 15 | 6.04e-01 | 7.74e-02 | 9.28e-01 |
Mucopolysaccharidoses | 10 | 6.72e-01 | 7.73e-02 | 9.51e-01 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 29 | 4.72e-01 | 7.72e-02 | 8.80e-01 |
Trafficking of AMPA receptors | 29 | 4.72e-01 | 7.72e-02 | 8.80e-01 |
mRNA 3’-end processing | 53 | 3.31e-01 | 7.71e-02 | 8.37e-01 |
Interleukin-7 signaling | 21 | 5.41e-01 | -7.71e-02 | 9.11e-01 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 16 | 5.93e-01 | 7.71e-02 | 9.28e-01 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 5.44e-01 | 7.65e-02 | 9.11e-01 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 5.44e-01 | 7.65e-02 | 9.11e-01 |
Activation of NF-kappaB in B cells | 64 | 2.91e-01 | 7.63e-02 | 8.21e-01 |
Adenylate cyclase inhibitory pathway | 14 | 6.21e-01 | 7.63e-02 | 9.28e-01 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 2.55e-01 | 7.60e-02 | 8.14e-01 |
PKMTs methylate histone lysines | 37 | 4.25e-01 | -7.58e-02 | 8.76e-01 |
FGFR2c ligand binding and activation | 12 | 6.50e-01 | 7.57e-02 | 9.43e-01 |
Azathioprine ADME | 22 | 5.40e-01 | 7.55e-02 | 9.11e-01 |
Intraflagellar transport | 36 | 4.33e-01 | -7.55e-02 | 8.76e-01 |
Keratan sulfate/keratin metabolism | 33 | 4.54e-01 | -7.53e-02 | 8.76e-01 |
RHOBTB GTPase Cycle | 34 | 4.48e-01 | -7.51e-02 | 8.76e-01 |
Mitochondrial protein import | 54 | 3.40e-01 | -7.51e-02 | 8.37e-01 |
HIV Infection | 216 | 5.74e-02 | 7.50e-02 | 5.83e-01 |
PI-3K cascade:FGFR2 | 22 | 5.44e-01 | 7.47e-02 | 9.11e-01 |
EPHA-mediated growth cone collapse | 15 | 6.17e-01 | 7.45e-02 | 9.28e-01 |
Peptide hormone biosynthesis | 11 | 6.70e-01 | 7.43e-02 | 9.50e-01 |
Drug ADME | 104 | 1.92e-01 | -7.41e-02 | 7.71e-01 |
PTEN Regulation | 150 | 1.17e-01 | 7.40e-02 | 7.06e-01 |
Regulation of BACH1 activity | 15 | 6.20e-01 | 7.39e-02 | 9.28e-01 |
Downstream signaling of activated FGFR2 | 29 | 4.92e-01 | 7.37e-02 | 8.92e-01 |
SUMOylation of transcription factors | 20 | 5.69e-01 | 7.35e-02 | 9.18e-01 |
Signalling to RAS | 20 | 5.70e-01 | 7.34e-02 | 9.18e-01 |
Molecules associated with elastic fibres | 29 | 4.94e-01 | 7.34e-02 | 8.92e-01 |
Base-Excision Repair, AP Site Formation | 18 | 5.90e-01 | -7.34e-02 | 9.27e-01 |
RHOJ GTPase cycle | 51 | 3.65e-01 | -7.33e-02 | 8.48e-01 |
FCGR3A-mediated IL10 synthesis | 37 | 4.40e-01 | -7.33e-02 | 8.76e-01 |
Transcriptional Regulation by TP53 | 346 | 1.91e-02 | 7.32e-02 | 3.10e-01 |
Regulation of insulin secretion | 77 | 2.67e-01 | 7.32e-02 | 8.19e-01 |
Activation of SMO | 17 | 6.03e-01 | -7.29e-02 | 9.28e-01 |
Killing mechanisms | 11 | 6.75e-01 | -7.29e-02 | 9.51e-01 |
WNT5:FZD7-mediated leishmania damping | 11 | 6.75e-01 | -7.29e-02 | 9.51e-01 |
Regulation of RUNX3 expression and activity | 53 | 3.59e-01 | 7.28e-02 | 8.43e-01 |
Downstream signaling events of B Cell Receptor (BCR) | 78 | 2.68e-01 | 7.26e-02 | 8.19e-01 |
Assembly of the ORC complex at the origin of replication | 10 | 6.91e-01 | -7.25e-02 | 9.56e-01 |
Regulation of TP53 Activity through Phosphorylation | 88 | 2.40e-01 | 7.25e-02 | 8.03e-01 |
Sensory processing of sound | 69 | 3.00e-01 | 7.21e-02 | 8.21e-01 |
Metabolic disorders of biological oxidation enzymes | 32 | 4.81e-01 | 7.20e-02 | 8.86e-01 |
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | 12 | 6.66e-01 | 7.20e-02 | 9.49e-01 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 72 | 2.92e-01 | 7.18e-02 | 8.21e-01 |
Resolution of Abasic Sites (AP sites) | 37 | 4.50e-01 | 7.17e-02 | 8.76e-01 |
Telomere Extension By Telomerase | 22 | 5.60e-01 | -7.17e-02 | 9.18e-01 |
Interactions of Rev with host cellular proteins | 35 | 4.63e-01 | -7.17e-02 | 8.77e-01 |
SHC-mediated cascade:FGFR2 | 22 | 5.61e-01 | 7.16e-02 | 9.18e-01 |
Processive synthesis on the C-strand of the telomere | 19 | 5.90e-01 | -7.13e-02 | 9.27e-01 |
CDC42 GTPase cycle | 143 | 1.41e-01 | -7.12e-02 | 7.37e-01 |
RORA activates gene expression | 17 | 6.13e-01 | -7.09e-02 | 9.28e-01 |
FGFR2 ligand binding and activation | 19 | 5.93e-01 | 7.09e-02 | 9.28e-01 |
Interleukin-1 signaling | 109 | 2.03e-01 | 7.06e-02 | 7.79e-01 |
MyD88 cascade initiated on plasma membrane | 91 | 2.45e-01 | 7.04e-02 | 8.07e-01 |
Toll Like Receptor 10 (TLR10) Cascade | 91 | 2.45e-01 | 7.04e-02 | 8.07e-01 |
Toll Like Receptor 5 (TLR5) Cascade | 91 | 2.45e-01 | 7.04e-02 | 8.07e-01 |
Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 39 | 4.47e-01 | 7.04e-02 | 8.76e-01 |
Diseases of DNA Double-Strand Break Repair | 39 | 4.47e-01 | 7.04e-02 | 8.76e-01 |
Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 14 | 6.48e-01 | -7.04e-02 | 9.42e-01 |
Dectin-2 family | 28 | 5.20e-01 | -7.03e-02 | 8.95e-01 |
RHO GTPases activate IQGAPs | 11 | 6.88e-01 | 7.00e-02 | 9.56e-01 |
PLC beta mediated events | 47 | 4.07e-01 | -6.99e-02 | 8.66e-01 |
RIP-mediated NFkB activation via ZBP1 | 16 | 6.29e-01 | 6.97e-02 | 9.29e-01 |
GPCR ligand binding | 443 | 1.19e-02 | -6.96e-02 | 2.30e-01 |
Cargo recognition for clathrin-mediated endocytosis | 98 | 2.34e-01 | 6.95e-02 | 7.96e-01 |
Glycogen synthesis | 13 | 6.65e-01 | 6.94e-02 | 9.49e-01 |
Ca-dependent events | 35 | 4.79e-01 | -6.92e-02 | 8.84e-01 |
Thrombin signalling through proteinase activated receptors (PARs) | 32 | 4.99e-01 | -6.90e-02 | 8.92e-01 |
RNA Polymerase III Abortive And Retractive Initiation | 41 | 4.44e-01 | 6.90e-02 | 8.76e-01 |
RNA Polymerase III Transcription | 41 | 4.44e-01 | 6.90e-02 | 8.76e-01 |
GABA synthesis, release, reuptake and degradation | 19 | 6.03e-01 | 6.89e-02 | 9.28e-01 |
CLEC7A (Dectin-1) induces NFAT activation | 11 | 6.93e-01 | -6.87e-02 | 9.56e-01 |
Diseases of programmed cell death | 43 | 4.36e-01 | -6.87e-02 | 8.76e-01 |
Basigin interactions | 24 | 5.62e-01 | 6.84e-02 | 9.18e-01 |
Regulation of RAS by GAPs | 65 | 3.42e-01 | 6.81e-02 | 8.37e-01 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 37 | 4.74e-01 | -6.81e-02 | 8.81e-01 |
Signal amplification | 33 | 4.99e-01 | -6.80e-02 | 8.92e-01 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 12 | 6.83e-01 | -6.80e-02 | 9.54e-01 |
FRS-mediated FGFR2 signaling | 24 | 5.64e-01 | 6.80e-02 | 9.18e-01 |
Global Genome Nucleotide Excision Repair (GG-NER) | 81 | 2.90e-01 | 6.79e-02 | 8.21e-01 |
Regulation of TP53 Activity through Acetylation | 29 | 5.28e-01 | 6.77e-02 | 9.00e-01 |
Gap junction trafficking | 27 | 5.43e-01 | -6.76e-02 | 9.11e-01 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 93 | 2.61e-01 | 6.75e-02 | 8.19e-01 |
Signalling to ERKs | 34 | 4.97e-01 | 6.73e-02 | 8.92e-01 |
CLEC7A (Dectin-1) signaling | 96 | 2.55e-01 | 6.71e-02 | 8.14e-01 |
Prostacyclin signalling through prostacyclin receptor | 19 | 6.13e-01 | -6.71e-02 | 9.28e-01 |
Activation of the TFAP2 (AP-2) family of transcription factors | 11 | 7.01e-01 | -6.70e-02 | 9.59e-01 |
Ethanol oxidation | 12 | 6.89e-01 | 6.68e-02 | 9.56e-01 |
Regulation of PTEN gene transcription | 59 | 3.76e-01 | 6.67e-02 | 8.58e-01 |
Deadenylation of mRNA | 25 | 5.64e-01 | -6.67e-02 | 9.18e-01 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 51 | 4.10e-01 | 6.66e-02 | 8.66e-01 |
Constitutive Signaling by EGFRvIII | 15 | 6.55e-01 | 6.66e-02 | 9.47e-01 |
Signaling by EGFRvIII in Cancer | 15 | 6.55e-01 | 6.66e-02 | 9.47e-01 |
Retrograde transport at the Trans-Golgi-Network | 47 | 4.31e-01 | -6.64e-02 | 8.76e-01 |
Activation of kainate receptors upon glutamate binding | 29 | 5.37e-01 | -6.62e-02 | 9.10e-01 |
DNA Damage Bypass | 46 | 4.38e-01 | 6.61e-02 | 8.76e-01 |
TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 6.94e-01 | 6.57e-02 | 9.56e-01 |
Phase II - Conjugation of compounds | 106 | 2.43e-01 | -6.56e-02 | 8.07e-01 |
RAF activation | 33 | 5.15e-01 | 6.55e-02 | 8.95e-01 |
Termination of O-glycan biosynthesis | 25 | 5.73e-01 | 6.51e-02 | 9.21e-01 |
Translation of Replicase and Assembly of the Replication Transcription Complex 9694676 | 14 | 6.73e-01 | 6.51e-02 | 9.51e-01 |
Activation of the pre-replicative complex | 31 | 5.32e-01 | -6.48e-02 | 9.03e-01 |
Anti-inflammatory response favouring Leishmania parasite infection | 75 | 3.34e-01 | -6.45e-02 | 8.37e-01 |
Leishmania parasite growth and survival | 75 | 3.34e-01 | -6.45e-02 | 8.37e-01 |
UCH proteinases | 81 | 3.16e-01 | 6.44e-02 | 8.26e-01 |
Ephrin signaling | 17 | 6.46e-01 | 6.43e-02 | 9.42e-01 |
SHC1 events in ERBB4 signaling | 14 | 6.77e-01 | -6.42e-02 | 9.51e-01 |
ADORA2B mediated anti-inflammatory cytokines production | 42 | 4.72e-01 | -6.42e-02 | 8.80e-01 |
WNT ligand biogenesis and trafficking | 25 | 5.81e-01 | 6.38e-02 | 9.24e-01 |
Signaling by ALK fusions and activated point mutants | 51 | 4.31e-01 | -6.37e-02 | 8.76e-01 |
Signaling by ALK in cancer | 51 | 4.31e-01 | -6.37e-02 | 8.76e-01 |
Regulation of Apoptosis | 51 | 4.32e-01 | 6.36e-02 | 8.76e-01 |
Recognition of DNA damage by PCNA-containing replication complex | 29 | 5.53e-01 | 6.36e-02 | 9.18e-01 |
Digestion and absorption | 23 | 5.99e-01 | -6.33e-02 | 9.28e-01 |
Serotonin receptors | 11 | 7.16e-01 | 6.33e-02 | 9.66e-01 |
Cellular responses to stress | 682 | 4.75e-03 | 6.33e-02 | 1.21e-01 |
Degradation of DVL | 55 | 4.17e-01 | 6.33e-02 | 8.71e-01 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 54 | 4.23e-01 | 6.31e-02 | 8.76e-01 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 54 | 4.23e-01 | 6.31e-02 | 8.76e-01 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 54 | 4.23e-01 | 6.31e-02 | 8.76e-01 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 54 | 4.23e-01 | 6.31e-02 | 8.76e-01 |
Signaling by NOTCH1 in Cancer | 54 | 4.23e-01 | 6.31e-02 | 8.76e-01 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 50 | 4.41e-01 | 6.30e-02 | 8.76e-01 |
p53-Independent DNA Damage Response | 50 | 4.41e-01 | 6.30e-02 | 8.76e-01 |
p53-Independent G1/S DNA damage checkpoint | 50 | 4.41e-01 | 6.30e-02 | 8.76e-01 |
NR1H2 and NR1H3-mediated signaling | 53 | 4.29e-01 | 6.28e-02 | 8.76e-01 |
Amino acid transport across the plasma membrane | 30 | 5.52e-01 | 6.28e-02 | 9.16e-01 |
Termination of translesion DNA synthesis | 31 | 5.46e-01 | 6.27e-02 | 9.11e-01 |
Hemostasis | 555 | 1.15e-02 | -6.26e-02 | 2.29e-01 |
Sema3A PAK dependent Axon repulsion | 14 | 6.85e-01 | 6.25e-02 | 9.56e-01 |
Signaling by FGFR3 in disease | 21 | 6.20e-01 | 6.25e-02 | 9.28e-01 |
Signaling by PDGFRA extracellular domain mutants | 12 | 7.08e-01 | -6.25e-02 | 9.60e-01 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 7.08e-01 | -6.25e-02 | 9.60e-01 |
Platelet activation, signaling and aggregation | 245 | 9.24e-02 | -6.24e-02 | 6.73e-01 |
Regulation of TP53 Activity | 154 | 1.82e-01 | 6.23e-02 | 7.64e-01 |
Signaling by NTRK2 (TRKB) | 25 | 5.90e-01 | 6.22e-02 | 9.27e-01 |
Regulation of PLK1 Activity at G2/M Transition | 83 | 3.28e-01 | 6.21e-02 | 8.37e-01 |
Signaling by BRAF and RAF1 fusions | 60 | 4.05e-01 | -6.21e-02 | 8.66e-01 |
Cellular responses to stimuli | 696 | 5.25e-03 | 6.19e-02 | 1.29e-01 |
Regulation of MECP2 expression and activity | 30 | 5.58e-01 | -6.19e-02 | 9.18e-01 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 117 | 2.48e-01 | -6.18e-02 | 8.07e-01 |
Protein-protein interactions at synapses | 78 | 3.45e-01 | 6.18e-02 | 8.37e-01 |
EPH-Ephrin signaling | 90 | 3.11e-01 | 6.18e-02 | 8.23e-01 |
MAPK6/MAPK4 signaling | 89 | 3.14e-01 | 6.18e-02 | 8.23e-01 |
Vif-mediated degradation of APOBEC3G | 50 | 4.50e-01 | 6.17e-02 | 8.76e-01 |
DARPP-32 events | 24 | 6.02e-01 | 6.16e-02 | 9.28e-01 |
Removal of the Flap Intermediate from the C-strand | 17 | 6.61e-01 | -6.14e-02 | 9.49e-01 |
Metabolism of carbohydrates | 275 | 7.95e-02 | 6.14e-02 | 6.39e-01 |
Free fatty acids regulate insulin secretion | 10 | 7.38e-01 | 6.10e-02 | 9.66e-01 |
Gamma carboxylation, hypusine formation and arylsulfatase activation | 34 | 5.38e-01 | 6.10e-02 | 9.10e-01 |
Estrogen-dependent gene expression | 91 | 3.15e-01 | 6.10e-02 | 8.23e-01 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 41 | 5.01e-01 | -6.07e-02 | 8.92e-01 |
Signaling by RAS mutants | 41 | 5.01e-01 | -6.07e-02 | 8.92e-01 |
Signaling by moderate kinase activity BRAF mutants | 41 | 5.01e-01 | -6.07e-02 | 8.92e-01 |
Signaling downstream of RAS mutants | 41 | 5.01e-01 | -6.07e-02 | 8.92e-01 |
SUMO E3 ligases SUMOylate target proteins | 158 | 1.92e-01 | -6.02e-02 | 7.71e-01 |
E3 ubiquitin ligases ubiquitinate target proteins | 43 | 4.95e-01 | -6.01e-02 | 8.92e-01 |
G-protein mediated events | 52 | 4.55e-01 | -5.99e-02 | 8.76e-01 |
Recycling pathway of L1 | 23 | 6.20e-01 | -5.97e-02 | 9.28e-01 |
Regulation of actin dynamics for phagocytic cup formation | 59 | 4.30e-01 | 5.94e-02 | 8.76e-01 |
Protein folding | 96 | 3.14e-01 | -5.94e-02 | 8.23e-01 |
SUMOylation | 164 | 1.89e-01 | -5.94e-02 | 7.71e-01 |
Phosphorylation of CD3 and TCR zeta chains | 20 | 6.46e-01 | -5.94e-02 | 9.42e-01 |
FGFR3 mutant receptor activation | 11 | 7.34e-01 | 5.93e-02 | 9.66e-01 |
Signaling by activated point mutants of FGFR3 | 11 | 7.34e-01 | 5.93e-02 | 9.66e-01 |
Factors involved in megakaryocyte development and platelet production | 128 | 2.48e-01 | -5.91e-02 | 8.07e-01 |
GPCR downstream signalling | 603 | 1.31e-02 | -5.90e-02 | 2.39e-01 |
RHO GTPases Activate Formins | 114 | 2.77e-01 | 5.89e-02 | 8.20e-01 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 7.04e-01 | 5.87e-02 | 9.60e-01 |
KSRP (KHSRP) binds and destabilizes mRNA | 17 | 6.75e-01 | 5.87e-02 | 9.51e-01 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 27 | 5.99e-01 | 5.85e-02 | 9.28e-01 |
Synthesis of PIPs at the Golgi membrane | 17 | 6.77e-01 | -5.84e-02 | 9.51e-01 |
Trafficking of GluR2-containing AMPA receptors | 15 | 6.95e-01 | 5.84e-02 | 9.56e-01 |
TRP channels | 24 | 6.21e-01 | 5.83e-02 | 9.28e-01 |
Trafficking and processing of endosomal TLR | 11 | 7.38e-01 | 5.83e-02 | 9.66e-01 |
G1/S Transition | 126 | 2.60e-01 | 5.81e-02 | 8.19e-01 |
Translesion synthesis by POLI | 17 | 6.79e-01 | 5.81e-02 | 9.51e-01 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 6.81e-01 | 5.75e-02 | 9.53e-01 |
Cellular response to heat stress | 95 | 3.33e-01 | 5.74e-02 | 8.37e-01 |
RHO GTPase Effectors | 232 | 1.32e-01 | 5.74e-02 | 7.28e-01 |
Activated NTRK2 signals through FRS2 and FRS3 | 11 | 7.42e-01 | 5.72e-02 | 9.66e-01 |
Class I peroxisomal membrane protein import | 19 | 6.66e-01 | 5.71e-02 | 9.49e-01 |
Elastic fibre formation | 40 | 5.33e-01 | 5.70e-02 | 9.03e-01 |
SLC-mediated transmembrane transport | 238 | 1.29e-01 | 5.70e-02 | 7.28e-01 |
DNA Damage/Telomere Stress Induced Senescence | 28 | 6.02e-01 | -5.69e-02 | 9.28e-01 |
Innate Immune System | 999 | 2.28e-03 | -5.69e-02 | 6.76e-02 |
Immune System | 1870 | 4.26e-05 | -5.67e-02 | 2.06e-03 |
activated TAK1 mediates p38 MAPK activation | 16 | 6.95e-01 | 5.65e-02 | 9.56e-01 |
Cellular Senescence | 130 | 2.67e-01 | -5.63e-02 | 8.19e-01 |
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 7.47e-01 | -5.61e-02 | 9.66e-01 |
Adaptive Immune System | 709 | 1.08e-02 | -5.60e-02 | 2.23e-01 |
E2F mediated regulation of DNA replication | 20 | 6.65e-01 | 5.60e-02 | 9.49e-01 |
RAC3 GTPase cycle | 84 | 3.76e-01 | -5.58e-02 | 8.58e-01 |
Metabolism | 1963 | 4.12e-05 | 5.56e-02 | 2.05e-03 |
TNFR1-induced NFkappaB signaling pathway | 22 | 6.53e-01 | 5.54e-02 | 9.45e-01 |
Stabilization of p53 | 55 | 4.78e-01 | 5.53e-02 | 8.84e-01 |
Signaling by RAF1 mutants | 37 | 5.61e-01 | -5.52e-02 | 9.18e-01 |
Chaperonin-mediated protein folding | 90 | 3.66e-01 | -5.52e-02 | 8.48e-01 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 27 | 6.20e-01 | 5.51e-02 | 9.28e-01 |
Synthesis of IP3 and IP4 in the cytosol | 25 | 6.34e-01 | 5.51e-02 | 9.31e-01 |
Synthesis of PIPs at the plasma membrane | 48 | 5.10e-01 | -5.49e-02 | 8.93e-01 |
ERBB2 Activates PTK6 Signaling | 13 | 7.32e-01 | 5.49e-02 | 9.66e-01 |
TNFR2 non-canonical NF-kB pathway | 94 | 3.57e-01 | 5.49e-02 | 8.43e-01 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 38 | 5.59e-01 | -5.47e-02 | 9.18e-01 |
SHC1 events in ERBB2 signaling | 22 | 6.59e-01 | -5.44e-02 | 9.49e-01 |
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 50 | 5.08e-01 | 5.42e-02 | 8.93e-01 |
NGF-stimulated transcription | 39 | 5.59e-01 | -5.41e-02 | 9.18e-01 |
Peptide hormone metabolism | 83 | 3.95e-01 | -5.40e-02 | 8.64e-01 |
ALK mutants bind TKIs | 12 | 7.47e-01 | -5.38e-02 | 9.66e-01 |
ABC-family proteins mediated transport | 98 | 3.59e-01 | 5.36e-02 | 8.43e-01 |
TICAM1, RIP1-mediated IKK complex recruitment | 18 | 6.94e-01 | 5.36e-02 | 9.56e-01 |
Death Receptor Signalling | 134 | 2.85e-01 | 5.34e-02 | 8.21e-01 |
DAG and IP3 signaling | 39 | 5.65e-01 | -5.32e-02 | 9.18e-01 |
PKA activation in glucagon signalling | 17 | 7.05e-01 | 5.30e-02 | 9.60e-01 |
Signaling by NOTCH | 183 | 2.16e-01 | 5.29e-02 | 7.82e-01 |
Activation of G protein gated Potassium channels | 29 | 6.22e-01 | -5.29e-02 | 9.28e-01 |
G protein gated Potassium channels | 29 | 6.22e-01 | -5.29e-02 | 9.28e-01 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 29 | 6.22e-01 | -5.29e-02 | 9.28e-01 |
Regulation of signaling by CBL | 18 | 6.99e-01 | -5.27e-02 | 9.58e-01 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 30 | 6.18e-01 | -5.26e-02 | 9.28e-01 |
Signaling by Insulin receptor | 77 | 4.25e-01 | 5.26e-02 | 8.76e-01 |
G2/M Checkpoints | 129 | 3.02e-01 | 5.26e-02 | 8.21e-01 |
Signaling by GPCR | 670 | 2.04e-02 | -5.24e-02 | 3.19e-01 |
Formation of the cornified envelope | 73 | 4.39e-01 | 5.23e-02 | 8.76e-01 |
Neddylation | 228 | 1.73e-01 | 5.23e-02 | 7.58e-01 |
Switching of origins to a post-replicative state | 90 | 3.92e-01 | 5.21e-02 | 8.64e-01 |
Dual Incision in GG-NER | 39 | 5.73e-01 | 5.21e-02 | 9.21e-01 |
VEGFR2 mediated vascular permeability | 26 | 6.48e-01 | 5.18e-02 | 9.42e-01 |
DCC mediated attractive signaling | 14 | 7.38e-01 | -5.17e-02 | 9.66e-01 |
HCMV Early Events | 55 | 5.08e-01 | -5.16e-02 | 8.93e-01 |
Transcriptional regulation of pluripotent stem cells | 30 | 6.25e-01 | 5.16e-02 | 9.29e-01 |
TGF-beta receptor signaling activates SMADs | 45 | 5.49e-01 | 5.16e-02 | 9.14e-01 |
PKA-mediated phosphorylation of CREB | 19 | 6.98e-01 | -5.14e-02 | 9.58e-01 |
Mitotic G1 phase and G1/S transition | 144 | 2.87e-01 | 5.14e-02 | 8.21e-01 |
Clathrin-mediated endocytosis | 135 | 3.03e-01 | 5.13e-02 | 8.21e-01 |
Pyruvate metabolism | 29 | 6.34e-01 | 5.10e-02 | 9.32e-01 |
Cellular response to hypoxia | 71 | 4.58e-01 | 5.09e-02 | 8.76e-01 |
Metabolism of steroids | 148 | 2.86e-01 | -5.08e-02 | 8.21e-01 |
APC truncation mutants have impaired AXIN binding | 13 | 7.51e-01 | 5.08e-02 | 9.66e-01 |
AXIN missense mutants destabilize the destruction complex | 13 | 7.51e-01 | 5.08e-02 | 9.66e-01 |
Signaling by AMER1 mutants | 13 | 7.51e-01 | 5.08e-02 | 9.66e-01 |
Signaling by APC mutants | 13 | 7.51e-01 | 5.08e-02 | 9.66e-01 |
Signaling by AXIN mutants | 13 | 7.51e-01 | 5.08e-02 | 9.66e-01 |
Truncations of AMER1 destabilize the destruction complex | 13 | 7.51e-01 | 5.08e-02 | 9.66e-01 |
Tryptophan catabolism | 12 | 7.61e-01 | -5.07e-02 | 9.68e-01 |
Cyclin A/B1/B2 associated events during G2/M transition | 24 | 6.69e-01 | 5.04e-02 | 9.50e-01 |
Nucleotide salvage | 21 | 6.91e-01 | -5.01e-02 | 9.56e-01 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 7.46e-01 | -5.00e-02 | 9.66e-01 |
Signaling by TGF-beta Receptor Complex | 90 | 4.13e-01 | 5.00e-02 | 8.69e-01 |
Stimuli-sensing channels | 96 | 3.97e-01 | 5.00e-02 | 8.64e-01 |
Class A/1 (Rhodopsin-like receptors) | 311 | 1.30e-01 | -4.98e-02 | 7.28e-01 |
Mitotic Prophase | 78 | 4.47e-01 | -4.98e-02 | 8.76e-01 |
Effects of PIP2 hydrolysis | 26 | 6.61e-01 | -4.97e-02 | 9.49e-01 |
IRF3-mediated induction of type I IFN | 11 | 7.76e-01 | -4.95e-02 | 9.73e-01 |
Protein localization | 147 | 3.00e-01 | 4.95e-02 | 8.21e-01 |
Signaling by ERBB2 in Cancer | 25 | 6.70e-01 | 4.93e-02 | 9.50e-01 |
FCERI mediated NF-kB activation | 74 | 4.64e-01 | 4.93e-02 | 8.77e-01 |
Miscellaneous substrates | 12 | 7.68e-01 | 4.91e-02 | 9.70e-01 |
TRAF6-mediated induction of TAK1 complex within TLR4 complex | 15 | 7.42e-01 | -4.91e-02 | 9.66e-01 |
Maturation of nucleoprotein 9694631 | 15 | 7.43e-01 | 4.90e-02 | 9.66e-01 |
Generation of second messenger molecules | 30 | 6.42e-01 | -4.90e-02 | 9.40e-01 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 35 | 6.16e-01 | 4.89e-02 | 9.28e-01 |
Signaling by ERBB2 KD Mutants | 24 | 6.78e-01 | 4.89e-02 | 9.51e-01 |
Deposition of new CENPA-containing nucleosomes at the centromere | 26 | 6.66e-01 | -4.89e-02 | 9.49e-01 |
Nucleosome assembly | 26 | 6.66e-01 | -4.89e-02 | 9.49e-01 |
Cross-presentation of soluble exogenous antigens (endosomes) | 46 | 5.67e-01 | 4.88e-02 | 9.18e-01 |
Assembly of the pre-replicative complex | 82 | 4.45e-01 | 4.88e-02 | 8.76e-01 |
Ion channel transport | 168 | 2.77e-01 | 4.86e-02 | 8.20e-01 |
Syndecan interactions | 19 | 7.14e-01 | 4.86e-02 | 9.66e-01 |
APC/C-mediated degradation of cell cycle proteins | 86 | 4.37e-01 | 4.85e-02 | 8.76e-01 |
Regulation of mitotic cell cycle | 86 | 4.37e-01 | 4.85e-02 | 8.76e-01 |
Netrin-1 signaling | 49 | 5.58e-01 | -4.83e-02 | 9.18e-01 |
ERK/MAPK targets | 20 | 7.09e-01 | 4.82e-02 | 9.60e-01 |
Degradation of the extracellular matrix | 108 | 3.86e-01 | 4.82e-02 | 8.61e-01 |
Toll-like Receptor Cascades | 154 | 3.03e-01 | -4.80e-02 | 8.21e-01 |
DNA Repair | 276 | 1.69e-01 | 4.80e-02 | 7.53e-01 |
Extracellular matrix organization | 287 | 1.61e-01 | 4.80e-02 | 7.37e-01 |
DNA Replication | 125 | 3.54e-01 | 4.79e-02 | 8.43e-01 |
Activation of the AP-1 family of transcription factors | 10 | 7.94e-01 | 4.78e-02 | 9.77e-01 |
ESR-mediated signaling | 160 | 2.97e-01 | 4.78e-02 | 8.21e-01 |
Long-term potentiation | 22 | 6.98e-01 | -4.77e-02 | 9.58e-01 |
Collagen formation | 88 | 4.42e-01 | 4.74e-02 | 8.76e-01 |
mRNA decay by 5’ to 3’ exoribonuclease | 15 | 7.51e-01 | 4.73e-02 | 9.66e-01 |
Reduction of cytosolic Ca++ levels | 11 | 7.86e-01 | 4.73e-02 | 9.75e-01 |
Cell Cycle Checkpoints | 248 | 2.00e-01 | 4.72e-02 | 7.74e-01 |
Nuclear Receptor transcription pathway | 51 | 5.60e-01 | -4.72e-02 | 9.18e-01 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 14 | 7.61e-01 | -4.69e-02 | 9.68e-01 |
Processing of DNA double-strand break ends | 61 | 5.28e-01 | 4.68e-02 | 9.00e-01 |
Digestion | 18 | 7.32e-01 | -4.66e-02 | 9.66e-01 |
G alpha (q) signalling events | 206 | 2.49e-01 | -4.66e-02 | 8.07e-01 |
COPII-mediated vesicle transport | 66 | 5.13e-01 | 4.65e-02 | 8.94e-01 |
DNA Double Strand Break Response | 42 | 6.02e-01 | 4.65e-02 | 9.28e-01 |
Pentose phosphate pathway | 12 | 7.81e-01 | -4.64e-02 | 9.74e-01 |
Vasopressin regulates renal water homeostasis via Aquaporins | 42 | 6.03e-01 | -4.63e-02 | 9.28e-01 |
Toll Like Receptor 4 (TLR4) Cascade | 135 | 3.53e-01 | -4.62e-02 | 8.43e-01 |
RHO GTPase cycle | 420 | 1.05e-01 | -4.61e-02 | 6.75e-01 |
Response of EIF2AK1 (HRI) to heme deficiency | 14 | 7.65e-01 | -4.61e-02 | 9.70e-01 |
Extension of Telomeres | 48 | 5.81e-01 | -4.61e-02 | 9.24e-01 |
RNA Polymerase II Transcription | 1284 | 5.43e-03 | 4.60e-02 | 1.29e-01 |
Hedgehog ‘on’ state | 83 | 4.70e-01 | 4.59e-02 | 8.80e-01 |
Early SARS-CoV-2 Infection Events | 34 | 6.43e-01 | 4.59e-02 | 9.40e-01 |
Amine ligand-binding receptors | 41 | 6.12e-01 | -4.58e-02 | 9.28e-01 |
Purine ribonucleoside monophosphate biosynthesis | 11 | 7.93e-01 | -4.58e-02 | 9.77e-01 |
Signaling by Hippo | 19 | 7.30e-01 | 4.57e-02 | 9.66e-01 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 42 | 6.08e-01 | -4.57e-02 | 9.28e-01 |
Oncogenic MAPK signaling | 76 | 4.91e-01 | -4.57e-02 | 8.92e-01 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 15 | 7.60e-01 | -4.56e-02 | 9.68e-01 |
Generic Transcription Pathway | 1163 | 8.60e-03 | 4.55e-02 | 1.82e-01 |
Neuronal System | 371 | 1.32e-01 | 4.55e-02 | 7.28e-01 |
Negative regulation of MET activity | 20 | 7.25e-01 | 4.55e-02 | 9.66e-01 |
PCP/CE pathway | 90 | 4.57e-01 | 4.54e-02 | 8.76e-01 |
Cell recruitment (pro-inflammatory response) | 25 | 6.95e-01 | -4.53e-02 | 9.56e-01 |
Purinergic signaling in leishmaniasis infection | 25 | 6.95e-01 | -4.53e-02 | 9.56e-01 |
Translation of Structural Proteins 9694635 | 55 | 5.61e-01 | -4.53e-02 | 9.18e-01 |
Regulation of TP53 Activity through Methylation | 18 | 7.39e-01 | 4.53e-02 | 9.66e-01 |
Degradation of GLI2 by the proteasome | 58 | 5.51e-01 | 4.53e-02 | 9.16e-01 |
RAB GEFs exchange GTP for GDP on RABs | 82 | 4.80e-01 | -4.51e-02 | 8.85e-01 |
Synthesis of DNA | 118 | 3.99e-01 | 4.49e-02 | 8.64e-01 |
Regulated Necrosis | 53 | 5.76e-01 | -4.44e-02 | 9.23e-01 |
Reversible hydration of carbon dioxide | 11 | 7.99e-01 | -4.43e-02 | 9.80e-01 |
SUMOylation of DNA replication proteins | 44 | 6.11e-01 | -4.43e-02 | 9.28e-01 |
Phospholipid metabolism | 192 | 2.90e-01 | 4.43e-02 | 8.21e-01 |
Sialic acid metabolism | 33 | 6.60e-01 | -4.42e-02 | 9.49e-01 |
Gene expression (Transcription) | 1420 | 5.19e-03 | 4.41e-02 | 1.29e-01 |
Transport of small molecules | 689 | 4.84e-02 | 4.40e-02 | 5.32e-01 |
Glutathione conjugation | 36 | 6.48e-01 | 4.40e-02 | 9.42e-01 |
Transcriptional regulation by RUNX3 | 93 | 4.63e-01 | 4.40e-02 | 8.77e-01 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 41 | 6.27e-01 | 4.39e-02 | 9.29e-01 |
Signaling by VEGF | 101 | 4.46e-01 | 4.39e-02 | 8.76e-01 |
Nucleotide-like (purinergic) receptors | 13 | 7.86e-01 | 4.36e-02 | 9.75e-01 |
Bicarbonate transporters | 10 | 8.12e-01 | 4.35e-02 | 9.83e-01 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 5.84e-01 | 4.34e-02 | 9.26e-01 |
O-linked glycosylation | 107 | 4.39e-01 | 4.33e-02 | 8.76e-01 |
Amyloid fiber formation | 53 | 5.86e-01 | 4.33e-02 | 9.27e-01 |
Asparagine N-linked glycosylation | 278 | 2.16e-01 | 4.30e-02 | 7.82e-01 |
Polo-like kinase mediated events | 16 | 7.66e-01 | -4.30e-02 | 9.70e-01 |
PIP3 activates AKT signaling | 275 | 2.20e-01 | 4.29e-02 | 7.82e-01 |
Inactivation of CSF3 (G-CSF) signaling | 23 | 7.23e-01 | 4.27e-02 | 9.66e-01 |
PI3K events in ERBB4 signaling | 10 | 8.16e-01 | -4.26e-02 | 9.83e-01 |
Deubiquitination | 226 | 2.71e-01 | -4.24e-02 | 8.19e-01 |
Metabolism of vitamins and cofactors | 181 | 3.27e-01 | 4.22e-02 | 8.37e-01 |
Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 7.77e-01 | 4.22e-02 | 9.74e-01 |
Regulation of lipid metabolism by PPARalpha | 116 | 4.33e-01 | 4.22e-02 | 8.76e-01 |
Collagen biosynthesis and modifying enzymes | 65 | 5.57e-01 | 4.21e-02 | 9.18e-01 |
Disorders of transmembrane transporters | 167 | 3.47e-01 | 4.21e-02 | 8.37e-01 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 21 | 7.39e-01 | 4.21e-02 | 9.66e-01 |
Glycosaminoglycan metabolism | 116 | 4.34e-01 | 4.20e-02 | 8.76e-01 |
RND1 GTPase cycle | 41 | 6.42e-01 | 4.19e-02 | 9.40e-01 |
Presynaptic phase of homologous DNA pairing and strand exchange | 38 | 6.56e-01 | 4.17e-02 | 9.47e-01 |
Separation of Sister Chromatids | 161 | 3.61e-01 | 4.17e-02 | 8.43e-01 |
Keratan sulfate biosynthesis | 28 | 7.03e-01 | -4.16e-02 | 9.60e-01 |
RHOQ GTPase cycle | 57 | 5.88e-01 | -4.15e-02 | 9.27e-01 |
Signaling by Erythropoietin | 25 | 7.20e-01 | -4.14e-02 | 9.66e-01 |
Signaling by ERBB2 TMD/JMD mutants | 21 | 7.43e-01 | 4.14e-02 | 9.66e-01 |
GABA receptor activation | 57 | 5.89e-01 | -4.13e-02 | 9.27e-01 |
Leishmania infection | 156 | 3.73e-01 | -4.13e-02 | 8.58e-01 |
Protein ubiquitination | 61 | 5.78e-01 | -4.12e-02 | 9.23e-01 |
Post-translational modification: synthesis of GPI-anchored proteins | 89 | 5.02e-01 | 4.11e-02 | 8.92e-01 |
Signaling by Nuclear Receptors | 237 | 2.75e-01 | 4.11e-02 | 8.20e-01 |
Glucose metabolism | 87 | 5.07e-01 | 4.11e-02 | 8.93e-01 |
Disorders of Developmental Biology | 11 | 8.15e-01 | 4.08e-02 | 9.83e-01 |
Disorders of Nervous System Development | 11 | 8.15e-01 | 4.08e-02 | 9.83e-01 |
Loss of function of MECP2 in Rett syndrome | 11 | 8.15e-01 | 4.08e-02 | 9.83e-01 |
Pervasive developmental disorders | 11 | 8.15e-01 | 4.08e-02 | 9.83e-01 |
Cell-cell junction organization | 56 | 5.98e-01 | -4.08e-02 | 9.28e-01 |
Mitotic Metaphase and Anaphase | 222 | 2.96e-01 | 4.07e-02 | 8.21e-01 |
Maturation of nucleoprotein 9683610 | 11 | 8.15e-01 | 4.06e-02 | 9.83e-01 |
Gap junction trafficking and regulation | 29 | 7.08e-01 | -4.02e-02 | 9.60e-01 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation | 15 | 7.88e-01 | -4.01e-02 | 9.75e-01 |
Interferon Signaling | 191 | 3.40e-01 | -4.00e-02 | 8.37e-01 |
Prolonged ERK activation events | 14 | 7.97e-01 | 3.97e-02 | 9.79e-01 |
G alpha (s) signalling events | 153 | 4.00e-01 | -3.94e-02 | 8.64e-01 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 68 | 5.75e-01 | 3.93e-02 | 9.22e-01 |
Detoxification of Reactive Oxygen Species | 35 | 6.87e-01 | 3.93e-02 | 9.56e-01 |
Integrin signaling | 27 | 7.25e-01 | -3.92e-02 | 9.66e-01 |
Ribavirin ADME | 11 | 8.22e-01 | 3.91e-02 | 9.84e-01 |
Metalloprotease DUBs | 19 | 7.68e-01 | -3.90e-02 | 9.70e-01 |
KEAP1-NFE2L2 pathway | 103 | 4.94e-01 | 3.89e-02 | 8.92e-01 |
Cytochrome P450 - arranged by substrate type | 64 | 5.94e-01 | 3.86e-02 | 9.28e-01 |
Extra-nuclear estrogen signaling | 73 | 5.70e-01 | 3.85e-02 | 9.18e-01 |
RND3 GTPase cycle | 41 | 6.72e-01 | 3.82e-02 | 9.51e-01 |
Regulation of RUNX2 expression and activity | 71 | 5.79e-01 | 3.81e-02 | 9.23e-01 |
Glycosphingolipid metabolism | 40 | 6.78e-01 | 3.80e-02 | 9.51e-01 |
CaM pathway | 33 | 7.06e-01 | -3.79e-02 | 9.60e-01 |
Calmodulin induced events | 33 | 7.06e-01 | -3.79e-02 | 9.60e-01 |
PPARA activates gene expression | 114 | 4.86e-01 | 3.77e-02 | 8.92e-01 |
DNA Replication Pre-Initiation | 97 | 5.22e-01 | 3.76e-02 | 8.96e-01 |
Assembly and cell surface presentation of NMDA receptors | 23 | 7.55e-01 | -3.76e-02 | 9.67e-01 |
MHC class II antigen presentation | 104 | 5.08e-01 | 3.76e-02 | 8.93e-01 |
Platelet degranulation | 115 | 4.87e-01 | -3.75e-02 | 8.92e-01 |
Mitotic Anaphase | 221 | 3.37e-01 | 3.75e-02 | 8.37e-01 |
Metal ion SLC transporters | 25 | 7.47e-01 | 3.73e-02 | 9.66e-01 |
S Phase | 157 | 4.20e-01 | 3.73e-02 | 8.76e-01 |
TRAF6 mediated NF-kB activation | 24 | 7.52e-01 | -3.73e-02 | 9.66e-01 |
RAF-independent MAPK1/3 activation | 22 | 7.62e-01 | 3.73e-02 | 9.68e-01 |
The canonical retinoid cycle in rods (twilight vision) | 23 | 7.57e-01 | 3.73e-02 | 9.67e-01 |
Physiological factors | 14 | 8.10e-01 | -3.72e-02 | 9.83e-01 |
Lewis blood group biosynthesis | 18 | 7.85e-01 | -3.71e-02 | 9.75e-01 |
Inflammasomes | 21 | 7.69e-01 | -3.70e-02 | 9.70e-01 |
TP53 Regulates Transcription of Caspase Activators and Caspases | 12 | 8.25e-01 | -3.68e-02 | 9.84e-01 |
Ca2+ pathway | 62 | 6.16e-01 | -3.68e-02 | 9.28e-01 |
FGFR2b ligand binding and activation | 10 | 8.41e-01 | 3.67e-02 | 9.90e-01 |
SUMOylation of transcription cofactors | 43 | 6.78e-01 | -3.66e-02 | 9.51e-01 |
Transcriptional regulation of white adipocyte differentiation | 81 | 5.69e-01 | 3.66e-02 | 9.18e-01 |
Cellular hexose transport | 21 | 7.73e-01 | 3.64e-02 | 9.70e-01 |
RUNX3 regulates NOTCH signaling | 13 | 8.21e-01 | 3.63e-02 | 9.84e-01 |
Processive synthesis on the lagging strand | 14 | 8.16e-01 | 3.60e-02 | 9.83e-01 |
MyD88 dependent cascade initiated on endosome | 96 | 5.45e-01 | 3.58e-02 | 9.11e-01 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 96 | 5.45e-01 | 3.58e-02 | 9.11e-01 |
Host Interactions of HIV factors | 122 | 4.99e-01 | 3.54e-02 | 8.92e-01 |
O-linked glycosylation of mucins | 62 | 6.31e-01 | -3.53e-02 | 9.30e-01 |
Platelet calcium homeostasis | 27 | 7.52e-01 | 3.52e-02 | 9.66e-01 |
Signaling by Receptor Tyrosine Kinases | 493 | 1.81e-01 | 3.51e-02 | 7.64e-01 |
Infectious disease | 830 | 8.48e-02 | 3.51e-02 | 6.52e-01 |
Processing of SMDT1 | 15 | 8.14e-01 | 3.50e-02 | 9.83e-01 |
Telomere Maintenance | 62 | 6.36e-01 | 3.47e-02 | 9.33e-01 |
Pre-NOTCH Processing in Golgi | 18 | 8.00e-01 | -3.46e-02 | 9.80e-01 |
Biotin transport and metabolism | 10 | 8.50e-01 | 3.46e-02 | 9.94e-01 |
RNA Polymerase III Transcription Initiation | 36 | 7.22e-01 | 3.43e-02 | 9.66e-01 |
Downstream signaling of activated FGFR3 | 24 | 7.71e-01 | 3.43e-02 | 9.70e-01 |
Asymmetric localization of PCP proteins | 62 | 6.43e-01 | 3.41e-02 | 9.40e-01 |
Nicotinate metabolism | 29 | 7.53e-01 | 3.37e-02 | 9.67e-01 |
HDR through MMEJ (alt-NHEJ) | 11 | 8.47e-01 | 3.36e-02 | 9.92e-01 |
COPI-independent Golgi-to-ER retrograde traffic | 34 | 7.35e-01 | 3.35e-02 | 9.66e-01 |
Developmental Biology | 1027 | 6.87e-02 | 3.35e-02 | 6.23e-01 |
Triglyceride biosynthesis | 13 | 8.35e-01 | -3.34e-02 | 9.90e-01 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 62 | 6.51e-01 | 3.32e-02 | 9.43e-01 |
tRNA modification in the nucleus and cytosol | 38 | 7.25e-01 | 3.30e-02 | 9.66e-01 |
Formation of Incision Complex in GG-NER | 40 | 7.19e-01 | 3.29e-02 | 9.66e-01 |
Intracellular signaling by second messengers | 313 | 3.18e-01 | 3.28e-02 | 8.29e-01 |
VEGFA-VEGFR2 Pathway | 93 | 5.85e-01 | 3.27e-02 | 9.27e-01 |
TCF dependent signaling in response to WNT | 168 | 4.65e-01 | 3.26e-02 | 8.77e-01 |
Degradation of AXIN | 53 | 6.82e-01 | 3.26e-02 | 9.53e-01 |
Activation of Matrix Metalloproteinases | 31 | 7.54e-01 | 3.24e-02 | 9.67e-01 |
TCR signaling | 112 | 5.55e-01 | -3.22e-02 | 9.18e-01 |
Inositol phosphate metabolism | 45 | 7.08e-01 | 3.22e-02 | 9.60e-01 |
Opioid Signalling | 88 | 6.03e-01 | -3.21e-02 | 9.28e-01 |
Chromatin modifying enzymes | 186 | 4.56e-01 | 3.17e-02 | 8.76e-01 |
Chromatin organization | 186 | 4.56e-01 | 3.17e-02 | 8.76e-01 |
RAS processing | 19 | 8.12e-01 | -3.16e-02 | 9.83e-01 |
Glucagon signaling in metabolic regulation | 33 | 7.55e-01 | -3.14e-02 | 9.67e-01 |
Fatty acid metabolism | 167 | 4.84e-01 | 3.14e-02 | 8.89e-01 |
Meiotic synapsis | 32 | 7.60e-01 | -3.12e-02 | 9.68e-01 |
Class I MHC mediated antigen processing & presentation | 361 | 3.09e-01 | -3.11e-02 | 8.23e-01 |
Ras activation upon Ca2+ influx through NMDA receptor | 19 | 8.15e-01 | 3.10e-02 | 9.83e-01 |
tRNA Aminoacylation | 24 | 7.93e-01 | 3.10e-02 | 9.77e-01 |
Synthesis of PC | 27 | 7.81e-01 | 3.10e-02 | 9.74e-01 |
Disease | 1567 | 4.03e-02 | 3.09e-02 | 4.72e-01 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 14 | 8.42e-01 | -3.08e-02 | 9.90e-01 |
Signaling by Hedgehog | 133 | 5.39e-01 | 3.08e-02 | 9.11e-01 |
Transcriptional Regulation by VENTX | 41 | 7.37e-01 | 3.03e-02 | 9.66e-01 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 95 | 6.14e-01 | 2.99e-02 | 9.28e-01 |
Beta-catenin phosphorylation cascade | 16 | 8.36e-01 | -2.99e-02 | 9.90e-01 |
CD28 dependent PI3K/Akt signaling | 22 | 8.08e-01 | 2.99e-02 | 9.83e-01 |
Response to elevated platelet cytosolic Ca2+ | 120 | 5.74e-01 | -2.97e-02 | 9.21e-01 |
Assembly of collagen fibrils and other multimeric structures | 56 | 7.01e-01 | 2.96e-02 | 9.60e-01 |
Transcriptional regulation by RUNX2 | 116 | 5.82e-01 | 2.96e-02 | 9.25e-01 |
Viral Messenger RNA Synthesis | 42 | 7.40e-01 | -2.95e-02 | 9.66e-01 |
Downregulation of TGF-beta receptor signaling | 26 | 7.94e-01 | 2.95e-02 | 9.77e-01 |
Cilium Assembly | 174 | 5.02e-01 | -2.95e-02 | 8.92e-01 |
Ub-specific processing proteases | 153 | 5.33e-01 | -2.92e-02 | 9.03e-01 |
Translation of Structural Proteins 9683701 | 29 | 7.86e-01 | 2.91e-02 | 9.75e-01 |
Mitotic Spindle Checkpoint | 106 | 6.05e-01 | 2.90e-02 | 9.28e-01 |
GLI3 is processed to GLI3R by the proteasome | 58 | 7.02e-01 | 2.90e-02 | 9.60e-01 |
Transcriptional regulation of granulopoiesis | 31 | 7.80e-01 | -2.90e-02 | 9.74e-01 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 104 | 6.10e-01 | 2.89e-02 | 9.28e-01 |
Orc1 removal from chromatin | 69 | 6.79e-01 | 2.88e-02 | 9.51e-01 |
Nuclear events mediated by NFE2L2 | 76 | 6.64e-01 | 2.88e-02 | 9.49e-01 |
PCNA-Dependent Long Patch Base Excision Repair | 21 | 8.19e-01 | 2.88e-02 | 9.84e-01 |
Platelet sensitization by LDL | 17 | 8.38e-01 | 2.87e-02 | 9.90e-01 |
HDMs demethylate histones | 18 | 8.33e-01 | 2.87e-02 | 9.89e-01 |
NRAGE signals death through JNK | 53 | 7.19e-01 | 2.85e-02 | 9.66e-01 |
Membrane Trafficking | 585 | 2.43e-01 | 2.82e-02 | 8.07e-01 |
Nuclear signaling by ERBB4 | 32 | 7.83e-01 | -2.81e-02 | 9.75e-01 |
Regulation of HSF1-mediated heat shock response | 78 | 6.69e-01 | 2.80e-02 | 9.50e-01 |
Peptide ligand-binding receptors | 190 | 5.09e-01 | -2.78e-02 | 8.93e-01 |
Collagen degradation | 39 | 7.66e-01 | 2.75e-02 | 9.70e-01 |
TNFs bind their physiological receptors | 25 | 8.12e-01 | -2.75e-02 | 9.83e-01 |
Rab regulation of trafficking | 113 | 6.14e-01 | 2.74e-02 | 9.28e-01 |
Signaling by CSF3 (G-CSF) | 28 | 8.02e-01 | -2.74e-02 | 9.82e-01 |
Pre-NOTCH Transcription and Translation | 45 | 7.51e-01 | 2.74e-02 | 9.66e-01 |
Branched-chain amino acid catabolism | 20 | 8.32e-01 | 2.73e-02 | 9.89e-01 |
Transcriptional regulation by RUNX1 | 183 | 5.24e-01 | 2.73e-02 | 8.97e-01 |
Neurotransmitter release cycle | 47 | 7.46e-01 | 2.73e-02 | 9.66e-01 |
Signaling by FGFR in disease | 61 | 7.13e-01 | 2.72e-02 | 9.65e-01 |
Cellular response to chemical stress | 187 | 5.22e-01 | 2.71e-02 | 8.96e-01 |
Retrograde neurotrophin signalling | 14 | 8.61e-01 | 2.71e-02 | 9.96e-01 |
eNOS activation | 11 | 8.76e-01 | 2.71e-02 | 9.96e-01 |
Fc epsilon receptor (FCERI) signaling | 126 | 6.00e-01 | -2.71e-02 | 9.28e-01 |
Transcription of E2F targets under negative control by DREAM complex | 19 | 8.39e-01 | 2.70e-02 | 9.90e-01 |
Signal transduction by L1 | 20 | 8.35e-01 | 2.68e-02 | 9.90e-01 |
Elevation of cytosolic Ca2+ levels | 16 | 8.53e-01 | 2.68e-02 | 9.96e-01 |
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | 10 | 8.84e-01 | 2.66e-02 | 9.96e-01 |
tRNA processing in the nucleus | 55 | 7.33e-01 | -2.66e-02 | 9.66e-01 |
Postmitotic nuclear pore complex (NPC) reformation | 26 | 8.15e-01 | -2.65e-02 | 9.83e-01 |
Toll Like Receptor 3 (TLR3) Cascade | 99 | 6.51e-01 | 2.63e-02 | 9.43e-01 |
Golgi-to-ER retrograde transport | 115 | 6.28e-01 | 2.62e-02 | 9.29e-01 |
Hyaluronan metabolism | 17 | 8.52e-01 | 2.61e-02 | 9.96e-01 |
Glycolysis | 68 | 7.17e-01 | 2.54e-02 | 9.66e-01 |
ATF6 (ATF6-alpha) activates chaperone genes | 10 | 8.90e-01 | -2.53e-02 | 9.96e-01 |
Cytokine Signaling in Immune system | 670 | 2.63e-01 | -2.53e-02 | 8.19e-01 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 8.57e-01 | -2.52e-02 | 9.96e-01 |
Defects in cobalamin (B12) metabolism | 12 | 8.81e-01 | 2.50e-02 | 9.96e-01 |
C-type lectin receptors (CLRs) | 137 | 6.15e-01 | 2.49e-02 | 9.28e-01 |
HATs acetylate histones | 71 | 7.18e-01 | -2.48e-02 | 9.66e-01 |
Interleukin-35 Signalling | 12 | 8.82e-01 | -2.47e-02 | 9.96e-01 |
PKA activation | 18 | 8.58e-01 | -2.44e-02 | 9.96e-01 |
SARS-CoV-2-host interactions | 183 | 5.70e-01 | -2.43e-02 | 9.18e-01 |
Nonhomologous End-Joining (NHEJ) | 32 | 8.12e-01 | 2.43e-02 | 9.83e-01 |
Mitochondrial tRNA aminoacylation | 18 | 8.62e-01 | 2.38e-02 | 9.96e-01 |
Chondroitin sulfate biosynthesis | 18 | 8.62e-01 | -2.37e-02 | 9.96e-01 |
ECM proteoglycans | 55 | 7.61e-01 | 2.37e-02 | 9.68e-01 |
Interleukin-12 signaling | 43 | 7.88e-01 | 2.36e-02 | 9.75e-01 |
Antigen processing-Cross presentation | 100 | 6.84e-01 | 2.36e-02 | 9.54e-01 |
Signaling by ERBB4 | 57 | 7.60e-01 | 2.34e-02 | 9.68e-01 |
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 8.98e-01 | -2.34e-02 | 9.96e-01 |
Metabolism of proteins | 1767 | 1.02e-01 | 2.33e-02 | 6.75e-01 |
Signaling by WNT | 263 | 5.17e-01 | 2.32e-02 | 8.95e-01 |
Signaling by WNT in cancer | 32 | 8.21e-01 | 2.31e-02 | 9.84e-01 |
COPI-dependent Golgi-to-ER retrograde traffic | 81 | 7.20e-01 | 2.30e-02 | 9.66e-01 |
Antigen processing: Ubiquitination & Proteasome degradation | 293 | 5.03e-01 | -2.27e-02 | 8.92e-01 |
GPER1 signaling | 44 | 7.95e-01 | 2.26e-02 | 9.77e-01 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 8.93e-01 | 2.25e-02 | 9.96e-01 |
alpha-linolenic acid (ALA) metabolism | 12 | 8.93e-01 | 2.25e-02 | 9.96e-01 |
STING mediated induction of host immune responses | 13 | 8.89e-01 | 2.24e-02 | 9.96e-01 |
Sealing of the nuclear envelope (NE) by ESCRT-III | 31 | 8.29e-01 | 2.24e-02 | 9.88e-01 |
ER to Golgi Anterograde Transport | 134 | 6.57e-01 | 2.22e-02 | 9.47e-01 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 106 | 6.93e-01 | 2.22e-02 | 9.56e-01 |
Toll Like Receptor 2 (TLR2) Cascade | 106 | 6.93e-01 | 2.22e-02 | 9.56e-01 |
Toll Like Receptor TLR1:TLR2 Cascade | 106 | 6.93e-01 | 2.22e-02 | 9.56e-01 |
Toll Like Receptor TLR6:TLR2 Cascade | 106 | 6.93e-01 | 2.22e-02 | 9.56e-01 |
Degradation of beta-catenin by the destruction complex | 81 | 7.31e-01 | 2.21e-02 | 9.66e-01 |
Gene Silencing by RNA | 80 | 7.34e-01 | -2.20e-02 | 9.66e-01 |
Fatty acyl-CoA biosynthesis | 36 | 8.20e-01 | 2.20e-02 | 9.84e-01 |
Degradation of GLI1 by the proteasome | 58 | 7.73e-01 | 2.19e-02 | 9.70e-01 |
Nuclear Events (kinase and transcription factor activation) | 60 | 7.70e-01 | -2.18e-02 | 9.70e-01 |
The NLRP3 inflammasome | 16 | 8.81e-01 | -2.16e-02 | 9.96e-01 |
Downstream TCR signaling | 92 | 7.21e-01 | 2.15e-02 | 9.66e-01 |
Centrosome maturation | 76 | 7.47e-01 | -2.14e-02 | 9.66e-01 |
Recruitment of mitotic centrosome proteins and complexes | 76 | 7.47e-01 | -2.14e-02 | 9.66e-01 |
G2/M Transition | 175 | 6.27e-01 | 2.13e-02 | 9.29e-01 |
Heme biosynthesis | 13 | 8.95e-01 | -2.12e-02 | 9.96e-01 |
Constitutive Signaling by Aberrant PI3K in Cancer | 77 | 7.48e-01 | -2.12e-02 | 9.66e-01 |
Resolution of Sister Chromatid Cohesion | 98 | 7.18e-01 | 2.11e-02 | 9.66e-01 |
NOD1/2 Signaling Pathway | 29 | 8.45e-01 | -2.10e-02 | 9.90e-01 |
RHOF GTPase cycle | 40 | 8.18e-01 | -2.10e-02 | 9.84e-01 |
Regulation of beta-cell development | 41 | 8.16e-01 | -2.10e-02 | 9.83e-01 |
Interleukin-1 family signaling | 145 | 6.63e-01 | 2.10e-02 | 9.49e-01 |
G2/M DNA damage checkpoint | 58 | 7.84e-01 | 2.08e-02 | 9.75e-01 |
Mitotic G2-G2/M phases | 177 | 6.33e-01 | 2.08e-02 | 9.31e-01 |
Cell Cycle | 601 | 3.89e-01 | 2.05e-02 | 8.64e-01 |
Signaling by NOTCH1 | 70 | 7.67e-01 | 2.05e-02 | 9.70e-01 |
Signal attenuation | 10 | 9.11e-01 | 2.04e-02 | 9.96e-01 |
RHOA GTPase cycle | 140 | 6.77e-01 | -2.04e-02 | 9.51e-01 |
Costimulation by the CD28 family | 65 | 7.78e-01 | 2.02e-02 | 9.74e-01 |
tRNA processing | 98 | 7.29e-01 | -2.02e-02 | 9.66e-01 |
M Phase | 335 | 5.26e-01 | 2.02e-02 | 8.99e-01 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 34 | 8.40e-01 | 2.00e-02 | 9.90e-01 |
Fcgamma receptor (FCGR) dependent phagocytosis | 82 | 7.56e-01 | 1.99e-02 | 9.67e-01 |
Signaling by PDGF | 52 | 8.05e-01 | -1.98e-02 | 9.83e-01 |
EPHB-mediated forward signaling | 34 | 8.42e-01 | -1.98e-02 | 9.90e-01 |
Organelle biogenesis and maintenance | 243 | 5.97e-01 | -1.97e-02 | 9.28e-01 |
SLC transporter disorders | 92 | 7.45e-01 | -1.96e-02 | 9.66e-01 |
Diseases associated with N-glycosylation of proteins | 19 | 8.83e-01 | -1.95e-02 | 9.96e-01 |
Diseases associated with visual transduction | 11 | 9.11e-01 | -1.94e-02 | 9.96e-01 |
Diseases of the neuronal system | 11 | 9.11e-01 | -1.94e-02 | 9.96e-01 |
Retinoid cycle disease events | 11 | 9.11e-01 | -1.94e-02 | 9.96e-01 |
RHOC GTPase cycle | 69 | 7.80e-01 | -1.94e-02 | 9.74e-01 |
PI-3K cascade:FGFR3 | 17 | 8.90e-01 | 1.94e-02 | 9.96e-01 |
RUNX2 regulates osteoblast differentiation | 22 | 8.75e-01 | 1.94e-02 | 9.96e-01 |
Activation of ATR in response to replication stress | 37 | 8.39e-01 | -1.93e-02 | 9.90e-01 |
Circadian Clock | 69 | 7.83e-01 | 1.92e-02 | 9.75e-01 |
Diseases associated with glycosaminoglycan metabolism | 38 | 8.38e-01 | 1.92e-02 | 9.90e-01 |
Cell junction organization | 79 | 7.69e-01 | 1.91e-02 | 9.70e-01 |
Sphingolipid metabolism | 81 | 7.70e-01 | 1.88e-02 | 9.70e-01 |
Platelet homeostasis | 85 | 7.65e-01 | -1.88e-02 | 9.70e-01 |
Processing and activation of SUMO | 10 | 9.19e-01 | -1.85e-02 | 9.96e-01 |
Pre-NOTCH Expression and Processing | 61 | 8.02e-01 | 1.85e-02 | 9.82e-01 |
Vesicle-mediated transport | 623 | 4.32e-01 | 1.84e-02 | 8.76e-01 |
Pyrimidine catabolism | 12 | 9.14e-01 | -1.81e-02 | 9.96e-01 |
Aquaporin-mediated transport | 51 | 8.25e-01 | -1.79e-02 | 9.84e-01 |
ATF4 activates genes in response to endoplasmic reticulum stress | 28 | 8.70e-01 | 1.79e-02 | 9.96e-01 |
PI3K events in ERBB2 signaling | 16 | 9.01e-01 | 1.79e-02 | 9.96e-01 |
ERBB2 Regulates Cell Motility | 15 | 9.05e-01 | 1.79e-02 | 9.96e-01 |
Growth hormone receptor signaling | 24 | 8.80e-01 | 1.78e-02 | 9.96e-01 |
Signaling by NTRKs | 133 | 7.23e-01 | 1.78e-02 | 9.66e-01 |
Mitochondrial Fatty Acid Beta-Oxidation | 35 | 8.56e-01 | 1.77e-02 | 9.96e-01 |
Caspase-mediated cleavage of cytoskeletal proteins | 12 | 9.17e-01 | -1.75e-02 | 9.96e-01 |
Negative regulators of DDX58/IFIH1 signaling | 34 | 8.61e-01 | -1.74e-02 | 9.96e-01 |
IRS-related events triggered by IGF1R | 50 | 8.33e-01 | 1.73e-02 | 9.89e-01 |
DSCAM interactions | 11 | 9.21e-01 | 1.73e-02 | 9.96e-01 |
PI Metabolism | 79 | 7.91e-01 | -1.72e-02 | 9.77e-01 |
Deadenylation-dependent mRNA decay | 56 | 8.24e-01 | -1.72e-02 | 9.84e-01 |
MET activates RAS signaling | 11 | 9.22e-01 | 1.70e-02 | 9.96e-01 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 8.77e-01 | 1.69e-02 | 9.96e-01 |
Gastrulation | 21 | 8.94e-01 | -1.68e-02 | 9.96e-01 |
Notch-HLH transcription pathway | 24 | 8.87e-01 | -1.68e-02 | 9.96e-01 |
G alpha (z) signalling events | 48 | 8.41e-01 | -1.68e-02 | 9.90e-01 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 9.00e-01 | 1.67e-02 | 9.96e-01 |
Mitochondrial calcium ion transport | 22 | 8.92e-01 | -1.67e-02 | 9.96e-01 |
FRS-mediated FGFR3 signaling | 19 | 9.00e-01 | 1.67e-02 | 9.96e-01 |
Metabolism of amine-derived hormones | 17 | 9.06e-01 | -1.65e-02 | 9.96e-01 |
Cargo trafficking to the periciliary membrane | 49 | 8.43e-01 | -1.64e-02 | 9.90e-01 |
Metabolism of lipids | 696 | 4.62e-01 | 1.63e-02 | 8.77e-01 |
FGFR3 ligand binding and activation | 12 | 9.22e-01 | 1.62e-02 | 9.96e-01 |
FGFR3c ligand binding and activation | 12 | 9.22e-01 | 1.62e-02 | 9.96e-01 |
Cytoprotection by HMOX1 | 58 | 8.31e-01 | 1.62e-02 | 9.89e-01 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 89 | 7.93e-01 | 1.61e-02 | 9.77e-01 |
Amplification of signal from the kinetochores | 89 | 7.93e-01 | 1.61e-02 | 9.77e-01 |
Purine salvage | 12 | 9.23e-01 | 1.60e-02 | 9.96e-01 |
Interleukin-17 signaling | 66 | 8.22e-01 | -1.60e-02 | 9.84e-01 |
RND2 GTPase cycle | 42 | 8.58e-01 | 1.60e-02 | 9.96e-01 |
Beta-oxidation of very long chain fatty acids | 10 | 9.31e-01 | 1.58e-02 | 9.96e-01 |
Infection with Mycobacterium tuberculosis | 25 | 8.92e-01 | -1.57e-02 | 9.96e-01 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 67 | 8.25e-01 | 1.56e-02 | 9.84e-01 |
Toll Like Receptor 9 (TLR9) Cascade | 100 | 7.87e-01 | 1.56e-02 | 9.75e-01 |
Signaling by NTRK1 (TRKA) | 114 | 7.74e-01 | 1.56e-02 | 9.71e-01 |
CD28 dependent Vav1 pathway | 11 | 9.29e-01 | -1.55e-02 | 9.96e-01 |
Transport to the Golgi and subsequent modification | 165 | 7.31e-01 | -1.55e-02 | 9.66e-01 |
Metabolism of steroid hormones | 33 | 8.78e-01 | 1.54e-02 | 9.96e-01 |
SARS-CoV-2 Infection | 276 | 6.60e-01 | -1.54e-02 | 9.49e-01 |
Lagging Strand Synthesis | 19 | 9.08e-01 | -1.54e-02 | 9.96e-01 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 181 | 7.22e-01 | -1.53e-02 | 9.66e-01 |
SHC-mediated cascade:FGFR3 | 17 | 9.13e-01 | 1.53e-02 | 9.96e-01 |
Cell Cycle, Mitotic | 476 | 5.70e-01 | 1.52e-02 | 9.18e-01 |
SARS-CoV Infections | 387 | 6.09e-01 | 1.51e-02 | 9.28e-01 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 25 | 8.96e-01 | -1.51e-02 | 9.96e-01 |
Defective Intrinsic Pathway for Apoptosis | 25 | 8.97e-01 | 1.49e-02 | 9.96e-01 |
ATF6 (ATF6-alpha) activates chaperones | 11 | 9.32e-01 | -1.49e-02 | 9.96e-01 |
DNA strand elongation | 31 | 8.88e-01 | -1.47e-02 | 9.96e-01 |
Repression of WNT target genes | 13 | 9.28e-01 | 1.45e-02 | 9.96e-01 |
Leading Strand Synthesis | 13 | 9.28e-01 | -1.44e-02 | 9.96e-01 |
Polymerase switching | 13 | 9.28e-01 | -1.44e-02 | 9.96e-01 |
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 603 | 5.46e-01 | -1.44e-02 | 9.11e-01 |
Metabolism of cofactors | 19 | 9.14e-01 | 1.43e-02 | 9.96e-01 |
Gastrin-CREB signalling pathway via PKC and MAPK | 17 | 9.19e-01 | -1.43e-02 | 9.96e-01 |
Response of Mtb to phagocytosis | 22 | 9.08e-01 | -1.42e-02 | 9.96e-01 |
Impaired BRCA2 binding to RAD51 | 33 | 8.88e-01 | -1.42e-02 | 9.96e-01 |
AURKA Activation by TPX2 | 68 | 8.40e-01 | 1.41e-02 | 9.90e-01 |
Loss of Nlp from mitotic centrosomes | 65 | 8.44e-01 | 1.41e-02 | 9.90e-01 |
Loss of proteins required for interphase microtubule organization from the centrosome | 65 | 8.44e-01 | 1.41e-02 | 9.90e-01 |
PERK regulates gene expression | 32 | 8.91e-01 | -1.40e-02 | 9.96e-01 |
Signaling by the B Cell Receptor (BCR) | 105 | 8.06e-01 | 1.39e-02 | 9.83e-01 |
RUNX2 regulates bone development | 29 | 8.99e-01 | -1.36e-02 | 9.96e-01 |
Intrinsic Pathway for Apoptosis | 52 | 8.65e-01 | 1.36e-02 | 9.96e-01 |
Unwinding of DNA | 12 | 9.35e-01 | -1.35e-02 | 9.96e-01 |
HuR (ELAVL1) binds and stabilizes mRNA | 10 | 9.41e-01 | 1.35e-02 | 9.96e-01 |
Programmed Cell Death | 192 | 7.48e-01 | -1.34e-02 | 9.66e-01 |
Signaling by Retinoic Acid | 41 | 8.82e-01 | 1.34e-02 | 9.96e-01 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 9.27e-01 | 1.33e-02 | 9.96e-01 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 32 | 8.97e-01 | -1.33e-02 | 9.96e-01 |
Beta-catenin independent WNT signaling | 144 | 7.84e-01 | 1.32e-02 | 9.75e-01 |
Nucleotide catabolism | 35 | 8.93e-01 | 1.31e-02 | 9.96e-01 |
TP53 Regulates Transcription of Cell Death Genes | 42 | 8.84e-01 | 1.31e-02 | 9.96e-01 |
NOTCH4 Intracellular Domain Regulates Transcription | 19 | 9.22e-01 | -1.30e-02 | 9.96e-01 |
Cell-Cell communication | 112 | 8.13e-01 | -1.30e-02 | 9.83e-01 |
CTLA4 inhibitory signaling | 21 | 9.19e-01 | 1.29e-02 | 9.96e-01 |
Nuclear Envelope (NE) Reassembly | 73 | 8.49e-01 | 1.29e-02 | 9.94e-01 |
Negative regulation of MAPK pathway | 41 | 8.87e-01 | 1.28e-02 | 9.96e-01 |
MyD88-independent TLR4 cascade | 103 | 8.24e-01 | -1.27e-02 | 9.84e-01 |
TRIF(TICAM1)-mediated TLR4 signaling | 103 | 8.24e-01 | -1.27e-02 | 9.84e-01 |
Collagen chain trimerization | 42 | 8.87e-01 | 1.27e-02 | 9.96e-01 |
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 16 | 9.30e-01 | -1.26e-02 | 9.96e-01 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 22 | 9.18e-01 | 1.26e-02 | 9.96e-01 |
Neurodegenerative Diseases | 22 | 9.18e-01 | 1.26e-02 | 9.96e-01 |
Purine catabolism | 17 | 9.29e-01 | 1.25e-02 | 9.96e-01 |
MET activates RAP1 and RAC1 | 11 | 9.44e-01 | -1.23e-02 | 9.96e-01 |
Transmission across Chemical Synapses | 237 | 7.44e-01 | 1.23e-02 | 9.66e-01 |
Interleukin-4 and Interleukin-13 signaling | 104 | 8.29e-01 | 1.23e-02 | 9.88e-01 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 27 | 9.12e-01 | 1.23e-02 | 9.96e-01 |
Transport of Mature Transcript to Cytoplasm | 76 | 8.56e-01 | 1.21e-02 | 9.96e-01 |
Kinesins | 42 | 8.92e-01 | 1.21e-02 | 9.96e-01 |
mitochondrial fatty acid beta-oxidation of saturated fatty acids | 11 | 9.45e-01 | 1.20e-02 | 9.96e-01 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 29 | 9.11e-01 | -1.20e-02 | 9.96e-01 |
Dissolution of Fibrin Clot | 13 | 9.40e-01 | 1.20e-02 | 9.96e-01 |
IGF1R signaling cascade | 51 | 8.84e-01 | 1.18e-02 | 9.96e-01 |
Signaling by Rho GTPases | 589 | 6.24e-01 | -1.18e-02 | 9.29e-01 |
Translesion synthesis by REV1 | 16 | 9.35e-01 | 1.17e-02 | 9.96e-01 |
Late SARS-CoV-2 Infection Events | 67 | 8.70e-01 | -1.16e-02 | 9.96e-01 |
Insulin receptor signalling cascade | 53 | 8.85e-01 | 1.15e-02 | 9.96e-01 |
Regulation of gene expression in beta cells | 21 | 9.27e-01 | -1.15e-02 | 9.96e-01 |
MAPK3 (ERK1) activation | 10 | 9.50e-01 | 1.15e-02 | 9.96e-01 |
G1/S-Specific Transcription | 28 | 9.16e-01 | 1.15e-02 | 9.96e-01 |
trans-Golgi Network Vesicle Budding | 67 | 8.73e-01 | 1.13e-02 | 9.96e-01 |
Activation of NMDA receptors and postsynaptic events | 69 | 8.74e-01 | -1.10e-02 | 9.96e-01 |
PRC2 methylates histones and DNA | 13 | 9.45e-01 | 1.10e-02 | 9.96e-01 |
Nephrin family interactions | 21 | 9.31e-01 | -1.10e-02 | 9.96e-01 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 49 | 8.95e-01 | -1.09e-02 | 9.96e-01 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 52 | 8.92e-01 | 1.09e-02 | 9.96e-01 |
Prefoldin mediated transfer of substrate to CCT/TriC | 27 | 9.22e-01 | 1.09e-02 | 9.96e-01 |
Activation of GABAB receptors | 43 | 9.02e-01 | -1.08e-02 | 9.96e-01 |
GABA B receptor activation | 43 | 9.02e-01 | -1.08e-02 | 9.96e-01 |
GRB2 events in ERBB2 signaling | 16 | 9.41e-01 | -1.07e-02 | 9.96e-01 |
Chromosome Maintenance | 86 | 8.68e-01 | 1.04e-02 | 9.96e-01 |
G alpha (12/13) signalling events | 74 | 8.77e-01 | -1.04e-02 | 9.96e-01 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 15 | 9.45e-01 | -1.02e-02 | 9.96e-01 |
EML4 and NUDC in mitotic spindle formation | 93 | 8.65e-01 | -1.02e-02 | 9.96e-01 |
Mismatch Repair | 15 | 9.45e-01 | 1.02e-02 | 9.96e-01 |
Carboxyterminal post-translational modifications of tubulin | 40 | 9.11e-01 | 1.02e-02 | 9.96e-01 |
Translesion synthesis by POLK | 17 | 9.43e-01 | 1.01e-02 | 9.96e-01 |
Signaling by TGFB family members | 118 | 8.54e-01 | 9.83e-03 | 9.96e-01 |
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 12 | 9.54e-01 | -9.71e-03 | 9.97e-01 |
Interferon gamma signaling | 89 | 8.79e-01 | -9.35e-03 | 9.96e-01 |
Apoptotic execution phase | 43 | 9.16e-01 | -9.27e-03 | 9.96e-01 |
Removal of the Flap Intermediate | 13 | 9.54e-01 | 9.14e-03 | 9.97e-01 |
Gap junction assembly | 18 | 9.48e-01 | 8.96e-03 | 9.96e-01 |
MAP kinase activation | 58 | 9.06e-01 | 8.94e-03 | 9.96e-01 |
Formation of the beta-catenin:TCF transactivating complex | 32 | 9.31e-01 | 8.79e-03 | 9.96e-01 |
Cargo concentration in the ER | 32 | 9.32e-01 | -8.73e-03 | 9.96e-01 |
Signaling by Interleukins | 434 | 7.56e-01 | -8.68e-03 | 9.67e-01 |
Hyaluronan uptake and degradation | 12 | 9.60e-01 | 8.45e-03 | 9.97e-01 |
Hedgehog ‘off’ state | 97 | 8.86e-01 | 8.40e-03 | 9.96e-01 |
Integrin cell surface interactions | 66 | 9.10e-01 | -8.03e-03 | 9.96e-01 |
Tight junction interactions | 28 | 9.43e-01 | 7.82e-03 | 9.96e-01 |
Platelet Aggregation (Plug Formation) | 37 | 9.35e-01 | -7.74e-03 | 9.96e-01 |
Rap1 signalling | 16 | 9.57e-01 | 7.74e-03 | 9.97e-01 |
The phototransduction cascade | 32 | 9.41e-01 | 7.61e-03 | 9.96e-01 |
L1CAM interactions | 92 | 9.00e-01 | 7.59e-03 | 9.96e-01 |
PI3K Cascade | 43 | 9.34e-01 | 7.25e-03 | 9.96e-01 |
Apoptosis | 164 | 8.73e-01 | -7.21e-03 | 9.96e-01 |
Regulation of PTEN stability and activity | 66 | 9.23e-01 | 6.86e-03 | 9.96e-01 |
Neurotransmitter receptors and postsynaptic signal transmission | 175 | 8.76e-01 | -6.82e-03 | 9.96e-01 |
Interleukin-12 family signaling | 53 | 9.32e-01 | -6.79e-03 | 9.96e-01 |
Signal Transduction | 2410 | 5.89e-01 | -6.68e-03 | 9.27e-01 |
ER-Phagosome pathway | 87 | 9.14e-01 | -6.67e-03 | 9.96e-01 |
WNT5A-dependent internalization of FZD4 | 15 | 9.65e-01 | -6.59e-03 | 9.97e-01 |
Synthesis of IP2, IP, and Ins in the cytosol | 13 | 9.68e-01 | 6.50e-03 | 9.97e-01 |
Regulation of RUNX1 Expression and Activity | 25 | 9.56e-01 | -6.43e-03 | 9.97e-01 |
Ion homeostasis | 50 | 9.39e-01 | 6.26e-03 | 9.96e-01 |
Golgi Associated Vesicle Biogenesis | 51 | 9.38e-01 | -6.25e-03 | 9.96e-01 |
HDR through Single Strand Annealing (SSA) | 36 | 9.49e-01 | 6.14e-03 | 9.96e-01 |
Post-translational protein modification | 1289 | 7.16e-01 | -6.01e-03 | 9.66e-01 |
Diseases of DNA repair | 49 | 9.43e-01 | 5.89e-03 | 9.96e-01 |
HCMV Infection | 79 | 9.29e-01 | 5.83e-03 | 9.96e-01 |
Transcriptional activation of mitochondrial biogenesis | 51 | 9.43e-01 | 5.76e-03 | 9.96e-01 |
Aflatoxin activation and detoxification | 19 | 9.65e-01 | 5.74e-03 | 9.97e-01 |
Anchoring of the basal body to the plasma membrane | 92 | 9.25e-01 | -5.69e-03 | 9.96e-01 |
Biological oxidations | 213 | 8.86e-01 | 5.68e-03 | 9.96e-01 |
Processing of Intronless Pre-mRNAs | 19 | 9.66e-01 | -5.58e-03 | 9.97e-01 |
CD28 co-stimulation | 32 | 9.57e-01 | -5.48e-03 | 9.97e-01 |
Class B/2 (Secretin family receptors) | 94 | 9.28e-01 | -5.41e-03 | 9.96e-01 |
RHOB GTPase cycle | 66 | 9.40e-01 | 5.38e-03 | 9.96e-01 |
Transcriptional regulation by small RNAs | 46 | 9.50e-01 | -5.37e-03 | 9.96e-01 |
Mitochondrial biogenesis | 69 | 9.39e-01 | 5.34e-03 | 9.96e-01 |
Inactivation, recovery and regulation of the phototransduction cascade | 31 | 9.59e-01 | 5.30e-03 | 9.97e-01 |
RA biosynthesis pathway | 22 | 9.66e-01 | -5.28e-03 | 9.97e-01 |
Defects in vitamin and cofactor metabolism | 20 | 9.68e-01 | -5.19e-03 | 9.97e-01 |
RET signaling | 41 | 9.55e-01 | 5.12e-03 | 9.97e-01 |
Downstream signal transduction | 29 | 9.62e-01 | -5.09e-03 | 9.97e-01 |
Response to metal ions | 14 | 9.74e-01 | -4.94e-03 | 9.99e-01 |
RAF/MAP kinase cascade | 264 | 8.92e-01 | -4.85e-03 | 9.96e-01 |
RIPK1-mediated regulated necrosis | 27 | 9.66e-01 | 4.81e-03 | 9.97e-01 |
Regulation of necroptotic cell death | 27 | 9.66e-01 | 4.81e-03 | 9.97e-01 |
FCGR3A-mediated phagocytosis | 57 | 9.51e-01 | 4.75e-03 | 9.96e-01 |
Leishmania phagocytosis | 57 | 9.51e-01 | 4.75e-03 | 9.96e-01 |
Parasite infection | 57 | 9.51e-01 | 4.75e-03 | 9.96e-01 |
Post NMDA receptor activation events | 58 | 9.50e-01 | -4.74e-03 | 9.96e-01 |
ISG15 antiviral mechanism | 71 | 9.46e-01 | -4.64e-03 | 9.96e-01 |
Apoptotic cleavage of cellular proteins | 35 | 9.64e-01 | -4.46e-03 | 9.97e-01 |
Negative regulation of the PI3K/AKT network | 111 | 9.36e-01 | 4.39e-03 | 9.96e-01 |
RAB geranylgeranylation | 57 | 9.54e-01 | -4.39e-03 | 9.97e-01 |
MAPK1/MAPK3 signaling | 270 | 9.04e-01 | -4.25e-03 | 9.96e-01 |
CaMK IV-mediated phosphorylation of CREB | 10 | 9.82e-01 | -4.20e-03 | 9.99e-01 |
Synthesis of very long-chain fatty acyl-CoAs | 23 | 9.74e-01 | 3.99e-03 | 9.99e-01 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 11 | 9.82e-01 | -3.96e-03 | 9.99e-01 |
MAPK targets/ Nuclear events mediated by MAP kinases | 29 | 9.71e-01 | -3.85e-03 | 9.99e-01 |
Interleukin-27 signaling | 11 | 9.82e-01 | 3.84e-03 | 9.99e-01 |
Synthesis of PA | 35 | 9.69e-01 | 3.82e-03 | 9.97e-01 |
TNFR1-induced proapoptotic signaling | 13 | 9.81e-01 | -3.77e-03 | 9.99e-01 |
RHOD GTPase cycle | 48 | 9.65e-01 | -3.71e-03 | 9.97e-01 |
Regulation of IFNG signaling | 14 | 9.81e-01 | -3.60e-03 | 9.99e-01 |
Sensory processing of sound by outer hair cells of the cochlea | 49 | 9.67e-01 | 3.46e-03 | 9.97e-01 |
RHO GTPases Activate WASPs and WAVEs | 34 | 9.73e-01 | -3.32e-03 | 9.99e-01 |
IRS-mediated signalling | 47 | 9.69e-01 | 3.31e-03 | 9.97e-01 |
Inwardly rectifying K+ channels | 35 | 9.73e-01 | 3.27e-03 | 9.99e-01 |
Cholesterol biosynthesis | 24 | 9.79e-01 | 3.14e-03 | 9.99e-01 |
Metabolism of water-soluble vitamins and cofactors | 118 | 9.53e-01 | 3.12e-03 | 9.97e-01 |
Glucagon-type ligand receptors | 33 | 9.77e-01 | 2.85e-03 | 9.99e-01 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 9.82e-01 | 2.73e-03 | 9.99e-01 |
Antiviral mechanism by IFN-stimulated genes | 78 | 9.69e-01 | -2.58e-03 | 9.97e-01 |
Metallothioneins bind metals | 11 | 9.88e-01 | -2.57e-03 | 9.99e-01 |
Transport of inorganic cations/anions and amino acids/oligopeptides | 101 | 9.65e-01 | 2.55e-03 | 9.97e-01 |
NOTCH3 Intracellular Domain Regulates Transcription | 24 | 9.83e-01 | 2.45e-03 | 9.99e-01 |
NOTCH1 Intracellular Domain Regulates Transcription | 44 | 9.78e-01 | -2.38e-03 | 9.99e-01 |
Arachidonic acid metabolism | 56 | 9.76e-01 | 2.31e-03 | 9.99e-01 |
Interleukin-6 family signaling | 24 | 9.85e-01 | 2.23e-03 | 9.99e-01 |
Neurexins and neuroligins | 52 | 9.78e-01 | -2.23e-03 | 9.99e-01 |
ZBP1(DAI) mediated induction of type I IFNs | 20 | 9.87e-01 | -2.13e-03 | 9.99e-01 |
Diseases of signal transduction by growth factor receptors and second messengers | 410 | 9.45e-01 | -1.98e-03 | 9.96e-01 |
SARS-CoV-1 activates/modulates innate immune responses | 37 | 9.84e-01 | 1.88e-03 | 9.99e-01 |
Signaling by ALK | 26 | 9.89e-01 | -1.61e-03 | 9.99e-01 |
MAPK family signaling cascades | 311 | 9.64e-01 | -1.50e-03 | 9.97e-01 |
Interaction between L1 and Ankyrins | 28 | 9.89e-01 | 1.48e-03 | 9.99e-01 |
HCMV Late Events | 54 | 9.85e-01 | -1.46e-03 | 9.99e-01 |
Base Excision Repair | 45 | 9.87e-01 | 1.44e-03 | 9.99e-01 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 9.93e-01 | -1.37e-03 | 9.99e-01 |
Paracetamol ADME | 27 | 9.91e-01 | 1.30e-03 | 9.99e-01 |
Ion transport by P-type ATPases | 51 | 9.87e-01 | -1.27e-03 | 9.99e-01 |
COPI-mediated anterograde transport | 83 | 9.84e-01 | 1.24e-03 | 9.99e-01 |
Recruitment of NuMA to mitotic centrosomes | 75 | 9.86e-01 | 1.16e-03 | 9.99e-01 |
Mitotic Prometaphase | 174 | 9.84e-01 | -9.01e-04 | 9.99e-01 |
Blood group systems biosynthesis | 22 | 9.95e-01 | 7.85e-04 | 9.99e-01 |
PI3K/AKT Signaling in Cancer | 103 | 9.90e-01 | -7.24e-04 | 9.99e-01 |
CTNNB1 S33 mutants aren’t phosphorylated | 14 | 9.97e-01 | -6.00e-04 | 9.99e-01 |
CTNNB1 S37 mutants aren’t phosphorylated | 14 | 9.97e-01 | -6.00e-04 | 9.99e-01 |
CTNNB1 S45 mutants aren’t phosphorylated | 14 | 9.97e-01 | -6.00e-04 | 9.99e-01 |
CTNNB1 T41 mutants aren’t phosphorylated | 14 | 9.97e-01 | -6.00e-04 | 9.99e-01 |
Signaling by CTNNB1 phospho-site mutants | 14 | 9.97e-01 | -6.00e-04 | 9.99e-01 |
Signaling by GSK3beta mutants | 14 | 9.97e-01 | -6.00e-04 | 9.99e-01 |
Role of phospholipids in phagocytosis | 23 | 9.97e-01 | 5.07e-04 | 9.99e-01 |
Oncogene Induced Senescence | 35 | 9.97e-01 | -3.36e-04 | 9.99e-01 |
mRNA decay by 3’ to 5’ exoribonuclease | 16 | 9.99e-01 | -2.33e-04 | 1.00e+00 |
Translation of Replicase and Assembly of the Replication Transcription Complex 9679504 | 13 | 1.00e+00 | -7.18e-05 | 1.00e+00 |
Sphingolipid de novo biosynthesis | 41 | 1.00e+00 | -4.18e-05 | 1.00e+00 |
Chylomicron remodeling
206 | |
---|---|
set | Chylomicron remodeling |
setSize | 10 |
pANOVA | 0.00305 |
s.dist | 0.541 |
p.adjustANOVA | 0.0813 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APOA2 | 17217 |
APOA4 | 17129 |
LPL | 16862 |
APOC3 | 15625 |
APOA5 | 15294 |
APOC2 | 14770 |
GPIHBP1 | 8361 |
APOA1 | 8252 |
APOE | 5656 |
APOB | 4266 |
GeneID | Gene Rank |
---|---|
APOA2 | 17217 |
APOA4 | 17129 |
LPL | 16862 |
APOC3 | 15625 |
APOA5 | 15294 |
APOC2 | 14770 |
GPIHBP1 | 8361 |
APOA1 | 8252 |
APOE | 5656 |
APOB | 4266 |
TRAF6 mediated IRF7 activation
1384 | |
---|---|
set | TRAF6 mediated IRF7 activation |
setSize | 26 |
pANOVA | 2.37e-05 |
s.dist | -0.479 |
p.adjustANOVA | 0.00127 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IFNA6 | -7468 |
IFNA16 | -7435 |
IFNA2 | -7322 |
IFNA21 | -7163 |
IFNB1 | -7151 |
IFNA14 | -7144 |
IFNA1 | -7016 |
TRIM4 | -6997 |
TANK | -5818 |
IFNA5 | -5642 |
SIKE1 | -5193 |
IFNA7 | -4213 |
DDX58 | -3097 |
TBK1 | -3086 |
IFNA8 | -2552 |
EP300 | -1077 |
TRIM25 | -689 |
MAVS | 1150 |
CREBBP | 1815 |
IRF3 | 6357 |
GeneID | Gene Rank |
---|---|
IFNA6 | -7468 |
IFNA16 | -7435 |
IFNA2 | -7322 |
IFNA21 | -7163 |
IFNB1 | -7151 |
IFNA14 | -7144 |
IFNA1 | -7016 |
TRIM4 | -6997 |
TANK | -5818 |
IFNA5 | -5642 |
SIKE1 | -5193 |
IFNA7 | -4213 |
DDX58 | -3097 |
TBK1 | -3086 |
IFNA8 | -2552 |
EP300 | -1077 |
TRIM25 | -689 |
MAVS | 1150 |
CREBBP | 1815 |
IRF3 | 6357 |
TRAF2 | 7594 |
RNF135 | 7867 |
IFIH1 | 7936 |
IKBKE | 10394 |
TRAF6 | 12950 |
IRF7 | 12961 |
SARS-CoV-1 modulates host translation machinery
1163 | |
---|---|
set | SARS-CoV-1 modulates host translation machinery |
setSize | 34 |
pANOVA | 8.57e-06 |
s.dist | 0.441 |
p.adjustANOVA | 0.000509 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPS10 | 17181.0 |
RPS16 | 16779.0 |
RPS27A | 16523.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
HNRNPA1 | 13954.0 |
RPS27L | 13689.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
RPS6 | 11935.0 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPS10 | 17181.0 |
RPS16 | 16779.0 |
RPS27A | 16523.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
HNRNPA1 | 13954.0 |
RPS27L | 13689.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
RPS6 | 11935.0 |
RPS7 | 11217.0 |
RPS8 | 10835.0 |
RPS2 | 9470.5 |
RPS18 | 8661.0 |
RPS15 | 7536.0 |
RPS5 | 6716.0 |
RPS15A | 6158.0 |
RPS3A | 4909.0 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
RPS20 | 2265.0 |
EEF1A1 | 748.0 |
RPS12 | -575.0 |
FAU | -3698.0 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
777 | |
---|---|
set | NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 |
setSize | 12 |
pANOVA | 0.00989 |
s.dist | -0.43 |
p.adjustANOVA | 0.207 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TRIM4 | -6997 |
FADD | -5407 |
CHUK | -3917 |
CASP10 | -3872 |
RIPK1 | -3687 |
DDX58 | -3097 |
TRIM25 | -689 |
MAVS | 1150 |
CASP8 | 3851 |
IKBKB | 5090 |
RNF135 | 7867 |
IFIH1 | 7936 |
GeneID | Gene Rank |
---|---|
TRIM4 | -6997 |
FADD | -5407 |
CHUK | -3917 |
CASP10 | -3872 |
RIPK1 | -3687 |
DDX58 | -3097 |
TRIM25 | -689 |
MAVS | 1150 |
CASP8 | 3851 |
IKBKB | 5090 |
RNF135 | 7867 |
IFIH1 | 7936 |
Interaction With Cumulus Cells And The Zona Pellucida
614 | |
---|---|
set | Interaction With Cumulus Cells And The Zona Pellucida |
setSize | 11 |
pANOVA | 0.017 |
s.dist | -0.416 |
p.adjustANOVA | 0.291 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SPAM1 | -6586 |
ADAM2 | -4450 |
ADAM21 | -4309 |
B4GALT1 | -3784 |
ADAM20 | -1435 |
ZP2 | 315 |
OVGP1 | 738 |
ADAM30 | 1659 |
ZP4 | 1996 |
ZP1 | 7373 |
ZP3 | 8909 |
GeneID | Gene Rank |
---|---|
SPAM1 | -6586 |
ADAM2 | -4450 |
ADAM21 | -4309 |
B4GALT1 | -3784 |
ADAM20 | -1435 |
ZP2 | 315 |
OVGP1 | 738 |
ADAM30 | 1659 |
ZP4 | 1996 |
ZP1 | 7373 |
ZP3 | 8909 |
Expression and translocation of olfactory receptors
399 | |
---|---|
set | Expression and translocation of olfactory receptors |
setSize | 358 |
pANOVA | 2.87e-37 |
s.dist | -0.391 |
p.adjustANOVA | 4.43e-34 |
Top enriched genes
GeneID | Gene Rank |
---|---|
OR8U1 | -7415 |
OR2A12 | -7413 |
OR52D1 | -7401 |
OR52A5 | -7378 |
OR7E24 | -7374 |
OR4Q3 | -7353 |
OR2W3 | -7342 |
OR5P2 | -7314 |
OR10H3 | -7308 |
OR52E4 | -7283 |
OR8D1 | -7276 |
OR6C1 | -7261 |
OR1J2 | -7257 |
OR5K1 | -7250 |
OR2G6 | -7245 |
OR5AC2 | -7221 |
OR52H1 | -7217 |
OR4N4 | -7215 |
OR51G2 | -7197 |
OR5T2 | -7167 |
GeneID | Gene Rank |
---|---|
OR8U1 | -7415.0 |
OR2A12 | -7413.0 |
OR52D1 | -7401.0 |
OR52A5 | -7378.0 |
OR7E24 | -7374.0 |
OR4Q3 | -7353.0 |
OR2W3 | -7342.0 |
OR5P2 | -7314.0 |
OR10H3 | -7308.0 |
OR52E4 | -7283.0 |
OR8D1 | -7276.0 |
OR6C1 | -7261.0 |
OR1J2 | -7257.0 |
OR5K1 | -7250.0 |
OR2G6 | -7245.0 |
OR5AC2 | -7221.0 |
OR52H1 | -7217.0 |
OR4N4 | -7215.0 |
OR51G2 | -7197.0 |
OR5T2 | -7167.0 |
OR6M1 | -7162.0 |
OR5F1 | -7155.0 |
OR8H1 | -7141.0 |
OR2G3 | -7131.0 |
OR6K6 | -7111.0 |
OR5K4 | -7089.0 |
OR9G1 | -7079.5 |
OR9G9 | -7079.5 |
OR14A16 | -7078.0 |
OR2B6 | -7058.0 |
OR8B2 | -7044.0 |
OR8K3 | -7017.0 |
OR13C8 | -7004.0 |
OR5AP2 | -6995.0 |
OR6Q1 | -6987.0 |
OR6C75 | -6982.0 |
OR2T10 | -6956.0 |
OR5D18 | -6950.0 |
OR10G8 | -6949.0 |
OR4E2 | -6945.0 |
OR8D2 | -6934.0 |
OR2T33 | -6894.0 |
OR5B12 | -6882.0 |
OR8I2 | -6881.0 |
OR51A7 | -6876.0 |
OR52I2 | -6858.0 |
OR5K3 | -6845.0 |
OR5K2 | -6803.0 |
OR9G4 | -6794.0 |
OR5M9 | -6769.0 |
OR13C4 | -6767.0 |
OR6C3 | -6755.0 |
OR8K1 | -6748.0 |
OR2K2 | -6744.0 |
OR4F15 | -6741.0 |
OR5AN1 | -6705.0 |
OR10W1 | -6693.0 |
OR6C2 | -6629.0 |
OR5AK2 | -6622.0 |
OR2B3 | -6599.0 |
OR6N2 | -6597.0 |
OR6C74 | -6594.0 |
OR4C45 | -6582.0 |
OR12D2 | -6563.0 |
OR51I2 | -6552.0 |
OR4N5 | -6525.0 |
OR10G4 | -6502.0 |
OR8U8 | -6474.0 |
OR1S1 | -6468.0 |
OR10G9 | -6425.0 |
OR56A3 | -6423.0 |
OR4D10 | -6390.0 |
OR7G2 | -6385.0 |
OR11G2 | -6311.0 |
OR2W1 | -6253.0 |
OR10J5 | -6237.0 |
OR5M10 | -6207.0 |
OR4K14 | -6193.0 |
OR51I1 | -6187.0 |
OR5H6 | -6135.0 |
OR5H1 | -6116.0 |
OR3A2 | -6102.0 |
OR13C3 | -6079.0 |
OR6C6 | -6059.0 |
OR1B1 | -6013.0 |
OR2T1 | -5989.0 |
OR8H2 | -5919.0 |
OR5D16 | -5918.0 |
OR10Q1 | -5916.0 |
OR13F1 | -5915.0 |
OR1J1 | -5885.0 |
OR5P3 | -5853.0 |
OR51V1 | -5847.0 |
OR4B1 | -5842.0 |
OR51B6 | -5810.0 |
OR4C46 | -5799.0 |
OR13G1 | -5760.0 |
OR4A16 | -5755.0 |
OR1A1 | -5717.0 |
OR52E6 | -5707.0 |
OR2J2 | -5690.0 |
OR10A4 | -5689.0 |
OR6P1 | -5653.0 |
OR2AG1 | -5641.0 |
OR5AS1 | -5633.0 |
OR6C70 | -5600.0 |
OR8H3 | -5585.0 |
OR5M11 | -5579.0 |
OR10A3 | -5426.0 |
OR13C2 | -5349.0 |
OR10H4 | -5297.0 |
OR1N2 | -5266.0 |
OR2M5 | -5243.0 |
OR5W2 | -5238.0 |
OR10AG1 | -5117.0 |
OR52K2 | -5107.0 |
OR2D3 | -5067.0 |
OR2M4 | -5042.0 |
OR1L3 | -5023.0 |
OR9A2 | -4989.0 |
OR8G1 | -4984.0 |
OR52I1 | -4983.0 |
OR10A6 | -4963.0 |
OR8J1 | -4942.0 |
OR5A1 | -4916.0 |
OR2T6 | -4912.0 |
OR4C13 | -4911.0 |
OR6C4 | -4891.0 |
OR5B3 | -4796.0 |
OR52B6 | -4712.0 |
OR10J1 | -4688.0 |
OR7D4 | -4606.0 |
OR51E2 | -4564.0 |
OR4C6 | -4554.0 |
OR6B3 | -4542.0 |
OR4P4 | -4500.0 |
OR10A7 | -4448.0 |
OR4D5 | -4446.0 |
OR1K1 | -4430.0 |
OR5B2 | -4429.0 |
OR7C1 | -4291.0 |
OR2A14 | -4259.0 |
OR4A47 | -4244.0 |
OR1E1 | -4195.0 |
OR52R1 | -4137.0 |
OR52M1 | -4117.0 |
OR52E8 | -4102.0 |
OR2AK2 | -4085.0 |
OR6F1 | -4068.0 |
OR2T8 | -3960.0 |
OR51B5 | -3930.0 |
OR5M8 | -3883.0 |
OR5M3 | -3864.0 |
OR6T1 | -3857.0 |
OR3A1 | -3848.0 |
OR2S2 | -3838.0 |
OR2L8 | -3769.0 |
OR10H1 | -3732.0 |
OR5T3 | -3725.0 |
OR11A1 | -3695.0 |
OR4C12 | -3693.0 |
OR2H1 | -3665.0 |
OR6C76 | -3663.0 |
OR5I1 | -3654.0 |
OR8J3 | -3642.0 |
OR10G3 | -3633.0 |
OR6B1 | -3604.0 |
OR56A1 | -3541.0 |
OR14J1 | -3539.0 |
OR10K2 | -3442.0 |
OR7A10 | -3399.0 |
OR6A2 | -3204.0 |
OR2L5 | -3158.0 |
OR10AD1 | -3091.0 |
OR11H4 | -3064.0 |
OR51B4 | -3056.0 |
OR51B2 | -3038.0 |
OR2L13 | -2905.0 |
OR4M1 | -2777.0 |
OR7G1 | -2716.0 |
OR4N2 | -2660.0 |
OR2B2 | -2565.0 |
OR5R1 | -2549.0 |
OR1A2 | -2366.0 |
OR1Q1 | -2210.0 |
OR4K13 | -2196.0 |
OR1C1 | -2191.0 |
OR2J3 | -2176.0 |
OR7D2 | -2098.0 |
OR52N1 | -1926.0 |
OR10G2 | -1792.0 |
OR5L2 | -1734.0 |
OR51D1 | -1660.0 |
OR10T2 | -1561.0 |
OR2Y1 | -1477.0 |
OR4X2 | -1471.0 |
OR8B12 | -1453.0 |
OR7A5 | -1450.0 |
OR5M1 | -1399.0 |
OR51L1 | -1394.0 |
OR51T1 | -1377.0 |
OR2T3 | -1289.0 |
OR4K17 | -1260.0 |
OR5H15 | -1237.0 |
OR5AU1 | -1176.0 |
OR5H2 | -1170.0 |
OR2F1 | -1152.0 |
OR10G7 | -1122.0 |
OR5C1 | -1040.0 |
OR1J4 | -1033.0 |
OR4D9 | -963.0 |
OR5V1 | -892.0 |
OR5T1 | -865.0 |
OR4F6 | -377.0 |
OR12D3 | -246.0 |
OR1N1 | -203.0 |
OR13C9 | -182.0 |
OR14C36 | -139.0 |
OR1D2 | 5.0 |
OR2V2 | 107.0 |
REEP1 | 338.0 |
OR52E2 | 485.0 |
OR14I1 | 553.0 |
OR10P1 | 630.0 |
OR10S1 | 728.0 |
OR2T34 | 756.0 |
OR6X1 | 773.0 |
OR4K1 | 993.0 |
OR52A1 | 1216.0 |
OR52N5 | 1226.0 |
OR7C2 | 1251.0 |
OR5A2 | 1277.0 |
OR51A2 | 1341.0 |
OR4K15 | 1465.0 |
OR1I1 | 1479.0 |
OR9Q1 | 1502.0 |
OR9Q2 | 1602.0 |
OR8S1 | 1629.0 |
OR5D14 | 1654.0 |
OR6C65 | 1715.0 |
OR6V1 | 2074.0 |
OR4X1 | 2329.0 |
OR56A4 | 2333.0 |
OR2A2 | 2444.0 |
OR11H6 | 2448.0 |
OR2T4 | 2667.0 |
OR1M1 | 2782.0 |
OR51M1 | 2883.0 |
OR52N2 | 2924.0 |
OR2T11 | 2943.0 |
OR52J3 | 2998.0 |
OR4A15 | 3223.0 |
OR10C1 | 3369.0 |
OR6S1 | 3452.0 |
OR2M3 | 3493.0 |
OR4L1 | 3533.0 |
OR4D1 | 3576.0 |
OR2T27 | 4184.0 |
OR4D2 | 4330.0 |
OR4K2 | 4470.0 |
OR8A1 | 4564.0 |
OR4D11 | 4681.0 |
OR2A25 | 4747.0 |
EBF1 | 4836.0 |
OR5B17 | 4937.0 |
OR9K2 | 5359.0 |
OR1E2 | 5639.0 |
OR52K1 | 5680.0 |
OR1L6 | 5790.0 |
OR9I1 | 5810.0 |
OR2M7 | 5875.0 |
OR4C15 | 6193.0 |
OR51S1 | 6242.0 |
OR4M2 | 6605.0 |
OR4D6 | 6636.0 |
OR6B2 | 6778.0 |
OR7A17 | 6824.0 |
OR13J1 | 6913.0 |
OR8G5 | 7155.0 |
OR1L8 | 7189.0 |
OR11L1 | 7390.0 |
OR2AE1 | 7447.0 |
OR4K5 | 7610.0 |
OR1L4 | 7886.0 |
OR1L1 | 8541.0 |
OR2W5 | 8612.0 |
OR6Y1 | 8617.0 |
OR6K3 | 8641.0 |
OR4C16 | 8753.0 |
OR56B1 | 8832.0 |
OR1F1 | 8880.0 |
OR8K5 | 8895.0 |
RTP1 | 9085.0 |
OR51G1 | 9321.0 |
OR10X1 | 9519.0 |
OR5D13 | 9650.0 |
OR51E1 | 9770.0 |
OR10A5 | 9803.0 |
OR2B11 | 9874.0 |
OR10A2 | 9973.0 |
OR52L1 | 10107.0 |
OR2C1 | 10203.0 |
OR2F2 | 10446.0 |
OR2Z1 | 10616.0 |
OR5J2 | 10713.0 |
OR2C3 | 10797.0 |
OR2AT4 | 10809.0 |
OR2H2 | 10855.0 |
OR5B21 | 11248.0 |
OR51F2 | 11292.0 |
OR11H2 | 11369.0 |
OR10Z1 | 11503.0 |
LHX2 | 11824.0 |
OR51A4 | 11831.0 |
OR10K1 | 12149.0 |
OR13A1 | 12233.0 |
OR2D2 | 12286.0 |
OR4S2 | 12406.0 |
OR3A3 | 12412.0 |
LDB1 | 12926.0 |
OR4C3 | 13177.0 |
OR2G2 | 13257.0 |
OR2L3 | 13426.0 |
OR4S1 | 13694.0 |
OR8D4 | 13815.0 |
OR9A4 | 14233.0 |
OR4A5 | 14257.0 |
OR10H5 | 14526.0 |
OR6K2 | 14556.0 |
OR1S2 | 14969.0 |
OR5L1 | 15152.0 |
OR10V1 | 15399.0 |
OR1G1 | 15541.0 |
OR5AR1 | 15552.0 |
OR51Q1 | 15584.0 |
OR10J3 | 15681.0 |
OR10R2 | 16010.0 |
OR10H2 | 16153.0 |
OR6N1 | 16233.0 |
OR56A5 | 16326.0 |
OR2V1 | 16484.0 |
OR2M2 | 16504.0 |
OR8B4 | 16713.0 |
OR2AP1 | 16838.0 |
OR6C68 | 16889.0 |
OR52B2 | 17034.0 |
OR2AG2 | 17037.0 |
OR51F1 | 17180.0 |
OR52W1 | 17351.0 |
OR2L2 | 17379.0 |
OR8B8 | 17557.0 |
RTP2 | 17644.0 |
OR56B4 | 17651.0 |
OR2A5 | 18021.0 |
OR8G2 | 18054.0 |
OR13D1 | 18175.0 |
OR4C11 | 18193.0 |
OR7G3 | 18240.0 |
Class C/3 (Metabotropic glutamate/pheromone receptors)
212 | |
---|---|
set | Class C/3 (Metabotropic glutamate/pheromone receptors) |
setSize | 39 |
pANOVA | 2.37e-05 |
s.dist | -0.391 |
p.adjustANOVA | 0.00127 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TAS2R46 | -7452 |
TAS2R10 | -7310 |
TAS2R14 | -6919 |
TAS2R30 | -6829 |
TAS2R50 | -6669 |
TAS2R4 | -6595 |
TAS2R3 | -6571 |
TAS2R43 | -6544 |
TAS2R39 | -6461 |
TAS2R13 | -6294 |
TAS2R8 | -6293 |
TAS2R60 | -6164 |
TAS2R7 | -5710 |
TAS2R31 | -5577 |
TAS2R16 | -4849 |
TAS2R5 | -4738 |
TAS2R42 | -4731 |
GRM5 | -3756 |
TAS1R2 | -1546 |
CASR | -216 |
GeneID | Gene Rank |
---|---|
TAS2R46 | -7452 |
TAS2R10 | -7310 |
TAS2R14 | -6919 |
TAS2R30 | -6829 |
TAS2R50 | -6669 |
TAS2R4 | -6595 |
TAS2R3 | -6571 |
TAS2R43 | -6544 |
TAS2R39 | -6461 |
TAS2R13 | -6294 |
TAS2R8 | -6293 |
TAS2R60 | -6164 |
TAS2R7 | -5710 |
TAS2R31 | -5577 |
TAS2R16 | -4849 |
TAS2R5 | -4738 |
TAS2R42 | -4731 |
GRM5 | -3756 |
TAS1R2 | -1546 |
CASR | -216 |
GRM2 | 1073 |
TAS2R20 | 1309 |
GRM1 | 1770 |
TAS2R19 | 2118 |
TAS2R1 | 2865 |
GRM7 | 3154 |
TAS2R9 | 3397 |
TAS1R3 | 4261 |
GRM6 | 4303 |
GABBR2 | 5340 |
GRM8 | 5532 |
GPRC6A | 7900 |
TAS2R41 | 9704 |
GRM4 | 9830 |
TAS2R38 | 10441 |
GABBR1 | 11256 |
TAS2R40 | 11572 |
GRM3 | 12751 |
TAS1R1 | 16655 |
Caspase activation via Death Receptors in the presence of ligand
172 | |
---|---|
set | Caspase activation via Death Receptors in the presence of ligand |
setSize | 16 |
pANOVA | 0.00813 |
s.dist | -0.382 |
p.adjustANOVA | 0.175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CD14 | -6790 |
LY96 | -6284 |
FADD | -5407 |
FASLG | -5334 |
RIPK1 | -3687 |
TICAM2 | -2212 |
CFLAR | -1598 |
TLR4 | -1541 |
TICAM1 | 541 |
TNFSF10 | 2616 |
TNFRSF10B | 2934 |
FAS | 3536 |
CASP8 | 3851 |
TNFRSF10A | 4713 |
TRAF2 | 7594 |
TRADD | 14572 |
GeneID | Gene Rank |
---|---|
CD14 | -6790 |
LY96 | -6284 |
FADD | -5407 |
FASLG | -5334 |
RIPK1 | -3687 |
TICAM2 | -2212 |
CFLAR | -1598 |
TLR4 | -1541 |
TICAM1 | 541 |
TNFSF10 | 2616 |
TNFRSF10B | 2934 |
FAS | 3536 |
CASP8 | 3851 |
TNFRSF10A | 4713 |
TRAF2 | 7594 |
TRADD | 14572 |
Olfactory Signaling Pathway
853 | |
---|---|
set | Olfactory Signaling Pathway |
setSize | 365 |
pANOVA | 4.02e-36 |
s.dist | -0.381 |
p.adjustANOVA | 3.11e-33 |
Top enriched genes
GeneID | Gene Rank |
---|---|
OR8U1 | -7415 |
OR2A12 | -7413 |
OR52D1 | -7401 |
OR52A5 | -7378 |
OR7E24 | -7374 |
OR4Q3 | -7353 |
OR2W3 | -7342 |
OR5P2 | -7314 |
OR10H3 | -7308 |
OR52E4 | -7283 |
OR8D1 | -7276 |
OR6C1 | -7261 |
OR1J2 | -7257 |
OR5K1 | -7250 |
OR2G6 | -7245 |
OR5AC2 | -7221 |
OR52H1 | -7217 |
OR4N4 | -7215 |
OR51G2 | -7197 |
OR5T2 | -7167 |
GeneID | Gene Rank |
---|---|
OR8U1 | -7415.0 |
OR2A12 | -7413.0 |
OR52D1 | -7401.0 |
OR52A5 | -7378.0 |
OR7E24 | -7374.0 |
OR4Q3 | -7353.0 |
OR2W3 | -7342.0 |
OR5P2 | -7314.0 |
OR10H3 | -7308.0 |
OR52E4 | -7283.0 |
OR8D1 | -7276.0 |
OR6C1 | -7261.0 |
OR1J2 | -7257.0 |
OR5K1 | -7250.0 |
OR2G6 | -7245.0 |
OR5AC2 | -7221.0 |
OR52H1 | -7217.0 |
OR4N4 | -7215.0 |
OR51G2 | -7197.0 |
OR5T2 | -7167.0 |
OR6M1 | -7162.0 |
OR5F1 | -7155.0 |
OR8H1 | -7141.0 |
OR2G3 | -7131.0 |
OR6K6 | -7111.0 |
OR5K4 | -7089.0 |
OR9G1 | -7079.5 |
OR9G9 | -7079.5 |
OR14A16 | -7078.0 |
OR2B6 | -7058.0 |
OR8B2 | -7044.0 |
OR8K3 | -7017.0 |
OR13C8 | -7004.0 |
OR5AP2 | -6995.0 |
OR6Q1 | -6987.0 |
OR6C75 | -6982.0 |
OR2T10 | -6956.0 |
OR5D18 | -6950.0 |
OR10G8 | -6949.0 |
OR4E2 | -6945.0 |
OR8D2 | -6934.0 |
OR2T33 | -6894.0 |
OR5B12 | -6882.0 |
OR8I2 | -6881.0 |
OR51A7 | -6876.0 |
OR52I2 | -6858.0 |
OR5K3 | -6845.0 |
OR5K2 | -6803.0 |
OR9G4 | -6794.0 |
OR5M9 | -6769.0 |
OR13C4 | -6767.0 |
OR6C3 | -6755.0 |
OR8K1 | -6748.0 |
OR2K2 | -6744.0 |
OR4F15 | -6741.0 |
OR5AN1 | -6705.0 |
OR10W1 | -6693.0 |
OR6C2 | -6629.0 |
OR5AK2 | -6622.0 |
OR2B3 | -6599.0 |
OR6N2 | -6597.0 |
OR6C74 | -6594.0 |
OR4C45 | -6582.0 |
OR12D2 | -6563.0 |
OR51I2 | -6552.0 |
OR4N5 | -6525.0 |
OR10G4 | -6502.0 |
OR8U8 | -6474.0 |
OR1S1 | -6468.0 |
OR10G9 | -6425.0 |
OR56A3 | -6423.0 |
OR4D10 | -6390.0 |
OR7G2 | -6385.0 |
OR11G2 | -6311.0 |
OR2W1 | -6253.0 |
OR10J5 | -6237.0 |
OR5M10 | -6207.0 |
OR4K14 | -6193.0 |
OR51I1 | -6187.0 |
OR5H6 | -6135.0 |
OR5H1 | -6116.0 |
OR3A2 | -6102.0 |
OR13C3 | -6079.0 |
OR6C6 | -6059.0 |
OR1B1 | -6013.0 |
OR2T1 | -5989.0 |
OR8H2 | -5919.0 |
OR5D16 | -5918.0 |
OR10Q1 | -5916.0 |
OR13F1 | -5915.0 |
OR1J1 | -5885.0 |
OR5P3 | -5853.0 |
OR51V1 | -5847.0 |
OR4B1 | -5842.0 |
OR51B6 | -5810.0 |
OR4C46 | -5799.0 |
OR13G1 | -5760.0 |
OR4A16 | -5755.0 |
OR1A1 | -5717.0 |
OR52E6 | -5707.0 |
OR2J2 | -5690.0 |
OR10A4 | -5689.0 |
OR6P1 | -5653.0 |
OR2AG1 | -5641.0 |
OR5AS1 | -5633.0 |
OR6C70 | -5600.0 |
OR8H3 | -5585.0 |
OR5M11 | -5579.0 |
OR10A3 | -5426.0 |
OR13C2 | -5349.0 |
OR10H4 | -5297.0 |
OR1N2 | -5266.0 |
OR2M5 | -5243.0 |
OR5W2 | -5238.0 |
OR10AG1 | -5117.0 |
OR52K2 | -5107.0 |
OR2D3 | -5067.0 |
OR2M4 | -5042.0 |
OR1L3 | -5023.0 |
OR9A2 | -4989.0 |
OR8G1 | -4984.0 |
OR52I1 | -4983.0 |
OR10A6 | -4963.0 |
OR8J1 | -4942.0 |
OR5A1 | -4916.0 |
OR2T6 | -4912.0 |
OR4C13 | -4911.0 |
OR6C4 | -4891.0 |
OR5B3 | -4796.0 |
OR52B6 | -4712.0 |
OR10J1 | -4688.0 |
OR7D4 | -4606.0 |
OR51E2 | -4564.0 |
OR4C6 | -4554.0 |
OR6B3 | -4542.0 |
OR4P4 | -4500.0 |
OR10A7 | -4448.0 |
OR4D5 | -4446.0 |
OR1K1 | -4430.0 |
OR5B2 | -4429.0 |
OR7C1 | -4291.0 |
OR2A14 | -4259.0 |
OR4A47 | -4244.0 |
OR1E1 | -4195.0 |
OR52R1 | -4137.0 |
OR52M1 | -4117.0 |
OR52E8 | -4102.0 |
OR2AK2 | -4085.0 |
OR6F1 | -4068.0 |
OR2T8 | -3960.0 |
OR51B5 | -3930.0 |
OR5M8 | -3883.0 |
OR5M3 | -3864.0 |
OR6T1 | -3857.0 |
OR3A1 | -3848.0 |
OR2S2 | -3838.0 |
OR2L8 | -3769.0 |
OR10H1 | -3732.0 |
OR5T3 | -3725.0 |
OR11A1 | -3695.0 |
OR4C12 | -3693.0 |
OR2H1 | -3665.0 |
OR6C76 | -3663.0 |
OR5I1 | -3654.0 |
OR8J3 | -3642.0 |
OR10G3 | -3633.0 |
OR6B1 | -3604.0 |
GNG13 | -3542.0 |
OR56A1 | -3541.0 |
OR14J1 | -3539.0 |
OR10K2 | -3442.0 |
OR7A10 | -3399.0 |
OR6A2 | -3204.0 |
OR2L5 | -3158.0 |
OR10AD1 | -3091.0 |
OR11H4 | -3064.0 |
OR51B4 | -3056.0 |
OR51B2 | -3038.0 |
OR2L13 | -2905.0 |
OR4M1 | -2777.0 |
OR7G1 | -2716.0 |
OR4N2 | -2660.0 |
OR2B2 | -2565.0 |
OR5R1 | -2549.0 |
OR1A2 | -2366.0 |
OR1Q1 | -2210.0 |
OR4K13 | -2196.0 |
OR1C1 | -2191.0 |
OR2J3 | -2176.0 |
OR7D2 | -2098.0 |
OR52N1 | -1926.0 |
OR10G2 | -1792.0 |
OR5L2 | -1734.0 |
OR51D1 | -1660.0 |
OR10T2 | -1561.0 |
OR2Y1 | -1477.0 |
OR4X2 | -1471.0 |
OR8B12 | -1453.0 |
OR7A5 | -1450.0 |
OR5M1 | -1399.0 |
OR51L1 | -1394.0 |
OR51T1 | -1377.0 |
OR2T3 | -1289.0 |
OR4K17 | -1260.0 |
OR5H15 | -1237.0 |
OR5AU1 | -1176.0 |
OR5H2 | -1170.0 |
OR2F1 | -1152.0 |
OR10G7 | -1122.0 |
OR5C1 | -1040.0 |
OR1J4 | -1033.0 |
OR4D9 | -963.0 |
OR5V1 | -892.0 |
OR5T1 | -865.0 |
OR4F6 | -377.0 |
OR12D3 | -246.0 |
OR1N1 | -203.0 |
OR13C9 | -182.0 |
OR14C36 | -139.0 |
OR1D2 | 5.0 |
OR2V2 | 107.0 |
REEP1 | 338.0 |
OR52E2 | 485.0 |
OR14I1 | 553.0 |
OR10P1 | 630.0 |
OR10S1 | 728.0 |
OR2T34 | 756.0 |
OR6X1 | 773.0 |
OR4K1 | 993.0 |
OR52A1 | 1216.0 |
OR52N5 | 1226.0 |
OR7C2 | 1251.0 |
OR5A2 | 1277.0 |
OR51A2 | 1341.0 |
OR4K15 | 1465.0 |
OR1I1 | 1479.0 |
OR9Q1 | 1502.0 |
OR9Q2 | 1602.0 |
OR8S1 | 1629.0 |
OR5D14 | 1654.0 |
OR6C65 | 1715.0 |
OR6V1 | 2074.0 |
OR4X1 | 2329.0 |
OR56A4 | 2333.0 |
OR2A2 | 2444.0 |
OR11H6 | 2448.0 |
OR2T4 | 2667.0 |
OR1M1 | 2782.0 |
OR51M1 | 2883.0 |
OR52N2 | 2924.0 |
OR2T11 | 2943.0 |
OR52J3 | 2998.0 |
ANO2 | 3156.0 |
OR4A15 | 3223.0 |
OR10C1 | 3369.0 |
OR6S1 | 3452.0 |
OR2M3 | 3493.0 |
OR4L1 | 3533.0 |
OR4D1 | 3576.0 |
OR2T27 | 4184.0 |
OR4D2 | 4330.0 |
OR4K2 | 4470.0 |
OR8A1 | 4564.0 |
OR4D11 | 4681.0 |
OR2A25 | 4747.0 |
GNB1 | 4758.0 |
EBF1 | 4836.0 |
OR5B17 | 4937.0 |
GNAL | 5309.0 |
OR9K2 | 5359.0 |
OR1E2 | 5639.0 |
OR52K1 | 5680.0 |
OR1L6 | 5790.0 |
OR9I1 | 5810.0 |
OR2M7 | 5875.0 |
OR4C15 | 6193.0 |
OR51S1 | 6242.0 |
OR4M2 | 6605.0 |
OR4D6 | 6636.0 |
OR6B2 | 6778.0 |
OR7A17 | 6824.0 |
OR13J1 | 6913.0 |
OR8G5 | 7155.0 |
OR1L8 | 7189.0 |
OR11L1 | 7390.0 |
OR2AE1 | 7447.0 |
OR4K5 | 7610.0 |
OR1L4 | 7886.0 |
OR1L1 | 8541.0 |
OR2W5 | 8612.0 |
OR6Y1 | 8617.0 |
OR6K3 | 8641.0 |
OR4C16 | 8753.0 |
OR56B1 | 8832.0 |
OR1F1 | 8880.0 |
OR8K5 | 8895.0 |
RTP1 | 9085.0 |
OR51G1 | 9321.0 |
OR10X1 | 9519.0 |
OR5D13 | 9650.0 |
OR51E1 | 9770.0 |
OR10A5 | 9803.0 |
OR2B11 | 9874.0 |
OR10A2 | 9973.0 |
OR52L1 | 10107.0 |
OR2C1 | 10203.0 |
OR2F2 | 10446.0 |
OR2Z1 | 10616.0 |
OR5J2 | 10713.0 |
OR2C3 | 10797.0 |
OR2AT4 | 10809.0 |
OR2H2 | 10855.0 |
OR5B21 | 11248.0 |
OR51F2 | 11292.0 |
OR11H2 | 11369.0 |
OR10Z1 | 11503.0 |
LHX2 | 11824.0 |
OR51A4 | 11831.0 |
OR10K1 | 12149.0 |
OR13A1 | 12233.0 |
OR2D2 | 12286.0 |
ADCY3 | 12397.0 |
OR4S2 | 12406.0 |
OR3A3 | 12412.0 |
LDB1 | 12926.0 |
CNGA4 | 13050.0 |
OR4C3 | 13177.0 |
OR2G2 | 13257.0 |
OR2L3 | 13426.0 |
OR4S1 | 13694.0 |
OR8D4 | 13815.0 |
OR9A4 | 14233.0 |
OR4A5 | 14257.0 |
OR10H5 | 14526.0 |
OR6K2 | 14556.0 |
CNGB1 | 14611.0 |
OR1S2 | 14969.0 |
OR5L1 | 15152.0 |
OR10V1 | 15399.0 |
OR1G1 | 15541.0 |
OR5AR1 | 15552.0 |
OR51Q1 | 15584.0 |
OR10J3 | 15681.0 |
OR10R2 | 16010.0 |
OR10H2 | 16153.0 |
OR6N1 | 16233.0 |
OR56A5 | 16326.0 |
OR2V1 | 16484.0 |
OR2M2 | 16504.0 |
OR8B4 | 16713.0 |
OR2AP1 | 16838.0 |
OR6C68 | 16889.0 |
OR52B2 | 17034.0 |
OR2AG2 | 17037.0 |
OR51F1 | 17180.0 |
OR52W1 | 17351.0 |
OR2L2 | 17379.0 |
OR8B8 | 17557.0 |
RTP2 | 17644.0 |
OR56B4 | 17651.0 |
OR2A5 | 18021.0 |
OR8G2 | 18054.0 |
OR13D1 | 18175.0 |
OR4C11 | 18193.0 |
OR7G3 | 18240.0 |
Glucuronidation
516 | |
---|---|
set | Glucuronidation |
setSize | 25 |
pANOVA | 0.00116 |
s.dist | -0.375 |
p.adjustANOVA | 0.0417 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UGT2A3 | -7350.0 |
UGT2A2 | -7243.0 |
UGT2B10 | -7237.0 |
UGT2A1 | -6534.0 |
UGT2B17 | -6267.0 |
UGT2B15 | -6266.0 |
UGT2B28 | -6112.0 |
UGT2B4 | -5459.0 |
SLC35D1 | -4152.0 |
UGT2B11 | -3483.0 |
UGT3A2 | -2945.0 |
UGT3A1 | -688.0 |
UGT1A1 | -650.0 |
UGP2 | 101.0 |
UGT1A4 | 1402.5 |
UGT1A5 | 1402.5 |
UGT1A3 | 3217.0 |
UGT2B7 | 6422.0 |
UGDH | 7285.0 |
UGT1A10 | 9182.0 |
GeneID | Gene Rank |
---|---|
UGT2A3 | -7350.0 |
UGT2A2 | -7243.0 |
UGT2B10 | -7237.0 |
UGT2A1 | -6534.0 |
UGT2B17 | -6267.0 |
UGT2B15 | -6266.0 |
UGT2B28 | -6112.0 |
UGT2B4 | -5459.0 |
SLC35D1 | -4152.0 |
UGT2B11 | -3483.0 |
UGT3A2 | -2945.0 |
UGT3A1 | -688.0 |
UGT1A1 | -650.0 |
UGP2 | 101.0 |
UGT1A4 | 1402.5 |
UGT1A5 | 1402.5 |
UGT1A3 | 3217.0 |
UGT2B7 | 6422.0 |
UGDH | 7285.0 |
UGT1A10 | 9182.0 |
UGT1A9 | 9455.0 |
UGT1A7 | 9811.5 |
UGT1A8 | 9811.5 |
UGT1A6 | 10117.0 |
ABHD10 | 10144.0 |
Diseases associated with glycosylation precursor biosynthesis
324 | |
---|---|
set | Diseases associated with glycosylation precursor biosynthesis |
setSize | 15 |
pANOVA | 0.0119 |
s.dist | 0.375 |
p.adjustANOVA | 0.23 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DPM3 | 17740.0 |
GFPT1 | 16865.0 |
DPM1 | 16184.5 |
DOLK | 15670.0 |
PGM1 | 15109.0 |
GALE | 13102.0 |
DPM2 | 13096.0 |
GALK1 | 13024.0 |
SRD5A3 | 10709.0 |
NUS1 | 10233.0 |
DHDDS | 9745.0 |
PMM2 | 2695.0 |
GALT | 2605.0 |
MPI | 73.0 |
GNE | -3747.0 |
GeneID | Gene Rank |
---|---|
DPM3 | 17740.0 |
GFPT1 | 16865.0 |
DPM1 | 16184.5 |
DOLK | 15670.0 |
PGM1 | 15109.0 |
GALE | 13102.0 |
DPM2 | 13096.0 |
GALK1 | 13024.0 |
SRD5A3 | 10709.0 |
NUS1 | 10233.0 |
DHDDS | 9745.0 |
PMM2 | 2695.0 |
GALT | 2605.0 |
MPI | 73.0 |
GNE | -3747.0 |
Chylomicron assembly
205 | |
---|---|
set | Chylomicron assembly |
setSize | 10 |
pANOVA | 0.0423 |
s.dist | 0.371 |
p.adjustANOVA | 0.491 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APOA2 | 17217.0 |
APOA4 | 17129.0 |
APOC3 | 15625.0 |
APOC2 | 14770.0 |
MTTP | 12552.5 |
APOA1 | 8252.0 |
SAR1B | 7161.0 |
APOE | 5656.0 |
APOB | 4266.0 |
P4HB | -1080.0 |
GeneID | Gene Rank |
---|---|
APOA2 | 17217.0 |
APOA4 | 17129.0 |
APOC3 | 15625.0 |
APOC2 | 14770.0 |
MTTP | 12552.5 |
APOA1 | 8252.0 |
SAR1B | 7161.0 |
APOE | 5656.0 |
APOB | 4266.0 |
P4HB | -1080.0 |
Phase 4 - resting membrane potential
913 | |
---|---|
set | Phase 4 - resting membrane potential |
setSize | 19 |
pANOVA | 0.00633 |
s.dist | 0.362 |
p.adjustANOVA | 0.146 |
Top enriched genes
GeneID | Gene Rank |
---|---|
KCNK18 | 17657 |
KCNK16 | 17623 |
KCNJ4 | 16023 |
KCNJ14 | 15907 |
KCNJ12 | 15499 |
KCNK6 | 14054 |
KCNK5 | 12973 |
KCNK15 | 11712 |
KCNJ2 | 11455 |
KCNK7 | 10824 |
KCNK17 | 9354 |
KCNK4 | 9125 |
KCNK3 | 9118 |
KCNK10 | 8755 |
KCNK12 | 5494 |
KCNK9 | 3675 |
KCNK13 | 1281 |
KCNK1 | 261 |
KCNK2 | -103 |
GeneID | Gene Rank |
---|---|
KCNK18 | 17657 |
KCNK16 | 17623 |
KCNJ4 | 16023 |
KCNJ14 | 15907 |
KCNJ12 | 15499 |
KCNK6 | 14054 |
KCNK5 | 12973 |
KCNK15 | 11712 |
KCNJ2 | 11455 |
KCNK7 | 10824 |
KCNK17 | 9354 |
KCNK4 | 9125 |
KCNK3 | 9118 |
KCNK10 | 8755 |
KCNK12 | 5494 |
KCNK9 | 3675 |
KCNK13 | 1281 |
KCNK1 | 261 |
KCNK2 | -103 |
mRNA Editing
1521 | |
---|---|
set | mRNA Editing |
setSize | 10 |
pANOVA | 0.0527 |
s.dist | -0.354 |
p.adjustANOVA | 0.569 |
Top enriched genes
GeneID | Gene Rank |
---|---|
A1CF | -6315 |
APOBEC4 | -3549 |
APOBEC3B | -2492 |
APOBEC3C | -1811 |
APOBEC3H | -1121 |
APOBEC3A | -1102 |
APOBEC1 | 982 |
ADARB1 | 3072 |
APOBEC2 | 5695 |
ADAR | 14963 |
GeneID | Gene Rank |
---|---|
A1CF | -6315 |
APOBEC4 | -3549 |
APOBEC3B | -2492 |
APOBEC3C | -1811 |
APOBEC3H | -1121 |
APOBEC3A | -1102 |
APOBEC1 | 982 |
ADARB1 | 3072 |
APOBEC2 | 5695 |
ADAR | 14963 |
NF-kB is activated and signals survival
778 | |
---|---|
set | NF-kB is activated and signals survival |
setSize | 12 |
pANOVA | 0.0344 |
s.dist | 0.353 |
p.adjustANOVA | 0.438 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | 16523 |
NFKBIA | 15601 |
UBC | 13572 |
TRAF6 | 12950 |
UBB | 12753 |
RELA | 12174 |
NGF | 9591 |
NGFR | 8785 |
SQSTM1 | 6440 |
IKBKB | 5090 |
UBA52 | 4986 |
NFKB1 | 571 |
GeneID | Gene Rank |
---|---|
RPS27A | 16523 |
NFKBIA | 15601 |
UBC | 13572 |
TRAF6 | 12950 |
UBB | 12753 |
RELA | 12174 |
NGF | 9591 |
NGFR | 8785 |
SQSTM1 | 6440 |
IKBKB | 5090 |
UBA52 | 4986 |
NFKB1 | 571 |
Signaling by cytosolic FGFR1 fusion mutants
1310 | |
---|---|
set | Signaling by cytosolic FGFR1 fusion mutants |
setSize | 17 |
pANOVA | 0.0124 |
s.dist | -0.35 |
p.adjustANOVA | 0.236 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ZMYM2 | -5033.0 |
GAB2 | -3577.0 |
STAT5B | -3526.0 |
FGFR1OP2 | -3190.5 |
STAT1 | -2931.0 |
TRIM24 | -2631.0 |
STAT5A | -2524.0 |
CNTRL | -1927.0 |
CUX1 | -1153.0 |
STAT3 | 287.0 |
LRRFIP1 | 2119.0 |
BCR | 4764.0 |
PIK3CA | 5312.0 |
GRB2 | 5702.0 |
PIK3R1 | 6497.0 |
CPSF6 | 7431.0 |
MYO18A | 9301.0 |
GeneID | Gene Rank |
---|---|
ZMYM2 | -5033.0 |
GAB2 | -3577.0 |
STAT5B | -3526.0 |
FGFR1OP2 | -3190.5 |
STAT1 | -2931.0 |
TRIM24 | -2631.0 |
STAT5A | -2524.0 |
CNTRL | -1927.0 |
CUX1 | -1153.0 |
STAT3 | 287.0 |
LRRFIP1 | 2119.0 |
BCR | 4764.0 |
PIK3CA | 5312.0 |
GRB2 | 5702.0 |
PIK3R1 | 6497.0 |
CPSF6 | 7431.0 |
MYO18A | 9301.0 |
Synthesis of PIPs at the late endosome membrane
1342 | |
---|---|
set | Synthesis of PIPs at the late endosome membrane |
setSize | 10 |
pANOVA | 0.0656 |
s.dist | -0.336 |
p.adjustANOVA | 0.611 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PIK3C2A | -6704 |
PIK3C3 | -4860 |
MTMR9 | -4044 |
PIKFYVE | -1808 |
MTMR2 | -1503 |
PIK3R4 | -343 |
MTMR7 | 537 |
FIG4 | 4347 |
VAC14 | 12173 |
MTMR4 | 12796 |
GeneID | Gene Rank |
---|---|
PIK3C2A | -6704 |
PIK3C3 | -4860 |
MTMR9 | -4044 |
PIKFYVE | -1808 |
MTMR2 | -1503 |
PIK3R4 | -343 |
MTMR7 | 537 |
FIG4 | 4347 |
VAC14 | 12173 |
MTMR4 | 12796 |
Viral mRNA Translation
1496 | |
---|---|
set | Viral mRNA Translation |
setSize | 84 |
pANOVA | 1.4e-07 |
s.dist | 0.332 |
p.adjustANOVA | 2.7e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928 |
RPL10L | 17345 |
RPL34 | 17330 |
RPL27 | 17307 |
RPL23 | 17292 |
RPL18A | 17183 |
RPS10 | 17181 |
RPL35A | 17098 |
RPS16 | 16779 |
RPL32 | 16664 |
RPS27A | 16523 |
RPL24 | 16506 |
RPS28 | 16458 |
RPS14 | 16358 |
RPL17 | 16189 |
RPS29 | 16138 |
RPS9 | 16050 |
RPSA | 16030 |
RPS19 | 15679 |
RPL28 | 15605 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPL10L | 17345.0 |
RPL34 | 17330.0 |
RPL27 | 17307.0 |
RPL23 | 17292.0 |
RPL18A | 17183.0 |
RPS10 | 17181.0 |
RPL35A | 17098.0 |
RPS16 | 16779.0 |
RPL32 | 16664.0 |
RPS27A | 16523.0 |
RPL24 | 16506.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPL17 | 16189.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPL28 | 15605.0 |
RPL26L1 | 15561.5 |
RPL38 | 14997.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
RPL7 | 13881.0 |
RPL13A | 13855.5 |
RPS27L | 13689.0 |
GRSF1 | 13560.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
RPL19 | 12327.0 |
RPS6 | 11935.0 |
RPL41 | 11601.0 |
RPS7 | 11217.0 |
RPL7A | 11203.5 |
RPS8 | 10835.0 |
RPL3L | 10775.0 |
RPL9 | 10376.0 |
RPLP2 | 10294.0 |
RPL36AL | 9850.0 |
RPLP1 | 9499.0 |
RPS2 | 9470.5 |
RPL13 | 9381.5 |
RPL30 | 9189.0 |
RPL29 | 9040.0 |
RPS18 | 8661.0 |
DNAJC3 | 8441.0 |
RPL4 | 8015.0 |
RPL14 | 7987.0 |
RPL26 | 7877.0 |
RPS15 | 7536.0 |
RPL23A | 7183.0 |
RPL12 | 7117.0 |
RPS5 | 6716.0 |
RPL21 | 6561.0 |
RPL8 | 6517.0 |
RPL37 | 6491.0 |
RPL37A | 6372.0 |
RPS15A | 6158.0 |
RPL22 | 5299.0 |
UBA52 | 4986.0 |
RPS3A | 4909.0 |
RPL22L1 | 4649.0 |
RPL3 | 4399.5 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
RPL5 | 2965.0 |
RPL31 | 2893.0 |
RPS20 | 2265.0 |
RPL18 | 2245.0 |
RPL11 | 1692.0 |
RPL36 | 1435.0 |
RPL39L | 484.0 |
RPL10A | 307.0 |
RPLP0 | -192.0 |
RPS12 | -575.0 |
RPL35 | -1039.0 |
RPL6 | -1615.0 |
RPL15 | -2406.5 |
RPL27A | -3404.0 |
FAU | -3698.0 |
Cytosolic iron-sulfur cluster assembly
252 | |
---|---|
set | Cytosolic iron-sulfur cluster assembly |
setSize | 10 |
pANOVA | 0.0701 |
s.dist | 0.331 |
p.adjustANOVA | 0.623 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NDOR1 | 14654.0 |
POLD1 | 14360.0 |
CIAPIN1 | 12843.0 |
RTEL1 | 12506.0 |
NUBP1 | 10970.0 |
MMS19 | 9469.0 |
BRIP1 | 6658.0 |
NUBP2 | 6265.0 |
CIAO1 | 5409.5 |
ERCC2 | 3252.0 |
GeneID | Gene Rank |
---|---|
NDOR1 | 14654.0 |
POLD1 | 14360.0 |
CIAPIN1 | 12843.0 |
RTEL1 | 12506.0 |
NUBP1 | 10970.0 |
MMS19 | 9469.0 |
BRIP1 | 6658.0 |
NUBP2 | 6265.0 |
CIAO1 | 5409.5 |
ERCC2 | 3252.0 |
Regulation of NF-kappa B signaling
1091 | |
---|---|
set | Regulation of NF-kappa B signaling |
setSize | 17 |
pANOVA | 0.0183 |
s.dist | 0.33 |
p.adjustANOVA | 0.305 |
Top enriched genes
GeneID | Gene Rank |
---|---|
LRRC14 | 16756 |
RPS27A | 16523 |
USP18 | 15611 |
UBC | 13572 |
TRAF6 | 12950 |
UBB | 12753 |
NLRC5 | 12511 |
IKBIP | 12175 |
USP14 | 11471 |
NLRX1 | 11084 |
TP53 | 10118 |
TRAF2 | 7594 |
IKBKB | 5090 |
UBA52 | 4986 |
CASP8 | 3851 |
N4BP1 | 642 |
CHUK | -3917 |
GeneID | Gene Rank |
---|---|
LRRC14 | 16756 |
RPS27A | 16523 |
USP18 | 15611 |
UBC | 13572 |
TRAF6 | 12950 |
UBB | 12753 |
NLRC5 | 12511 |
IKBIP | 12175 |
USP14 | 11471 |
NLRX1 | 11084 |
TP53 | 10118 |
TRAF2 | 7594 |
IKBKB | 5090 |
UBA52 | 4986 |
CASP8 | 3851 |
N4BP1 | 642 |
CHUK | -3917 |
Eukaryotic Translation Termination
397 | |
---|---|
set | Eukaryotic Translation Termination |
setSize | 87 |
pANOVA | 1.07e-07 |
s.dist | 0.329 |
p.adjustANOVA | 2.7e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928 |
RPL10L | 17345 |
RPL34 | 17330 |
RPL27 | 17307 |
RPL23 | 17292 |
RPL18A | 17183 |
RPS10 | 17181 |
RPL35A | 17098 |
APEH | 17003 |
RPS16 | 16779 |
RPL32 | 16664 |
RPS27A | 16523 |
RPL24 | 16506 |
RPS28 | 16458 |
RPS14 | 16358 |
RPL17 | 16189 |
RPS29 | 16138 |
RPS9 | 16050 |
RPSA | 16030 |
RPS19 | 15679 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPL10L | 17345.0 |
RPL34 | 17330.0 |
RPL27 | 17307.0 |
RPL23 | 17292.0 |
RPL18A | 17183.0 |
RPS10 | 17181.0 |
RPL35A | 17098.0 |
APEH | 17003.0 |
RPS16 | 16779.0 |
RPL32 | 16664.0 |
RPS27A | 16523.0 |
RPL24 | 16506.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPL17 | 16189.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPL28 | 15605.0 |
RPL26L1 | 15561.5 |
RPL38 | 14997.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
RPL7 | 13881.0 |
RPL13A | 13855.5 |
RPS27L | 13689.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
RPL19 | 12327.0 |
RPS6 | 11935.0 |
RPL41 | 11601.0 |
N6AMT1 | 11257.0 |
RPS7 | 11217.0 |
RPL7A | 11203.5 |
RPS8 | 10835.0 |
RPL3L | 10775.0 |
ETF1 | 10700.0 |
RPL9 | 10376.0 |
RPLP2 | 10294.0 |
RPL36AL | 9850.0 |
RPLP1 | 9499.0 |
RPS2 | 9470.5 |
RPL13 | 9381.5 |
RPL30 | 9189.0 |
RPL29 | 9040.0 |
RPS18 | 8661.0 |
RPL4 | 8015.0 |
RPL14 | 7987.0 |
RPL26 | 7877.0 |
RPS15 | 7536.0 |
RPL23A | 7183.0 |
RPL12 | 7117.0 |
RPS5 | 6716.0 |
RPL21 | 6561.0 |
RPL8 | 6517.0 |
RPL37 | 6491.0 |
RPL37A | 6372.0 |
GSPT1 | 6259.0 |
RPS15A | 6158.0 |
RPL22 | 5299.0 |
UBA52 | 4986.0 |
RPS3A | 4909.0 |
RPL22L1 | 4649.0 |
RPL3 | 4399.5 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
RPL5 | 2965.0 |
RPL31 | 2893.0 |
TRMT112 | 2583.5 |
RPS20 | 2265.0 |
RPL18 | 2245.0 |
RPL11 | 1692.0 |
RPL36 | 1435.0 |
RPL39L | 484.0 |
RPL10A | 307.0 |
RPLP0 | -192.0 |
RPS12 | -575.0 |
RPL35 | -1039.0 |
RPL6 | -1615.0 |
RPL15 | -2406.5 |
RPL27A | -3404.0 |
FAU | -3698.0 |
Peptide chain elongation
903 | |
---|---|
set | Peptide chain elongation |
setSize | 84 |
pANOVA | 2.21e-07 |
s.dist | 0.327 |
p.adjustANOVA | 3.45e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928 |
RPL10L | 17345 |
RPL34 | 17330 |
RPL27 | 17307 |
RPL23 | 17292 |
RPL18A | 17183 |
RPS10 | 17181 |
RPL35A | 17098 |
RPS16 | 16779 |
RPL32 | 16664 |
RPS27A | 16523 |
RPL24 | 16506 |
RPS28 | 16458 |
RPS14 | 16358 |
RPL17 | 16189 |
RPS29 | 16138 |
RPS9 | 16050 |
RPSA | 16030 |
RPS19 | 15679 |
RPL28 | 15605 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPL10L | 17345.0 |
RPL34 | 17330.0 |
RPL27 | 17307.0 |
RPL23 | 17292.0 |
RPL18A | 17183.0 |
RPS10 | 17181.0 |
RPL35A | 17098.0 |
RPS16 | 16779.0 |
RPL32 | 16664.0 |
RPS27A | 16523.0 |
RPL24 | 16506.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPL17 | 16189.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPL28 | 15605.0 |
RPL26L1 | 15561.5 |
EEF2 | 15497.5 |
RPL38 | 14997.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
RPL7 | 13881.0 |
RPL13A | 13855.5 |
RPS27L | 13689.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
RPL19 | 12327.0 |
RPS6 | 11935.0 |
RPL41 | 11601.0 |
RPS7 | 11217.0 |
RPL7A | 11203.5 |
RPS8 | 10835.0 |
RPL3L | 10775.0 |
RPL9 | 10376.0 |
RPLP2 | 10294.0 |
RPL36AL | 9850.0 |
RPLP1 | 9499.0 |
RPS2 | 9470.5 |
RPL13 | 9381.5 |
RPL30 | 9189.0 |
RPL29 | 9040.0 |
RPS18 | 8661.0 |
RPL4 | 8015.0 |
RPL14 | 7987.0 |
RPL26 | 7877.0 |
RPS15 | 7536.0 |
RPL23A | 7183.0 |
RPL12 | 7117.0 |
RPS5 | 6716.0 |
RPL21 | 6561.0 |
RPL8 | 6517.0 |
RPL37 | 6491.0 |
RPL37A | 6372.0 |
RPS15A | 6158.0 |
RPL22 | 5299.0 |
UBA52 | 4986.0 |
RPS3A | 4909.0 |
RPL22L1 | 4649.0 |
RPL3 | 4399.5 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
RPL5 | 2965.0 |
RPL31 | 2893.0 |
RPS20 | 2265.0 |
RPL18 | 2245.0 |
RPL11 | 1692.0 |
RPL36 | 1435.0 |
EEF1A1 | 748.0 |
RPL39L | 484.0 |
RPL10A | 307.0 |
RPLP0 | -192.0 |
RPS12 | -575.0 |
RPL35 | -1039.0 |
RPL6 | -1615.0 |
RPL15 | -2406.5 |
RPL27A | -3404.0 |
FAU | -3698.0 |
Regulation of IFNA/IFNB signaling
1086 | |
---|---|
set | Regulation of IFNA/IFNB signaling |
setSize | 22 |
pANOVA | 0.00814 |
s.dist | -0.326 |
p.adjustANOVA | 0.175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IFNA6 | -7468 |
IFNA16 | -7435 |
IFNA2 | -7322 |
IFNA21 | -7163 |
IFNB1 | -7151 |
IFNA14 | -7144 |
IFNA1 | -7016 |
IFNA5 | -5642 |
IFNA7 | -4213 |
PTPN11 | -3314 |
STAT1 | -2931 |
IFNA8 | -2552 |
IFNAR2 | 3502 |
JAK1 | 4808 |
TYK2 | 7179 |
PTPN6 | 8314 |
PTPN1 | 8759 |
STAT2 | 8811 |
IFNAR1 | 10813 |
SOCS3 | 12384 |
GeneID | Gene Rank |
---|---|
IFNA6 | -7468 |
IFNA16 | -7435 |
IFNA2 | -7322 |
IFNA21 | -7163 |
IFNB1 | -7151 |
IFNA14 | -7144 |
IFNA1 | -7016 |
IFNA5 | -5642 |
IFNA7 | -4213 |
PTPN11 | -3314 |
STAT1 | -2931 |
IFNA8 | -2552 |
IFNAR2 | 3502 |
JAK1 | 4808 |
TYK2 | 7179 |
PTPN6 | 8314 |
PTPN1 | 8759 |
STAT2 | 8811 |
IFNAR1 | 10813 |
SOCS3 | 12384 |
SOCS1 | 15437 |
USP18 | 15611 |
Pexophagy
910 | |
---|---|
set | Pexophagy |
setSize | 11 |
pANOVA | 0.0645 |
s.dist | 0.322 |
p.adjustANOVA | 0.608 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PEX5 | 16952 |
RPS27A | 16523 |
NBR1 | 14948 |
UBC | 13572 |
UBB | 12753 |
MAP1LC3B | 12681 |
ATM | 11795 |
SQSTM1 | 6440 |
UBA52 | 4986 |
EPAS1 | -89 |
USP30 | -5787 |
GeneID | Gene Rank |
---|---|
PEX5 | 16952 |
RPS27A | 16523 |
NBR1 | 14948 |
UBC | 13572 |
UBB | 12753 |
MAP1LC3B | 12681 |
ATM | 11795 |
SQSTM1 | 6440 |
UBA52 | 4986 |
EPAS1 | -89 |
USP30 | -5787 |
Telomere C-strand synthesis initiation
1394 | |
---|---|
set | Telomere C-strand synthesis initiation |
setSize | 11 |
pANOVA | 0.0669 |
s.dist | -0.319 |
p.adjustANOVA | 0.617 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ACD | -4052.5 |
TERF1 | -2922.0 |
POT1 | -1335.0 |
POLA2 | -633.0 |
TERF2 | 639.0 |
PRIM1 | 1086.0 |
PRIM2 | 2034.0 |
TERF2IP | 2397.0 |
TINF2 | 4897.0 |
CTC1 | 5758.0 |
TEN1 | 6202.5 |
GeneID | Gene Rank |
---|---|
ACD | -4052.5 |
TERF1 | -2922.0 |
POT1 | -1335.0 |
POLA2 | -633.0 |
TERF2 | 639.0 |
PRIM1 | 1086.0 |
PRIM2 | 2034.0 |
TERF2IP | 2397.0 |
TINF2 | 4897.0 |
CTC1 | 5758.0 |
TEN1 | 6202.5 |
p75NTR recruits signalling complexes
1536 | |
---|---|
set | p75NTR recruits signalling complexes |
setSize | 12 |
pANOVA | 0.0557 |
s.dist | 0.319 |
p.adjustANOVA | 0.583 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | 16523.0 |
UBC | 13572.0 |
TRAF6 | 12950.0 |
UBB | 12753.0 |
PRKCI | 10853.0 |
MYD88 | 10683.0 |
NGF | 9591.0 |
NGFR | 8785.0 |
SQSTM1 | 6440.0 |
IKBKB | 5090.0 |
UBA52 | 4986.0 |
RIPK2 | 1622.5 |
GeneID | Gene Rank |
---|---|
RPS27A | 16523.0 |
UBC | 13572.0 |
TRAF6 | 12950.0 |
UBB | 12753.0 |
PRKCI | 10853.0 |
MYD88 | 10683.0 |
NGF | 9591.0 |
NGFR | 8785.0 |
SQSTM1 | 6440.0 |
IKBKB | 5090.0 |
UBA52 | 4986.0 |
RIPK2 | 1622.5 |
p75NTR signals via NF-kB
1537 | |
---|---|
set | p75NTR signals via NF-kB |
setSize | 15 |
pANOVA | 0.0327 |
s.dist | 0.318 |
p.adjustANOVA | 0.429 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | 16523.0 |
NFKBIA | 15601.0 |
UBC | 13572.0 |
TRAF6 | 12950.0 |
UBB | 12753.0 |
RELA | 12174.0 |
PRKCI | 10853.0 |
MYD88 | 10683.0 |
NGF | 9591.0 |
NGFR | 8785.0 |
SQSTM1 | 6440.0 |
IKBKB | 5090.0 |
UBA52 | 4986.0 |
RIPK2 | 1622.5 |
NFKB1 | 571.0 |
GeneID | Gene Rank |
---|---|
RPS27A | 16523.0 |
NFKBIA | 15601.0 |
UBC | 13572.0 |
TRAF6 | 12950.0 |
UBB | 12753.0 |
RELA | 12174.0 |
PRKCI | 10853.0 |
MYD88 | 10683.0 |
NGF | 9591.0 |
NGFR | 8785.0 |
SQSTM1 | 6440.0 |
IKBKB | 5090.0 |
UBA52 | 4986.0 |
RIPK2 | 1622.5 |
NFKB1 | 571.0 |
Intrinsic Pathway of Fibrin Clot Formation
646 | |
---|---|
set | Intrinsic Pathway of Fibrin Clot Formation |
setSize | 21 |
pANOVA | 0.0115 |
s.dist | -0.318 |
p.adjustANOVA | 0.229 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PROS1 | -6588 |
SERPINC1 | -4940 |
GP5 | -4342 |
GP1BA | -3551 |
A2M | -3529 |
SERPINE2 | -3345 |
KLKB1 | -2046 |
PRCP | -1365 |
KNG1 | -978 |
GP9 | -235 |
SERPIND1 | 535 |
F10 | 1413 |
PROC | 2747 |
C1QBP | 3344 |
SERPING1 | 4245 |
F12 | 4865 |
SERPINA5 | 5251 |
F11 | 5906 |
GP1BB | 7191 |
VWF | 8926 |
GeneID | Gene Rank |
---|---|
PROS1 | -6588 |
SERPINC1 | -4940 |
GP5 | -4342 |
GP1BA | -3551 |
A2M | -3529 |
SERPINE2 | -3345 |
KLKB1 | -2046 |
PRCP | -1365 |
KNG1 | -978 |
GP9 | -235 |
SERPIND1 | 535 |
F10 | 1413 |
PROC | 2747 |
C1QBP | 3344 |
SERPING1 | 4245 |
F12 | 4865 |
SERPINA5 | 5251 |
F11 | 5906 |
GP1BB | 7191 |
VWF | 8926 |
F2 | 13579 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
829 | |
---|---|
set | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
setSize | 89 |
pANOVA | 2.67e-07 |
s.dist | 0.315 |
p.adjustANOVA | 3.45e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928 |
RPL10L | 17345 |
RPL34 | 17330 |
RPL27 | 17307 |
RPL23 | 17292 |
RPL18A | 17183 |
RPS10 | 17181 |
RPL35A | 17098 |
RPS16 | 16779 |
RPL32 | 16664 |
RPS27A | 16523 |
RPL24 | 16506 |
RPS28 | 16458 |
RPS14 | 16358 |
RPL17 | 16189 |
RPS29 | 16138 |
RPS9 | 16050 |
RPSA | 16030 |
RPS19 | 15679 |
RPL28 | 15605 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPL10L | 17345.0 |
RPL34 | 17330.0 |
RPL27 | 17307.0 |
RPL23 | 17292.0 |
RPL18A | 17183.0 |
RPS10 | 17181.0 |
RPL35A | 17098.0 |
RPS16 | 16779.0 |
RPL32 | 16664.0 |
RPS27A | 16523.0 |
RPL24 | 16506.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPL17 | 16189.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPL28 | 15605.0 |
RPL26L1 | 15561.5 |
RPL38 | 14997.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
RPL7 | 13881.0 |
RPL13A | 13855.5 |
RPS27L | 13689.0 |
EIF4G1 | 13084.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
RPL19 | 12327.0 |
RPS6 | 11935.0 |
RPL41 | 11601.0 |
RPS7 | 11217.0 |
RPL7A | 11203.5 |
RPS8 | 10835.0 |
RPL3L | 10775.0 |
ETF1 | 10700.0 |
RPL9 | 10376.0 |
RPLP2 | 10294.0 |
RPL36AL | 9850.0 |
RPLP1 | 9499.0 |
RPS2 | 9470.5 |
RPL13 | 9381.5 |
RPL30 | 9189.0 |
RPL29 | 9040.0 |
RPS18 | 8661.0 |
PABPC1 | 8154.0 |
RPL4 | 8015.0 |
RPL14 | 7987.0 |
RPL26 | 7877.0 |
RPS15 | 7536.0 |
RPL23A | 7183.0 |
RPL12 | 7117.0 |
UPF1 | 6830.0 |
RPS5 | 6716.0 |
RPL21 | 6561.0 |
RPL8 | 6517.0 |
RPL37 | 6491.0 |
RPL37A | 6372.0 |
GSPT1 | 6259.0 |
RPS15A | 6158.0 |
NCBP1 | 5667.0 |
RPL22 | 5299.0 |
UBA52 | 4986.0 |
RPS3A | 4909.0 |
RPL22L1 | 4649.0 |
RPL3 | 4399.5 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
RPL5 | 2965.0 |
RPL31 | 2893.0 |
RPS20 | 2265.0 |
RPL18 | 2245.0 |
RPL11 | 1692.0 |
RPL36 | 1435.0 |
RPL39L | 484.0 |
RPL10A | 307.0 |
NCBP2 | 247.0 |
RPLP0 | -192.0 |
RPS12 | -575.0 |
RPL35 | -1039.0 |
RPL6 | -1615.0 |
RPL15 | -2406.5 |
RPL27A | -3404.0 |
FAU | -3698.0 |
Selenocysteine synthesis
1208 | |
---|---|
set | Selenocysteine synthesis |
setSize | 87 |
pANOVA | 4.02e-07 |
s.dist | 0.314 |
p.adjustANOVA | 4.61e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928 |
RPL10L | 17345 |
RPL34 | 17330 |
RPL27 | 17307 |
RPL23 | 17292 |
RPL18A | 17183 |
RPS10 | 17181 |
RPL35A | 17098 |
RPS16 | 16779 |
RPL32 | 16664 |
RPS27A | 16523 |
RPL24 | 16506 |
RPS28 | 16458 |
RPS14 | 16358 |
RPL17 | 16189 |
RPS29 | 16138 |
RPS9 | 16050 |
RPSA | 16030 |
RPS19 | 15679 |
RPL28 | 15605 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPL10L | 17345.0 |
RPL34 | 17330.0 |
RPL27 | 17307.0 |
RPL23 | 17292.0 |
RPL18A | 17183.0 |
RPS10 | 17181.0 |
RPL35A | 17098.0 |
RPS16 | 16779.0 |
RPL32 | 16664.0 |
RPS27A | 16523.0 |
RPL24 | 16506.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPL17 | 16189.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPL28 | 15605.0 |
RPL26L1 | 15561.5 |
RPL38 | 14997.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
RPL7 | 13881.0 |
RPL13A | 13855.5 |
RPS27L | 13689.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
RPL19 | 12327.0 |
RPS6 | 11935.0 |
RPL41 | 11601.0 |
RPS7 | 11217.0 |
RPL7A | 11203.5 |
RPS8 | 10835.0 |
RPL3L | 10775.0 |
RPL9 | 10376.0 |
RPLP2 | 10294.0 |
RPL36AL | 9850.0 |
EEFSEC | 9735.0 |
RPLP1 | 9499.0 |
RPS2 | 9470.5 |
RPL13 | 9381.5 |
RPL30 | 9189.0 |
RPL29 | 9040.0 |
RPS18 | 8661.0 |
RPL4 | 8015.0 |
RPL14 | 7987.0 |
RPL26 | 7877.0 |
RPS15 | 7536.0 |
SEPHS2 | 7289.0 |
RPL23A | 7183.0 |
RPL12 | 7117.0 |
RPS5 | 6716.0 |
RPL21 | 6561.0 |
RPL8 | 6517.0 |
RPL37 | 6491.0 |
RPL37A | 6372.0 |
RPS15A | 6158.0 |
RPL22 | 5299.0 |
SEPSECS | 5265.0 |
PSTK | 5077.0 |
UBA52 | 4986.0 |
RPS3A | 4909.0 |
RPL22L1 | 4649.0 |
RPL3 | 4399.5 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
SECISBP2 | 3413.0 |
RPL5 | 2965.0 |
RPL31 | 2893.0 |
RPS20 | 2265.0 |
RPL18 | 2245.0 |
RPL11 | 1692.0 |
RPL36 | 1435.0 |
RPL39L | 484.0 |
RPL10A | 307.0 |
RPLP0 | -192.0 |
RPS12 | -575.0 |
RPL35 | -1039.0 |
RPL6 | -1615.0 |
RPL15 | -2406.5 |
RPL27A | -3404.0 |
FAU | -3698.0 |
Eukaryotic Translation Elongation
395 | |
---|---|
set | Eukaryotic Translation Elongation |
setSize | 88 |
pANOVA | 4.17e-07 |
s.dist | 0.312 |
p.adjustANOVA | 4.61e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928 |
RPL10L | 17345 |
RPL34 | 17330 |
RPL27 | 17307 |
RPL23 | 17292 |
RPL18A | 17183 |
RPS10 | 17181 |
RPL35A | 17098 |
RPS16 | 16779 |
RPL32 | 16664 |
RPS27A | 16523 |
RPL24 | 16506 |
RPS28 | 16458 |
RPS14 | 16358 |
RPL17 | 16189 |
RPS29 | 16138 |
RPS9 | 16050 |
RPSA | 16030 |
RPS19 | 15679 |
RPL28 | 15605 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPL10L | 17345.0 |
RPL34 | 17330.0 |
RPL27 | 17307.0 |
RPL23 | 17292.0 |
RPL18A | 17183.0 |
RPS10 | 17181.0 |
RPL35A | 17098.0 |
RPS16 | 16779.0 |
RPL32 | 16664.0 |
RPS27A | 16523.0 |
RPL24 | 16506.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPL17 | 16189.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPL28 | 15605.0 |
RPL26L1 | 15561.5 |
EEF2 | 15497.5 |
RPL38 | 14997.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
RPL7 | 13881.0 |
RPL13A | 13855.5 |
RPS27L | 13689.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
RPL19 | 12327.0 |
RPS6 | 11935.0 |
RPL41 | 11601.0 |
RPS7 | 11217.0 |
RPL7A | 11203.5 |
RPS8 | 10835.0 |
RPL3L | 10775.0 |
EEF1D | 10534.0 |
RPL9 | 10376.0 |
RPLP2 | 10294.0 |
RPL36AL | 9850.0 |
RPLP1 | 9499.0 |
RPS2 | 9470.5 |
RPL13 | 9381.5 |
RPL30 | 9189.0 |
RPL29 | 9040.0 |
RPS18 | 8661.0 |
RPL4 | 8015.0 |
RPL14 | 7987.0 |
RPL26 | 7877.0 |
EEF1G | 7745.0 |
RPS15 | 7536.0 |
RPL23A | 7183.0 |
RPL12 | 7117.0 |
RPS5 | 6716.0 |
RPL21 | 6561.0 |
RPL8 | 6517.0 |
RPL37 | 6491.0 |
RPL37A | 6372.0 |
RPS15A | 6158.0 |
RPL22 | 5299.0 |
UBA52 | 4986.0 |
RPS3A | 4909.0 |
RPL22L1 | 4649.0 |
RPL3 | 4399.5 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
EEF1A2 | 4115.0 |
RPL5 | 2965.0 |
RPL31 | 2893.0 |
RPS20 | 2265.0 |
RPL18 | 2245.0 |
RPL11 | 1692.0 |
RPL36 | 1435.0 |
EEF1A1 | 748.0 |
RPL39L | 484.0 |
RPL10A | 307.0 |
RPLP0 | -192.0 |
RPS12 | -575.0 |
EEF1B2 | -960.0 |
RPL35 | -1039.0 |
RPL6 | -1615.0 |
RPL15 | -2406.5 |
RPL27A | -3404.0 |
FAU | -3698.0 |
TRAF3-dependent IRF activation pathway
1383 | |
---|---|
set | TRAF3-dependent IRF activation pathway |
setSize | 15 |
pANOVA | 0.0368 |
s.dist | -0.311 |
p.adjustANOVA | 0.441 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IFNB1 | -7151 |
TRIM4 | -6997 |
SIKE1 | -5193 |
DDX58 | -3097 |
TBK1 | -3086 |
EP300 | -1077 |
TRIM25 | -689 |
TRAF3 | -490 |
MAVS | 1150 |
CREBBP | 1815 |
IRF3 | 6357 |
RNF135 | 7867 |
IFIH1 | 7936 |
IKBKE | 10394 |
IRF7 | 12961 |
GeneID | Gene Rank |
---|---|
IFNB1 | -7151 |
TRIM4 | -6997 |
SIKE1 | -5193 |
DDX58 | -3097 |
TBK1 | -3086 |
EP300 | -1077 |
TRIM25 | -689 |
TRAF3 | -490 |
MAVS | 1150 |
CREBBP | 1815 |
IRF3 | 6357 |
RNF135 | 7867 |
IFIH1 | 7936 |
IKBKE | 10394 |
IRF7 | 12961 |
Platelet Adhesion to exposed collagen
929 | |
---|---|
set | Platelet Adhesion to exposed collagen |
setSize | 13 |
pANOVA | 0.0524 |
s.dist | -0.311 |
p.adjustANOVA | 0.569 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FCER1G | -6019 |
GP6 | -5420 |
LYN | -4971 |
GP5 | -4342 |
GP1BA | -3551 |
FYN | -3315 |
GP9 | -235 |
ITGA10 | 910 |
ITGA1 | 5468 |
GP1BB | 7191 |
VWF | 8926 |
ITGB1 | 10814 |
ITGA2 | 12572 |
GeneID | Gene Rank |
---|---|
FCER1G | -6019 |
GP6 | -5420 |
LYN | -4971 |
GP5 | -4342 |
GP1BA | -3551 |
FYN | -3315 |
GP9 | -235 |
ITGA10 | 910 |
ITGA1 | 5468 |
GP1BB | 7191 |
VWF | 8926 |
ITGB1 | 10814 |
ITGA2 | 12572 |
SUMOylation of immune response proteins
1198 | |
---|---|
set | SUMOylation of immune response proteins |
setSize | 10 |
pANOVA | 0.0925 |
s.dist | 0.307 |
p.adjustANOVA | 0.673 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PIAS3 | 17371 |
NFKBIA | 15601 |
RELA | 12174 |
NFKB2 | 11668 |
IKBKE | 10394 |
UBE2I | 8613 |
TOPORS | 7344 |
PIAS4 | 6354 |
SUMO1 | 2999 |
SUMO3 | 846 |
GeneID | Gene Rank |
---|---|
PIAS3 | 17371 |
NFKBIA | 15601 |
RELA | 12174 |
NFKB2 | 11668 |
IKBKE | 10394 |
UBE2I | 8613 |
TOPORS | 7344 |
PIAS4 | 6354 |
SUMO1 | 2999 |
SUMO3 | 846 |
Metabolism of folate and pterines
721 | |
---|---|
set | Metabolism of folate and pterines |
setSize | 16 |
pANOVA | 0.0341 |
s.dist | -0.306 |
p.adjustANOVA | 0.438 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MTHFS | -5372 |
MTHFD2 | -4969 |
MTHFD2L | -4123 |
DHFR | -3241 |
FOLR2 | -2112 |
MTHFD1L | -1006 |
MTHFD1 | 111 |
ALDH1L1 | 1046 |
SLC46A1 | 1126 |
SHMT1 | 1228 |
ALDH1L2 | 2746 |
SHMT2 | 4529 |
FPGS | 5485 |
SLC25A32 | 5630 |
MTHFR | 10439 |
SLC19A1 | 11687 |
GeneID | Gene Rank |
---|---|
MTHFS | -5372 |
MTHFD2 | -4969 |
MTHFD2L | -4123 |
DHFR | -3241 |
FOLR2 | -2112 |
MTHFD1L | -1006 |
MTHFD1 | 111 |
ALDH1L1 | 1046 |
SLC46A1 | 1126 |
SHMT1 | 1228 |
ALDH1L2 | 2746 |
SHMT2 | 4529 |
FPGS | 5485 |
SLC25A32 | 5630 |
MTHFR | 10439 |
SLC19A1 | 11687 |
Alpha-protein kinase 1 signaling pathway
70 | |
---|---|
set | Alpha-protein kinase 1 signaling pathway |
setSize | 10 |
pANOVA | 0.0969 |
s.dist | 0.303 |
p.adjustANOVA | 0.675 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MAP3K7 | 17659 |
RPS27A | 16523 |
UBC | 13572 |
TRAF6 | 12950 |
UBB | 12753 |
TIFA | 9992 |
TAB1 | 7528 |
UBA52 | 4986 |
ALPK1 | 2214 |
TAB2 | -5339 |
GeneID | Gene Rank |
---|---|
MAP3K7 | 17659 |
RPS27A | 16523 |
UBC | 13572 |
TRAF6 | 12950 |
UBB | 12753 |
TIFA | 9992 |
TAB1 | 7528 |
UBA52 | 4986 |
ALPK1 | 2214 |
TAB2 | -5339 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
54 | |
---|---|
set | Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S |
setSize | 54 |
pANOVA | 0.000148 |
s.dist | 0.298 |
p.adjustANOVA | 0.00655 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928 |
RPS10 | 17181 |
RPS16 | 16779 |
EIF3G | 16747 |
RPS27A | 16523 |
RPS28 | 16458 |
RPS14 | 16358 |
RPS29 | 16138 |
RPS9 | 16050 |
RPSA | 16030 |
RPS19 | 15679 |
EIF3I | 15333 |
RPS26 | 14854 |
RPS11 | 14847 |
RPS27 | 14838 |
RPS21 | 14082 |
RPS24 | 14073 |
EIF4A2 | 13943 |
RPS27L | 13689 |
EIF4G1 | 13084 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPS10 | 17181.0 |
RPS16 | 16779.0 |
EIF3G | 16747.0 |
RPS27A | 16523.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
EIF3I | 15333.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
EIF4A2 | 13943.0 |
RPS27L | 13689.0 |
EIF4G1 | 13084.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
EIF3D | 12117.0 |
RPS6 | 11935.0 |
RPS7 | 11217.0 |
EIF4B | 10978.0 |
RPS8 | 10835.0 |
EIF3J | 10022.0 |
EIF4EBP1 | 9749.0 |
RPS2 | 9470.5 |
RPS18 | 8661.0 |
EIF4E | 8302.0 |
PABPC1 | 8154.0 |
RPS15 | 7536.0 |
EIF3E | 7423.0 |
EIF4H | 6966.0 |
RPS5 | 6716.0 |
RPS15A | 6158.0 |
EIF4A1 | 5479.0 |
RPS3A | 4909.0 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
EIF3L | 3674.0 |
EIF2S1 | 2961.0 |
EIF3B | 2802.0 |
EIF3F | 2533.0 |
RPS20 | 2265.0 |
EIF3H | 157.0 |
RPS12 | -575.0 |
EIF2S2 | -1094.0 |
EIF3K | -2241.0 |
FAU | -3698.0 |
EIF3M | -4899.0 |
EIF3A | -5567.0 |
Translation initiation complex formation
1446 | |
---|---|
set | Translation initiation complex formation |
setSize | 53 |
pANOVA | 0.000178 |
s.dist | 0.298 |
p.adjustANOVA | 0.00764 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928 |
RPS10 | 17181 |
RPS16 | 16779 |
EIF3G | 16747 |
RPS27A | 16523 |
RPS28 | 16458 |
RPS14 | 16358 |
RPS29 | 16138 |
RPS9 | 16050 |
RPSA | 16030 |
RPS19 | 15679 |
EIF3I | 15333 |
RPS26 | 14854 |
RPS11 | 14847 |
RPS27 | 14838 |
RPS21 | 14082 |
RPS24 | 14073 |
EIF4A2 | 13943 |
RPS27L | 13689 |
EIF4G1 | 13084 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPS10 | 17181.0 |
RPS16 | 16779.0 |
EIF3G | 16747.0 |
RPS27A | 16523.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
EIF3I | 15333.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
EIF4A2 | 13943.0 |
RPS27L | 13689.0 |
EIF4G1 | 13084.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
EIF3D | 12117.0 |
RPS6 | 11935.0 |
RPS7 | 11217.0 |
EIF4B | 10978.0 |
RPS8 | 10835.0 |
EIF3J | 10022.0 |
RPS2 | 9470.5 |
RPS18 | 8661.0 |
EIF4E | 8302.0 |
PABPC1 | 8154.0 |
RPS15 | 7536.0 |
EIF3E | 7423.0 |
EIF4H | 6966.0 |
RPS5 | 6716.0 |
RPS15A | 6158.0 |
EIF4A1 | 5479.0 |
RPS3A | 4909.0 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
EIF3L | 3674.0 |
EIF2S1 | 2961.0 |
EIF3B | 2802.0 |
EIF3F | 2533.0 |
RPS20 | 2265.0 |
EIF3H | 157.0 |
RPS12 | -575.0 |
EIF2S2 | -1094.0 |
EIF3K | -2241.0 |
FAU | -3698.0 |
EIF3M | -4899.0 |
EIF3A | -5567.0 |
Biosynthesis of DHA-derived SPMs
125 | |
---|---|
set | Biosynthesis of DHA-derived SPMs |
setSize | 17 |
pANOVA | 0.0348 |
s.dist | 0.296 |
p.adjustANOVA | 0.438 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PTGS2 | 17390 |
CYP2E1 | 16999 |
CYP2D6 | 16570 |
ALOX12 | 16192 |
GPX4 | 15656 |
CYP3A4 | 15346 |
LTA4H | 12808 |
HPGD | 12543 |
CYP1A2 | 8917 |
ALOX5 | 8859 |
LTC4S | 8623 |
ALOX15 | 7382 |
CYP1A1 | 5259 |
GSTM4 | 3097 |
EPHX2 | 341 |
CYP2C9 | -4318 |
CYP2C8 | -5503 |
GeneID | Gene Rank |
---|---|
PTGS2 | 17390 |
CYP2E1 | 16999 |
CYP2D6 | 16570 |
ALOX12 | 16192 |
GPX4 | 15656 |
CYP3A4 | 15346 |
LTA4H | 12808 |
HPGD | 12543 |
CYP1A2 | 8917 |
ALOX5 | 8859 |
LTC4S | 8623 |
ALOX15 | 7382 |
CYP1A1 | 5259 |
GSTM4 | 3097 |
EPHX2 | 341 |
CYP2C9 | -4318 |
CYP2C8 | -5503 |
Pausing and recovery of Tat-mediated HIV elongation
901 | |
---|---|
set | Pausing and recovery of Tat-mediated HIV elongation |
setSize | 27 |
pANOVA | 0.00816 |
s.dist | 0.294 |
p.adjustANOVA | 0.175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2K | 17670 |
POLR2J | 17325 |
SUPT5H | 17078 |
CDK9 | 16907 |
NELFB | 15934 |
POLR2E | 15207 |
CCNT1 | 13852 |
SSRP1 | 13740 |
ELL | 13364 |
NELFE | 12928 |
POLR2L | 12768 |
POLR2G | 11535 |
POLR2F | 11524 |
POLR2D | 11325 |
POLR2I | 10998 |
NELFCD | 10258 |
SUPT4H1 | 9057 |
TCEA1 | 8945 |
NELFA | 6999 |
POLR2H | 5804 |
GeneID | Gene Rank |
---|---|
POLR2K | 17670 |
POLR2J | 17325 |
SUPT5H | 17078 |
CDK9 | 16907 |
NELFB | 15934 |
POLR2E | 15207 |
CCNT1 | 13852 |
SSRP1 | 13740 |
ELL | 13364 |
NELFE | 12928 |
POLR2L | 12768 |
POLR2G | 11535 |
POLR2F | 11524 |
POLR2D | 11325 |
POLR2I | 10998 |
NELFCD | 10258 |
SUPT4H1 | 9057 |
TCEA1 | 8945 |
NELFA | 6999 |
POLR2H | 5804 |
POLR2A | 2766 |
GTF2F2 | 1608 |
POLR2B | 172 |
POLR2C | -1472 |
CTDP1 | -1587 |
GTF2F1 | -3495 |
SUPT16H | -3766 |
Tat-mediated HIV elongation arrest and recovery
1391 | |
---|---|
set | Tat-mediated HIV elongation arrest and recovery |
setSize | 27 |
pANOVA | 0.00816 |
s.dist | 0.294 |
p.adjustANOVA | 0.175 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2K | 17670 |
POLR2J | 17325 |
SUPT5H | 17078 |
CDK9 | 16907 |
NELFB | 15934 |
POLR2E | 15207 |
CCNT1 | 13852 |
SSRP1 | 13740 |
ELL | 13364 |
NELFE | 12928 |
POLR2L | 12768 |
POLR2G | 11535 |
POLR2F | 11524 |
POLR2D | 11325 |
POLR2I | 10998 |
NELFCD | 10258 |
SUPT4H1 | 9057 |
TCEA1 | 8945 |
NELFA | 6999 |
POLR2H | 5804 |
GeneID | Gene Rank |
---|---|
POLR2K | 17670 |
POLR2J | 17325 |
SUPT5H | 17078 |
CDK9 | 16907 |
NELFB | 15934 |
POLR2E | 15207 |
CCNT1 | 13852 |
SSRP1 | 13740 |
ELL | 13364 |
NELFE | 12928 |
POLR2L | 12768 |
POLR2G | 11535 |
POLR2F | 11524 |
POLR2D | 11325 |
POLR2I | 10998 |
NELFCD | 10258 |
SUPT4H1 | 9057 |
TCEA1 | 8945 |
NELFA | 6999 |
POLR2H | 5804 |
POLR2A | 2766 |
GTF2F2 | 1608 |
POLR2B | 172 |
POLR2C | -1472 |
CTDP1 | -1587 |
GTF2F1 | -3495 |
SUPT16H | -3766 |
Selenoamino acid metabolism
1207 | |
---|---|
set | Selenoamino acid metabolism |
setSize | 103 |
pANOVA | 2.62e-07 |
s.dist | 0.293 |
p.adjustANOVA | 3.45e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928 |
RPL10L | 17345 |
RPL34 | 17330 |
RPL27 | 17307 |
RPL23 | 17292 |
RPL18A | 17183 |
RPS10 | 17181 |
RPL35A | 17098 |
RPS16 | 16779 |
RPL32 | 16664 |
RPS27A | 16523 |
RPL24 | 16506 |
RPS28 | 16458 |
RPS14 | 16358 |
RPL17 | 16189 |
RPS29 | 16138 |
RPS9 | 16050 |
RPSA | 16030 |
RPS19 | 15679 |
RPL28 | 15605 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPL10L | 17345.0 |
RPL34 | 17330.0 |
RPL27 | 17307.0 |
RPL23 | 17292.0 |
RPL18A | 17183.0 |
RPS10 | 17181.0 |
RPL35A | 17098.0 |
RPS16 | 16779.0 |
RPL32 | 16664.0 |
RPS27A | 16523.0 |
RPL24 | 16506.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPL17 | 16189.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPL28 | 15605.0 |
RPL26L1 | 15561.5 |
GSR | 15369.0 |
RPL38 | 14997.0 |
RPS26 | 14854.0 |
MAT1A | 14850.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
RPL7 | 13881.0 |
RPL13A | 13855.5 |
RPS27L | 13689.0 |
PAPSS2 | 13191.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
RPL19 | 12327.0 |
RPS6 | 11935.0 |
GNMT | 11828.0 |
AHCY | 11748.0 |
RPL41 | 11601.0 |
RPS7 | 11217.0 |
RPL7A | 11203.5 |
CBS | 11070.0 |
RPS8 | 10835.0 |
RPL3L | 10775.0 |
RPL9 | 10376.0 |
RPLP2 | 10294.0 |
EEF1E1 | 10008.0 |
RPL36AL | 9850.0 |
EEFSEC | 9735.0 |
RPLP1 | 9499.0 |
RPS2 | 9470.5 |
RPL13 | 9381.5 |
RPL30 | 9189.0 |
RPL29 | 9040.0 |
RPS18 | 8661.0 |
NNMT | 8299.0 |
RPL4 | 8015.0 |
RPL14 | 7987.0 |
RPL26 | 7877.0 |
RPS15 | 7536.0 |
SEPHS2 | 7289.0 |
RPL23A | 7183.0 |
RPL12 | 7117.0 |
RPS5 | 6716.0 |
RPL21 | 6561.0 |
RPL8 | 6517.0 |
RPL37 | 6491.0 |
TXNRD1 | 6407.0 |
RPL37A | 6372.0 |
PAPSS1 | 6297.0 |
RPS15A | 6158.0 |
HNMT | 5720.0 |
RPL22 | 5299.0 |
SEPSECS | 5265.0 |
PSTK | 5077.0 |
UBA52 | 4986.0 |
RPS3A | 4909.0 |
RPL22L1 | 4649.0 |
RPL3 | 4399.5 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
SECISBP2 | 3413.0 |
AIMP2 | 3119.0 |
RPL5 | 2965.0 |
AIMP1 | 2909.0 |
RPL31 | 2893.0 |
RPS20 | 2265.0 |
RPL18 | 2245.0 |
CTH | 2035.0 |
RPL11 | 1692.0 |
RPL36 | 1435.0 |
INMT | 650.0 |
RPL39L | 484.0 |
RPL10A | 307.0 |
RPLP0 | -192.0 |
SCLY | -516.0 |
RPS12 | -575.0 |
RPL35 | -1039.0 |
RPL6 | -1615.0 |
RPL15 | -2406.5 |
RPL27A | -3404.0 |
FAU | -3698.0 |
Formation of the ternary complex, and subsequently, the 43S complex
455 | |
---|---|
set | Formation of the ternary complex, and subsequently, the 43S complex |
setSize | 46 |
pANOVA | 0.000576 |
s.dist | 0.293 |
p.adjustANOVA | 0.0233 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPS10 | 17181.0 |
RPS16 | 16779.0 |
EIF3G | 16747.0 |
RPS27A | 16523.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
EIF3I | 15333.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
RPS27L | 13689.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPS10 | 17181.0 |
RPS16 | 16779.0 |
EIF3G | 16747.0 |
RPS27A | 16523.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
EIF3I | 15333.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
RPS27L | 13689.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
EIF3D | 12117.0 |
RPS6 | 11935.0 |
RPS7 | 11217.0 |
RPS8 | 10835.0 |
EIF3J | 10022.0 |
RPS2 | 9470.5 |
RPS18 | 8661.0 |
RPS15 | 7536.0 |
EIF3E | 7423.0 |
RPS5 | 6716.0 |
RPS15A | 6158.0 |
RPS3A | 4909.0 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
EIF3L | 3674.0 |
EIF2S1 | 2961.0 |
EIF3B | 2802.0 |
EIF3F | 2533.0 |
RPS20 | 2265.0 |
EIF3H | 157.0 |
RPS12 | -575.0 |
EIF2S2 | -1094.0 |
EIF3K | -2241.0 |
FAU | -3698.0 |
EIF3M | -4899.0 |
EIF3A | -5567.0 |
SARS-CoV-2 modulates host translation machinery
1169 | |
---|---|
set | SARS-CoV-2 modulates host translation machinery |
setSize | 46 |
pANOVA | 0.000587 |
s.dist | 0.293 |
p.adjustANOVA | 0.0233 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPS10 | 17181.0 |
GEMIN6 | 17164.0 |
RPS16 | 16779.0 |
GEMIN4 | 16532.0 |
RPS27A | 16523.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
SNRPB | 14437.5 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
SNRPE | 13819.0 |
RPS27L | 13689.0 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPS10 | 17181.0 |
GEMIN6 | 17164.0 |
RPS16 | 16779.0 |
GEMIN4 | 16532.0 |
RPS27A | 16523.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
SNRPB | 14437.5 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
SNRPE | 13819.0 |
RPS27L | 13689.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
RPS6 | 11935.0 |
RPS7 | 11217.0 |
RPS8 | 10835.0 |
RPS2 | 9470.5 |
SNRPD2 | 8748.0 |
RPS18 | 8661.0 |
RPS15 | 7536.0 |
RPS5 | 6716.0 |
RPS15A | 6158.0 |
SNRPD3 | 5707.0 |
RPS3A | 4909.0 |
SNRPD1 | 4550.0 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
RPS20 | 2265.0 |
SNRPG | 1630.0 |
SNRPF | 369.0 |
RPS12 | -575.0 |
GEMIN5 | -1013.0 |
FAU | -3698.0 |
DDX20 | -3847.0 |
GEMIN2 | -5153.0 |
GEMIN7 | -5868.0 |
SMN1 | -7355.5 |
NOTCH4 Activation and Transmission of Signal to the Nucleus
787 | |
---|---|
set | NOTCH4 Activation and Transmission of Signal to the Nucleus |
setSize | 11 |
pANOVA | 0.0964 |
s.dist | 0.289 |
p.adjustANOVA | 0.675 |
Top enriched genes
GeneID | Gene Rank |
---|---|
APH1B | 17267 |
YWHAZ | 15300 |
APH1A | 15158 |
DLL4 | 13982 |
JAG1 | 10182 |
PSEN2 | 10125 |
ADAM10 | 6531 |
NOTCH4 | 6026 |
PSENEN | 4324 |
PSEN1 | 1535 |
NCSTN | -243 |
GeneID | Gene Rank |
---|---|
APH1B | 17267 |
YWHAZ | 15300 |
APH1A | 15158 |
DLL4 | 13982 |
JAG1 | 10182 |
PSEN2 | 10125 |
ADAM10 | 6531 |
NOTCH4 | 6026 |
PSENEN | 4324 |
PSEN1 | 1535 |
NCSTN | -243 |
STAT5 activation downstream of FLT3 ITD mutants
1188 | |
---|---|
set | STAT5 activation downstream of FLT3 ITD mutants |
setSize | 10 |
pANOVA | 0.113 |
s.dist | -0.289 |
p.adjustANOVA | 0.701 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NOX4 | -4403 |
GAB2 | -3577 |
STAT5B | -3526 |
PTPN11 | -3314 |
FLT3 | -2953 |
STAT5A | -2524 |
GRB2 | 5702 |
BCL2L1 | 6626 |
CDKN1A | 9088 |
PIM1 | 15521 |
GeneID | Gene Rank |
---|---|
NOX4 | -4403 |
GAB2 | -3577 |
STAT5B | -3526 |
PTPN11 | -3314 |
FLT3 | -2953 |
STAT5A | -2524 |
GRB2 | 5702 |
BCL2L1 | 6626 |
CDKN1A | 9088 |
PIM1 | 15521 |
Receptor Mediated Mitophagy
1065 | |
---|---|
set | Receptor Mediated Mitophagy |
setSize | 10 |
pANOVA | 0.113 |
s.dist | 0.289 |
p.adjustANOVA | 0.701 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CSNK2A1 | 15819.0 |
SRC | 15597.0 |
MAP1LC3B | 12681.0 |
ATG12 | 11335.0 |
ULK1 | 10261.0 |
MAP1LC3A | 10197.0 |
PGAM5 | 9388.0 |
CSNK2B | 6917.5 |
ATG5 | 2301.0 |
CSNK2A2 | -3460.0 |
GeneID | Gene Rank |
---|---|
CSNK2A1 | 15819.0 |
SRC | 15597.0 |
MAP1LC3B | 12681.0 |
ATG12 | 11335.0 |
ULK1 | 10261.0 |
MAP1LC3A | 10197.0 |
PGAM5 | 9388.0 |
CSNK2B | 6917.5 |
ATG5 | 2301.0 |
CSNK2A2 | -3460.0 |
DAP12 interactions
256 | |
---|---|
set | DAP12 interactions |
setSize | 40 |
pANOVA | 0.00156 |
s.dist | -0.289 |
p.adjustANOVA | 0.0536 |
Top enriched genes
GeneID | Gene Rank |
---|---|
KLRC2 | -7324 |
KLRK1 | -6536 |
PIK3CB | -6323 |
TREM2 | -6249 |
SIGLEC14 | -5757 |
TREM1 | -5726 |
CD300LB | -5380 |
CLEC5A | -5190 |
SIRPB1 | -4824 |
SOS1 | -4576 |
KLRD1 | -4335 |
TYROBP | -3829 |
GRAP2 | -3586 |
FYN | -3315 |
HLA-E | -2302 |
HLA-C | -1817 |
LCP2 | -1259 |
HLA-B | -1136 |
SIGLEC16 | 262 |
PLCG2 | 1272 |
GeneID | Gene Rank |
---|---|
KLRC2 | -7324 |
KLRK1 | -6536 |
PIK3CB | -6323 |
TREM2 | -6249 |
SIGLEC14 | -5757 |
TREM1 | -5726 |
CD300LB | -5380 |
CLEC5A | -5190 |
SIRPB1 | -4824 |
SOS1 | -4576 |
KLRD1 | -4335 |
TYROBP | -3829 |
GRAP2 | -3586 |
FYN | -3315 |
HLA-E | -2302 |
HLA-C | -1817 |
LCP2 | -1259 |
HLA-B | -1136 |
SIGLEC16 | 262 |
PLCG2 | 1272 |
SHC1 | 2027 |
SYK | 2787 |
KIR2DS4 | 2937 |
KRAS | 3589 |
VAV3 | 4129 |
B2M | 5148 |
PIK3CA | 5312 |
GRB2 | 5702 |
NRAS | 6359 |
PIK3R1 | 6497 |
VAV2 | 6610 |
LCK | 7358 |
RAC1 | 8519 |
SIGLEC15 | 9193 |
NCR2 | 9731 |
CD300E | 10183 |
LAT | 10400 |
PLCG1 | 11334 |
PIK3R2 | 12787 |
HRAS | 14159 |
Activation of PPARGC1A (PGC-1alpha) by phosphorylation
46 | |
---|---|
set | Activation of PPARGC1A (PGC-1alpha) by phosphorylation |
setSize | 10 |
pANOVA | 0.116 |
s.dist | 0.287 |
p.adjustANOVA | 0.706 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PRKAA2 | 17065 |
PRKAG1 | 15990 |
PPARGC1A | 15908 |
PRKAG3 | 13702 |
PRKAB1 | 13281 |
MAPK11 | 7550 |
PRKAG2 | 5531 |
MAPK12 | 3099 |
MAPK14 | 2376 |
PRKAB2 | -3763 |
GeneID | Gene Rank |
---|---|
PRKAA2 | 17065 |
PRKAG1 | 15990 |
PPARGC1A | 15908 |
PRKAG3 | 13702 |
PRKAB1 | 13281 |
MAPK11 | 7550 |
PRKAG2 | 5531 |
MAPK12 | 3099 |
MAPK14 | 2376 |
PRKAB2 | -3763 |
Ribosomal scanning and start codon recognition
1156 | |
---|---|
set | Ribosomal scanning and start codon recognition |
setSize | 53 |
pANOVA | 0.000312 |
s.dist | 0.286 |
p.adjustANOVA | 0.013 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS17 | 17928 |
RPS10 | 17181 |
RPS16 | 16779 |
EIF3G | 16747 |
RPS27A | 16523 |
RPS28 | 16458 |
RPS14 | 16358 |
RPS29 | 16138 |
RPS9 | 16050 |
RPSA | 16030 |
RPS19 | 15679 |
EIF3I | 15333 |
RPS26 | 14854 |
RPS11 | 14847 |
RPS27 | 14838 |
RPS21 | 14082 |
RPS24 | 14073 |
EIF4A2 | 13943 |
RPS27L | 13689 |
EIF4G1 | 13084 |
GeneID | Gene Rank |
---|---|
RPS17 | 17928.0 |
RPS10 | 17181.0 |
RPS16 | 16779.0 |
EIF3G | 16747.0 |
RPS27A | 16523.0 |
RPS28 | 16458.0 |
RPS14 | 16358.0 |
RPS29 | 16138.0 |
RPS9 | 16050.0 |
RPSA | 16030.0 |
RPS19 | 15679.0 |
EIF3I | 15333.0 |
RPS26 | 14854.0 |
RPS11 | 14847.0 |
RPS27 | 14838.0 |
RPS21 | 14082.0 |
RPS24 | 14073.0 |
EIF4A2 | 13943.0 |
RPS27L | 13689.0 |
EIF4G1 | 13084.0 |
RPS23 | 12899.0 |
RPS25 | 12714.5 |
EIF3D | 12117.0 |
RPS6 | 11935.0 |
RPS7 | 11217.0 |
EIF4B | 10978.0 |
RPS8 | 10835.0 |
EIF3J | 10022.0 |
RPS2 | 9470.5 |
RPS18 | 8661.0 |
EIF4E | 8302.0 |
RPS15 | 7536.0 |
EIF3E | 7423.0 |
EIF4H | 6966.0 |
RPS5 | 6716.0 |
RPS15A | 6158.0 |
EIF4A1 | 5479.0 |
RPS3A | 4909.0 |
RPS3 | 4337.0 |
RPS13 | 4131.0 |
EIF3L | 3674.0 |
EIF2S1 | 2961.0 |
EIF3B | 2802.0 |
EIF3F | 2533.0 |
RPS20 | 2265.0 |
EIF5 | 404.0 |
EIF3H | 157.0 |
RPS12 | -575.0 |
EIF2S2 | -1094.0 |
EIF3K | -2241.0 |
FAU | -3698.0 |
EIF3M | -4899.0 |
EIF3A | -5567.0 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.3.1 (2023-06-16)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.3 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## time zone: Australia/Melbourne
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats4 parallel stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.3.2.1
## [2] GGally_2.1.2
## [3] ggplot2_3.4.3
## [4] reshape2_1.4.4
## [5] beeswarm_0.4.0
## [6] gplots_3.1.3
## [7] gtools_3.9.4
## [8] tibble_3.2.1
## [9] dplyr_1.1.3
## [10] echarts4r_0.4.5
## [11] ebGSEA_0.1.0
## [12] globaltest_5.54.0
## [13] survival_3.5-7
## [14] tictoc_1.2
## [15] RIdeogram_0.2.2
## [16] eulerr_7.0.0
## [17] kableExtra_1.3.4
## [18] data.table_1.14.8
## [19] IlluminaHumanMethylationEPICanno.ilm10b4.hg19_0.6.0
## [20] minfi_1.46.0
## [21] bumphunter_1.42.0
## [22] locfit_1.5-9.8
## [23] iterators_1.0.14
## [24] foreach_1.5.2
## [25] Biostrings_2.68.1
## [26] XVector_0.40.0
## [27] SummarizedExperiment_1.30.2
## [28] Biobase_2.60.0
## [29] MatrixGenerics_1.12.3
## [30] matrixStats_1.0.0
## [31] GenomicRanges_1.52.0
## [32] GenomeInfoDb_1.36.3
## [33] IRanges_2.34.1
## [34] S4Vectors_0.38.1
## [35] BiocGenerics_0.46.0
## [36] mitch_1.12.0
## [37] limma_3.56.2
##
## loaded via a namespace (and not attached):
## [1] splines_4.3.1 later_1.3.1
## [3] BiocIO_1.10.0 bitops_1.0-7
## [5] filelock_1.0.2 preprocessCore_1.62.1
## [7] XML_3.99-0.14 lifecycle_1.0.3
## [9] lattice_0.21-8 MASS_7.3-60
## [11] base64_2.0.1 scrime_1.3.5
## [13] magrittr_2.0.3 sass_0.4.7
## [15] rmarkdown_2.24 jquerylib_0.1.4
## [17] yaml_2.3.7 httpuv_1.6.11
## [19] grImport2_0.2-0 doRNG_1.8.6
## [21] askpass_1.2.0 DBI_1.1.3
## [23] RColorBrewer_1.1-3 abind_1.4-5
## [25] zlibbioc_1.46.0 rvest_1.0.3
## [27] quadprog_1.5-8 purrr_1.0.2
## [29] RCurl_1.98-1.12 rappdirs_0.3.3
## [31] GenomeInfoDbData_1.2.10 genefilter_1.82.1
## [33] annotate_1.78.0 svglite_2.1.1
## [35] DelayedMatrixStats_1.22.6 codetools_0.2-19
## [37] DelayedArray_0.26.7 xml2_1.3.5
## [39] tidyselect_1.2.0 beanplot_1.3.1
## [41] base64enc_0.1-3 BiocFileCache_2.8.0
## [43] illuminaio_0.42.0 webshot_0.5.5
## [45] GenomicAlignments_1.36.0 jsonlite_1.8.7
## [47] multtest_2.56.0 ellipsis_0.3.2
## [49] systemfonts_1.0.4 tools_4.3.1
## [51] progress_1.2.2 Rcpp_1.0.11
## [53] glue_1.6.2 gridExtra_2.3
## [55] xfun_0.40 HDF5Array_1.28.1
## [57] withr_2.5.0 fastmap_1.1.1
## [59] rhdf5filters_1.12.1 fansi_1.0.4
## [61] openssl_2.1.0 caTools_1.18.2
## [63] digest_0.6.33 R6_2.5.1
## [65] mime_0.12 colorspace_2.1-0
## [67] rsvg_2.4.0 jpeg_0.1-10
## [69] biomaRt_2.56.1 RSQLite_2.3.1
## [71] tidyr_1.3.0 utf8_1.2.3
## [73] generics_0.1.3 rtracklayer_1.60.1
## [75] prettyunits_1.1.1 httr_1.4.7
## [77] htmlwidgets_1.6.2 S4Arrays_1.0.6
## [79] pkgconfig_2.0.3 gtable_0.3.4
## [81] blob_1.2.4 siggenes_1.74.0
## [83] htmltools_0.5.6 scales_1.2.1
## [85] png_0.1-8 knitr_1.44
## [87] rstudioapi_0.15.0 tzdb_0.4.0
## [89] rjson_0.2.21 nlme_3.1-163
## [91] curl_5.0.2 org.Hs.eg.db_3.17.0
## [93] cachem_1.0.8 rhdf5_2.44.0
## [95] stringr_1.5.0 KernSmooth_2.23-22
## [97] AnnotationDbi_1.62.2 restfulr_0.0.15
## [99] GEOquery_2.68.0 pillar_1.9.0
## [101] grid_4.3.1 reshape_0.8.9
## [103] vctrs_0.6.3 promises_1.2.1
## [105] dbplyr_2.3.3 xtable_1.8-4
## [107] evaluate_0.21 readr_2.1.4
## [109] GenomicFeatures_1.52.2 cli_3.6.1
## [111] compiler_4.3.1 Rsamtools_2.16.0
## [113] rlang_1.1.1 crayon_1.5.2
## [115] rngtools_1.5.2 kpmt_0.1.0
## [117] nor1mix_1.3-0 mclust_6.0.0
## [119] plyr_1.8.8 stringi_1.7.12
## [121] viridisLite_0.4.2 BiocParallel_1.34.2
## [123] munsell_0.5.0 Matrix_1.6-1
## [125] hms_1.1.3 sparseMatrixStats_1.12.2
## [127] bit64_4.0.5 Rhdf5lib_1.22.1
## [129] KEGGREST_1.40.0 shiny_1.7.5
## [131] highr_0.10 memoise_2.0.1
## [133] bslib_0.5.1 bit_4.0.5
END of report